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ABSTRACT
Two genomic clones, CoIIA and LIIA, encoding a protein highly homologous to
CYP2A7, were isolated. The clone CoIIA, isolated from a human cosmid library,
contained a full length version of the CYP2A7 gene. The sequence comparison
indicated that there were thirteen base pair differences resulting in five amino acid
changes between the new gene and CYP2A7, suggesting that the gene was an allele of
CYP2A7, designated CYP2A7A. The gene was about 8 kb long and contained 9 exons
encoding a protein of 494 amino acids. The 0.5 kb 5' flanking region of CYP2A7A
contained several putative promoter elements including a typical TATA box, a steroid
regulatory element (SRE), and a HepG2-specific factor-1 binding sequence (HPF-1).
The latter played an essential role in the expression of CYP2A7A in HepG2 cells.
However, the function of the SRE element is still unclear.
The restriction map and partial sequences of the second clone LIIA, isolated from a
human genomic DNA library EMBL3, showed that this gene was identical with neither
CYP2A7 nor CYP2A7A. The results indicated that it was another allele of CYP2A7,
designated CYP2A7B. Of the 18 individuals tested using PCR/restriction fragment
length polymorphism (RFLP), the frequency of CYP2A7B homozygotes was
approximately 44.4%; that of CYP2A7A homozygotes was 33.3% and the frequency
of heterozygotes of CYP2A7A /CYP2A7B was 22.2%.
In order to investigate the relationship between the expression levels of human CYP2A
alleles and the polymorphism of coumarin hydroxylase activity in man, three cDNAs,
CYP2A6, CYP2A7 and an alternatively spliced version of CYP2A7 (CYP2A7AS)
were cloned. The last one missed exon 2 but contained a 10 bp segment of intron 1.
Translation of CYP2A7AS resulted in an in frame deletion of 51 amino acids. The
expression of these cDNAs in COS-7 cells showed that both CYP2A6 and CYP2A7
generated a protein of 49 kDa, while the protein product of CYP2A7AS was about 44
1
kDa. Only CYP2A6 protein had the coumarin hydroxylase activity. The expressions of
CYP2A6 and CYP2A7 mRNAs were established in six human liver samples with RT-
PCR (reverse transcription followed by PCR) and Pstl digestion. The relative level of
CYP2A6 to CYP2A7 was found to range from 1:0.5 to 1:3. The expressions of
CYP2A7 and CYP2A7AS mRNA were also investigated. In one of the five liver RNAs
studied, the alternatively spliced CYP2A7 mRNA was 3 to 4-fold more abundant than
the normal mRNA. The other samples contained very low levels of this mRNA.
Interestingly, CYP2A7AS was the major CYP2A7 mRNA detected in a human skin
fibroblast cell line. These data have supported the previous findings that alternative




1.1 Metabolism of Xenobiotic and Cytochrome P450: General View and
Historical Background
Xenobiotic are compounds foreign to the body, including drugs, environmental
pollutants, industrial chemicals and plant metabolites. Many of these compounds are
lipophilic and readily absorbed across cell membranes. In mammals, however, these
nonpolar compounds cannot be excreted unless they are metabolised to more polar
products. Xenobiotic-metabolising enzymes in mammals are responsible for the
detoxification and excretion of these foreign chemicals (Schenkman, 1993). By a range
of chemical reactions these enzymes convert lipophilic chemicals into highly water-
soluble polar compounds that can be eliminated. The metabolic reactions of xenobiotic
are normally divided into phase I (functionalisation) and phase II (conjugation) (Table
1.1). The main function of phase I reactions is the creation of a chemically reactive
functional group, such as OH, -NH2, -SH and -COOH, in the substrate. Phase II
enzymes can then use these functional groups to yield hydrophilic products. The phase
I enzymes include, among others, cytochrome P450 (P450). P450s are very important
in the oxidative, peroxidative, and reductive metabolism of numerous xenobiotic as
well as endogenous compounds such as steroid hormones, bile acids, fatty acids,
prostaglandins and their derivatives (Zimniak and Waxman, 1993). With certain
compounds, however, the intermediates of oxygenation reactions catalysed by P450,
such as epoxides, can attack the cellular biomolecules DNA, RNA, and protein,
producing toxicity, cell death, mutation and transformation.
The metabolisms catalysed by P450s share some common features. First, a single P450
enzyme can metabolise numerous structurally diverse chemicals. For example, CYP2D
(P4502D, see section 1.2.1) is involved in the metabolism of at least 25 different
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chemicals (Gough et al., 1990). Second, a single substrate can be metabolised to
varying degrees by several different P450 enzymes. Testosterone can be metabolised at
different ring positions. Certain P450s are active toward hydroxylating testosterone in a
stereo-specific manner at one or more ring positions, while another form of P450 will
hydroxylate this substrate at other positions (Gonzalez, 1989).
P450 has been the subject of intense studies for over 40 years. Since the 1950s, it has
become clear (Miiller and Miller, 1953) that liver microsomes are the major source of
P450. In the 1960s, Hayashi and Nozaki (1969) discussed that the P450s catalysed the
incorporation of a single atom of molecular oxygen into the substrate with the
concomitant reduction of the other atom to water. After the isolation of a partially
purified P450 from phenobarbital-treated rabbit liver microsomes (Lu and Coon,
1968), a number of other forms of P450 were purified from different species, ranging
from primitive bacteria to highly developed mammals. Although liver is the major
source of P450s, they can be found in almost all other tissues to a variable extent
(Arinc, 1993; White et al., 1991; Bergh and Strobel, 1992). P450 has also been found
in some cultured cell lines, such as human colon tumour cell line LS174T (Strobel et
al., 1993), and human skin cell line (described in Chapter 4).
i
1.2 Evolution and Nomenclature
1.2.1 Cytochrome P450 nomenclature
Over the last 3 decades, tremendous progress has been made in understanding the P450
system. Since the first P450 enzyme was partially purified in the 1960's, a total of 214
P450 genes and 12 putative pseudogenes, which were isolated and characterised from
31 different eukaryotes and nine prokaryotes, have been listed to the end of October,
1992 (Nelson et al., 1993). The rapidly expanding number of genes within the P450
superfamily and a variety of different nomenclatures used in different laboratories made
it necessary to establish a standard nomenclature system of P450 genes.
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The name cytochrome P450 was first used to describe a hemoprotein having a major
absorption at 450 nm after binding carbon monoxide (Omura and Sato, 1962; 1964).
However, the Nomenclature Committee of the International Union of Biochemistry
(NCIUB) prefers the term "heme-thiolate protein" instead of "cytochrome" for P450,
because P450 proteins are, in fact, not "cytochrome" in the true meaning of this
terminology (Palmer and Reedijk, 1989).
It has been known that some P450s have very high substrate specificity, while other
P450s have broad substrate specificities. Orthologous P450s may have different
substrate specificities and, conversely, nonorthologous P450s or P450s in different
subfamilies may have similar substrate specificity, particularly the P450 genes in
Family 2. Therefore the nomenclature system cannot be based on P450 catalytic
activities or functions.
Based entirely on the homology of complete amino acid sequences, the first
nomenclature system was established in 1987 (Nebert et al., 1987) and extended in
subsequent updates (Nebert et al., 1989a; 1991, Nelson et al., 1993). This system
divides P450s into gene families and subfamilies. Each family has diverged from one
another about 600-900 million years ago (MYA), and the P450 protein sequences
within a single family are > 40% similar with a few exceptions, one of which is the
CYP2D subfamily. Some P450s in this family are slightly less than 40 % similar to
other proteins in the CYP2 family (Gonzalez, 1993). Any two mammalian sequences of
proteins within the same subfamily are greater than 55% identical, and they have
diverged from one another within 150 million years. All genes within a family have
been shown to contain the same number of exons and similar intron-exon boundaries..
Briefly, the nomenclature system includes the points as follows (Nelson et al., 1993)
1) A P450 gene or cDNA is named using the italicised root symbol "CYP" ("Cyp" for
the mouse), denoting cytochrome P450.
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2) An Arabic number designating the P450 family, and a letter indicating the subfamily
when two or more subfamilies are known to exist within that family, and another
Arabic numeral represents the individual gene. With mouse genes or cDNAs, the final
number is generally preceded by a hyphen. "P" ("p" in mouse) after the gene number is
used to denote a pseudogene.
3) It is recommended to non-italicise product of the gene (enzyme) by a similar
nomenclature system, for example, 'CYP1A1" for the mRNA and protein in all
species including mouse. The italicised "CYP1A1" ( "Cypla-1" in mouse)
represents the gene or cDNA. Another possibility for designating the protein might be
"P4501A1" or simply "1A1"
Based on these points, CYP2A6 represents a human P450 gene or cDNA, family 2,
the sixth gene in subfamily A; CYP2A6 is the enzyme or mRNA encoded by the
CYP2A6 gene. Cyp2a-4 represents a mouse P450 gene or cDNA, family 2, the fourth
gene in subfamily A, and Cyp2a4 is the enzyme or mRNA of the Cyp2a-4 gene.
Although the use of this nomenclature system is recommended, the trivial names can
still be used. For the protein, there is no hyphen in "P450", no Greek letters, and no
subscripts or superscripts. For example, P45O70, P45O170, and P450arom should be
referred to as P450c7, P450cl7 and P450arom, respectively.
1.2.2 Evolution of CYP superfamily
P450s are presumed to have been present in the earliest organisms, and all the existing
species of P450 are derived from a common ancestor more than 3 billion years ago
(Nelson et al., 1993). During the evolutionary process the P450 system has diverged
and duplicated to a superfamily, being found throughout the animal and plant
kingdoms. An evolution tree (Figure 1.1) for the CYP gene superfamily was generated
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Figure 1.1 Unweighted-pair-
group method of analysis
(UPGMA) of the P450
superfamily (Nebert et al., 1991).
The genes within each family
(denoted by numbers) represent
all those that have been
characterised in various species.
The divergence between bacterial
and eukaryotic genes
(evolutionary distance = 2.5) has
been set at 1400 million years-
base pairs (Mybp). Estimates of
branching in the oldest portion of
the tree are subject to the largest
error, and molecularly driven
events during evolution contribute
to the uncertainty of UPGMA
branching patterns. This tree was
calculated by using amino acid
sequences deduced from 147 of
the 154 cDNA sequences
available.
4.0 3.0 2.0 1.0 0
EVOLUTIONARY DISTANCE
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Strobel, 1987). Using the species divergence time generated from fossil evidence and
the amino acid differences between a P450 protein in two species, the evolutionary
distance and unit evolutionary period (UEP, the time in millions of years required for a
1% change in amino acid sequence) can be calculated. The UEPs of P450s range from
2.3 to 4.2 (Nelson and Strobel, 1987), suggesting that P450 genes are rapidly
diverging.
The earliest P450s are those that metabolise steroids and fatty acids; for example, the
fatty acid metabolising CYP4 and the steroid inducible CYP3 genes diverged more than
1 billion years ago. Then the CYP1 and CYP2 gene families formed about 800 MYA
followed by the expansion of the CYP2 gene family to eight subfamilies at
approximately 400 to 600 MYA. To date, a minimum of 54 genes have been found in
this family (Henderson and Wolf, 1992).
The 'explosion' in the number of new CYP2 genes may be related to the emergence of
mammals onto land several millions years after plants were established and most of
these genes are believed to represent a 'surviving warfare' between animal and plant
(Gonzalez and Nebert, 1990). After animals and plants diverged approximately 1.2
billion years ago, animals began to ingest plants. As a means of defence, plants
countered by developing new stress metabolites to make them less palatable and
digestible; then animals responded with new P450 genes. The presence of detoxifying
enzymes encoded by these P450 genes allowed animals to survive in their new
environment.
1.2.3 Evolution of CYP2A subfamily
During the process of evolution, a tremendous expansion in the CYP2 gene family has
occurred within the past 400 to 800 million years which resulted in a diverging of eight
subfamilies. This diversification has been suggested to coincide with emergence of
vertebrates on to land. These animals could only survive on plant diets if they had
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developed their own specialised battery of P450s, particular those in CYP2 family
(Gonzalez, 1992). CYP2 family is composed of ten subfamilies with different members
(Nelson et al., 1993). The enzymes within these subfamilies are involved in the
metabolism of many chemicals including drugs and procarcinogens, and the enzyme
activities are under distinct inducer-dependent and developmental control (Squres and
Negishi, 1988; Matsunaga et al., 1988).
About 75 - 80 million years ago, a duplication event occurred, generated the CYP2A3
gene and the precursor to the CYP2A1 and CYP2A2 genes in rat, followed by another
diverging event approximately 25 million years ago, which resulted in the CYP2A1 and
CYP2A2 genes (Gonzalez, 1989). The amino acid of the CYP2A3 exhibits 71% and
73% similarity to that of the CYP2A1 and CYP2A2 proteins, respectively, while the
CYP2A2 shares 88% of the amino acid sequence of CYP2A1 protein. In mouse, two
members of Cyp2a gene subfamily, designated Cyp2a-4 and Cyp2a-5, have been
discovered and the gene clusters are located on mouse chromosome 7. The deduced
amino acid sequences of both genes are 98% similar, indicating that they diverged
about 4 to 12 million years ago. In spite of their highly similar sequences, Cyp2a-4
encodes a 15a-hydroxylase, and Cyp2a-5 encodes a coumarin 7- hydroxylase. Both
mouse Cyp2a genes exhibit 70% and 75% deduced amino acid sequence similarity with
rat CYP2A1 and CYP2A2, respectively, but 90% similarity with rat CYP2A3.
Therefore, mouse genes have been designated as orthologous to the rat CYP2A3 gene.
Two human CYP2A cDNAs, designated CYP2A6 and CYP2A7, have been isolated
and located on chromosome 19, between 19ql2 and 19q 13.2 (Miles et al., 1988). The
deduced amino acid sequence of human CYP2A gene is 85% similar to CYP2A3, 69%
and 65% similar to CYP2A1 and CYP2A2, respectively.
Although the gene numbers of CYP2A subfamily are variable in different species, they
exhibit a single conserved activity, namely coumarin 7-hydroxylation. However, the
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substrate turnover in different mammals and strains is varied (Gonzalez, 1992;
Lindberg et al., 1989 and 1992).
1.2.4 The molecular mechanism of cytochrome P450 evolution
Gene duplication produces two identical copies and these may retain their original
function, producing the RNA species or protein. Alternatively, one of the copies may
diverge by the occurrence ofmolecular events at the DNA level, such as point mutation,
deletion and insertion, to form a functionless pseudogene. More importantly, the gene
duplication may result in the emergence of a new gene with markedly different function
(Li and Graur, 1991). If a new gene confers an evolutionary advantage(s), it can
become fixed under selective pressures, and can ultimately be spread throughout a
population (Nebert and Gonzalez, 1987; Nelson and Strobel, 1987). This is considered
as part of a process of molecular drive (Gonzalez and Nebert, 1990). Figure 1.2
represents schemes of CYP gene duplication.
One of the mechanisms involved in molecular drive is gene conversion. This event
takes place during gene duplication in which some portion of a gene is replaced by the
corresponding part of a nearby gene. Several reports have presented evidence for gene
conversion between closely linked CYP genes, for example within CYP2A and within
CYP2D genes (Figure 1.2) (Matsunaga et al., 1988; Gonzalez and Nebert, 1990),
therefore gene conversion is hypothesised as a major determinant in P450 evolution
(Nebert and Gonzalez, 1987). However based on the sequence comparison within the
rat CYP2D gene cluster (Matsunaga et al., 1990), in which several independent events
homogenised nucleotide sequences surrounding the site coding the heme binding
region, Gotoh (1993) argued that gene conversion appeared to be conservative rather
than progressive in nature, and was probably caused by a repair mechanism against
accidental gene disruptions. These results question whether gene conversion played a
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Figure 1.2 Schemes showing gene
duplication and divergence events during
evolution. The black boxes represent
functional genes in a subfamily along the
chromosome (denoted by line).
Transitions of gene 1 to two gene l's (A)
or of gene 2 to two gene 2's (B) are
examples of duplication events.
Formation of gene 2 from gene 1 (A and
B) or of gene 4 and 5 from gene 1 and 2,
respectively, (C and D), represent
examples of divergence events. It is
believed that the original human
complement 4 gene (C4A) and CYP21
gene (White et al., 1985), existed (F) as a
single gene 150 million years ago, and
constitutes an example in which both
genes duplicated together and occur in
tandem in present-day humans (G). The
X represents a pseudogene that has
formed as the result ofmutation, deletion,
or crossover. This figure is adapted from
Nebert et al., 1989b.
central role in the progressive evolution of P450. Taken together, the evolution of
P450, whatever the mechanism, appears to have been governed by a more complicated
process than previously thought.
1.3 Structure and Metabolic Reactions of Cytochrome P450
1.3.1 Structure of cytochrome P450
Cytochrome P450 has been classified as a heme-containing enzyme with a single iron
protoporphyrin IX as the prosthetic group. Dioxygen is bound, reduced and activated at
this site (figure 1.3, A). The amino acids surrounding the heme influence the spectral
characteristics of the heme resulting in a typical P450 absorption band at around 450
nm once the ferric iron has been reduced and carbon monoxide has bound
(Klingenberg, 1958). These enzymes exist in multiple forms with a molecular weight
of the monomers of approximately 45,000 - 55,000 (450-500 amino acid residues).
Several lines of evidence suggest that the P450 protein is tightly bound in the
membrane with its N-terminal (amino terminus) peptide serving as an anchor, and the
major part of the polypeptide chain is exposed to the cytoplasmic surface of the
endoplasmic reticulum to probably form a globular structure. The heme iron is parallel
to the endoplasmic reticulum membrane (Figure 1.3B).
At present, more than 160 primary structures of P450 protein have been characterised
and structural homology has been observed in some peptide regions among all of these
enzymes; for example, the heme-binding Cys residue near the C-terminus (carboxy
terminus) is invariant. The highly hydrophobic signal/anchor segment at the N-terminus
is followed by a short positively charged sequence and a proline rich cluster; the
remainder of the sequence exhibits alternating hydrophobic and hydrophilic character
(Black, 1993).
13
Figure 1.3A: Structure of ferric protoporphyrin IX, the prosthetic group of
cytochrome P450 (Adapted from Gibson and Skett, 1986).
Figure 1.3B: A model of microsomal cytochrome P450 structure (Nelson and
Strobel, 1988).
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Alignment of primary structure with X-ray crystallographic data has been used to
predict five substrate-binding domains (Gotoh and Fujii-Kuriyama, 1989). Based on
theoretical calculations, P450s contain a-helix as well as 6-sheet domains.
Experimentally, however, the tertiary structure is only known for P450 101 (P450cam)
from the bacterium Pseudomonas putida based on X-Ray analysis (Figure 1.4).
Although the three-dimensional structure is not yet known for any eukaryotic
cytochrome P450, many advances have been made to elucidate it, especially regarding
the membrane topology (Black, 1992). By alignment of 34 sequences of microsomal
P450, four to eight potential trans-membrane regions have been demonstrated (Nelson
and Strobel, 1988). However, recent experimental results showed that eukaryotic
P450s are anchored in the membrane by only one or two trans-membrane peptides
located at the N-terminal end, leaving the globular, "P450 101-like" domain outside the
membrane (Black, 1992).
1.3.2 Reactions catalysed by cytochrome P450
It is known that humans are exposed to more than 200,000 man-made chemicals or
environmental pollutants in their daily lives (Porter and Coon, 1991). Many of these
pollutants are believed to be potential substrates for P450, and many may also serve as
inducers or inhibitors of different P450 enzymes. Among the huge number of
structurally diverse chemicals, the only common feature appears to be a degree of
lipophilicity. The overall reaction is given in equation 1. It is in accord with findings in




NADPH + H+ + 02 + RH ► NADP+ + H20 + ROH
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Figure 1.4 High-resolution crystal structure of cytochrome P450cam (Poulos. 1991).
Helices are indicated by bars and 8 structure by arrows. The shaded region highlights
the antiparallel 8 pair and 8 bulge that contains the axial heme ligand, Cys-357.
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Where RH represents an oxidizable substrate and ROH the hydroxylated metabolite.
During the reaction, reducing equivalents derived from NADPH + H+ are consumed,
and one atom of molecular oxygen is incorporated into the substrate whereas the other
oxygen atom is reduced to water. In an enzyme-free system, two extremely high
activation energy barriers have to be surmounted during the reaction: the dissociation of
the dioxygen bond (460 kJ/mol) and the dissociation of the carbon hydrogen bond of
the substrate (420 kJ/mol) (Jung and Ristau, 1978). However, the reaction catalysed by
P450 can proceed with an activation energy of only 40-70 kJ/mol (Rein and Jung,
1993).
Figure 1.5 is a more detailed scheme of the reaction cycle catalysed by P450, which is
modified from an earlier version (White and Coon, 1980) The feature of the reaction is
the ability of the heme iron to undergo cyclic oxidation/reduction reactions in
conjunction with substrate binding and oxygen activation. It may be considered in two
steps. The first step in the reaction cycle is substrate binding, which perturbs the spin
state equilibrium of the cytochrome and facilitates uptake of the first electron.
Substrates that undergo reduction rather than oxygenation, such as epoxides, N-oxides,
nitro and azo compounds, and lipid hydroperoxides, accept two electrons to give
RH(H)2 (Porter and Coon, 1991; Kominami, 1993). To initiate the oxidative reactions,
02 is bound to the ferrous P450 with co-ordination to iron trans to thiolate. A substrate
binding-induced shift in mid-point redox potential of cytochrome P450 protein to a
more positive value results in a greater electromotive force for subsequent facile
electron transfer of the second electron (For review see Schenkman et al., 1982). The
next step is oxygen insertion and product release. The precise oxidation states of iron
and oxygen in this intermediate is far from being clear but involve splitting the oxygen-
oxygen bond with the uptake of two protons at some stage, and the reaction of an
activated oxygen and the release of H20. The Fe2+-02/substrate complex is unstable,
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Figure 1.5. Catalytic cycle of cytochrome P450. Fe represents the heme iron atom at
the active site, RH the substrate, RH(H)2 a reduction product, ROH the corresponding
hydroxylated metabolite, and XOOF1 a peroxy compound that serves as an alternative
















but has been characterised both with the bacterial P450 101 (P450cam) and mammalian
P450s (Oprian et al., 1983; Guengerich, 1991), and evidence for the other oxygenated
complexes has also been seen with P450 enzymes (Blake and Coon, 1989).
Under certain conditions, the oxidation of substrates is not tightly coupled to the
electron flow, the catalytic cycle results in the formation of hydrogen peroxide
(equation 2), and this uncoupling is dependent on substrate (RH) and its binding to the
active site of the heme moiety of P450 (Gorsky et al., 1984; Blanck et al., 1991).
Evidence has been accumulated that most of this H202 is formed from the non
enzymatic dismutation of superoxide anion, which is a breakdown product of the
(RH)Fe2+-02 complex (Kuthan and Ullrich, 1982; Figure 1.5).
Equation 2:
^ P-450
Oz + NADPH + H+ ► H2O2 +NADP+
On the other hand, it is clear that uncoupling is dependent on the individual P450
involved in the metabolism of a particular chemical. In vivo, different substrates lead to
a different spectrum of induced P450, thus changing the degree of uncoupling of the
specific chemical. The best examined example in this regard is ethanol, which induces
CYP2E (Kappus, 1993). Whereas hydrogen peroxide formation by ethanol in non-
induced liver microsomes is low, it is increased in ethanol-induced liver microsomes.
The hydrogen peroxide and hydroxyl radicals have been related to alcohol-induced liver
damage (Albano et al., 1991). This is probably the cause of reactive oxygen formation
in vitro and in vivo (for more detail about the formation of reactive oxygen species, see
Kappus, 1993).
P450s can also bioactivate certain environmental pro-carcinogens to cytotoxic and
carcinogenic products. In general, P450 enzymes use molecular oxygen in the
detoxification of foreign compounds. However, P450-mediated oxidation, at carbon
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atoms to form epoxides and at nitrogen and sulphur atoms, can give rise cytotoxic and
mutagenic products. The vast majority of environmental procarcinogens including
polycyclic aromatic hydrocarbons, nitrosamines and aromatic amines are converted to
their ultimate carcinogenic species by these reactions (Wolf, 1986).
Equation 3:
R' = R + O 2+ NADPH + H 1 ► R - R'+ H20 + NADP+
\/
O
A summary of these reactions is that P450 can play three distinct roles in the
metabolism of xenobiotic and endogenous compounds. First, the enzyme system is a
dominant route converting a lipophilic foreign chemical into a more water soluble
product, thereby facilitating excretion from the organism, this process is considered to
be the detoxification. Second, it can convert certain xenobiotic to more toxic products.
Many carcinogens are metabolically activated by P450s to ultimate carcinogenic
metabolites. Last, this enzyme system can also metabolise numerous endogenous
compounds including steroids, fatty acids, vitamins, and bile acids (Ying and Lu,
1987).
1.4 Roles of Cytochrome P450s in Activation of Chemical Carcinogens
and Genetic Susceptibility to Diseases
1.4.1 Activation of procarcinogens by P450
In general, P450s use molecular oxygen in the detoxification of foreign compounds. As
an unfortunate consequence of these reactions some procarcinogens are activated to
their ultimate carcinogenic forms (Harris, 1991; Guengerich, 1988; Kawajiri et al.,
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1990). Short-term mutagenicity testing has clearly shown that P450-containing
preparations in Salmonella typhimurium-based assays can convert the great majority of
pre-mutagens into mutagens (Ashby and Tennant, 1991). Since most of these mutagens
are also carcinogens, similar metabolic activation processes should occur in vivo, too.
Studies involving the metabolism of chemical carcinogens were important in the initial
characterisation of P450. Earfy evidence revealed that NADPH-dependent microsomal
enzymes metabolised azo dyes, and that administration of many different chemicals to
animals could alter the metabolism of carcinogens (Guengerich, 1988). Since then
many studies regarding the catalytic specificities of the P450 enzymes of rats, mice and
other experimental animals, as well as humans have been published. Table 1.2 lists
some carcinogens which can be activated by P450.
Aflatoxins comprise a structurally-related group of mycotoxin metabolites which are
present in a variety of human foodstuffs (Groopman et al., 1988; Wogan, 1973a).
Aflatoxin B] has been found to cause hepatocarcinogenesis in animals (Wogan, 1973b;
Vesselinovitch et al., 1972). Furthermore, there is epidemiological evidence that
humans may be susceptible to aEatoxin-induced hepatocarcinogenesis (Peers et al.,
1987). Aflatoxin B[ is considered to be the most carcinogenic of these toxins and
requires oxidation of the 8,9 double bond to yield the biologically active anatoxin B,-
8,9-epoxide which can react with DNA. In addition to the 8,9-epoxide, P450-mediated
anatoxin Bj oxidation also produces several hydroxylated metabolites including
aflatoxin M|, anatoxin Pj, and anatoxin Q], The metabolism of anatoxin B, is
illustrated in Fig 1.6. In humans, the enzymes in subfamilies CYP3A, CYP2A and
CYP2B have been reported to be involved in the bioactivation of anatoxin B, (Aoyama
et al., 1990), and the reactions involved are epoxidation, hydroxylation and
demethylation (Figure 1.6).
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Table 1.2. Association of cytochrome P450 and carcinogen activation (Adapted from
Yamazoe and Kato, 1993).
P-450 Type of carcinogen oxidation
family
1A1 Extrahepatic oxidation of arenes (polycyclic aromatic hydrocarbons) and
other carcinogens.
1A2 N-Oxidation of arylamines and arylamides
2A Epoxidation ofmycotoxins such as aflatoxin B \.
2B Oxidation of long alkyl-chain nitrosamines
2C Cytclophosphamide 4-hydroxylation. Basal level of hepatic oxidation of
arenes.
2E a-Oxidation of short alkyl chain nitrosamines and benzene oxidation
J.
3A Epoxidation of mycotoxins such as aflatoxin Bj. Oxidation of arenes
4A Azo dye reduction
4B Arylamine N-oxidation
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Nitrosamines are a potent group of environmental mutagens and carcinogens. For
example, nitrosodimethylamine (NDMA) has been shown to be both an acute
hepatotoxin and a potent carcinogen in many animal species (Magee and Barnes, 1967:
Druckrey et al., 1969). The tobacco-specific nitrosamines, nitrosamine 4-
(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK) and N'-nitrosonornicotine have
been suggested to play a role in human tobacco-related cancer (Hecht et al., 1983).
Metabolic activation ofNNK involves the a-Hydroxylation of either the methylene or
methyl carbon of NNK, resulting in the methylation or pyridyloxobutylation of DNA,
respectively (Figure 1.7) (Hecht et al., 1988). CYP2A6, CYP2E1, CYP2B1 and
CYP1A2 are effective in the activation ofNNK to a mutagen (Smith-TJ et al., 1992).
A therapeutic but carcinogenic agent, cyclophosphamide, must first undergo
bioactivation by P450 to manifest alkylating activity. The initial reaction,
cyclophosphamide 4-hydroxylation, is catalysed mainly by CYP2C6 and 2C11 in rat
liver (Clarke and Waxman, 1989).
1.4.2 Genetic susceptibility to disease
Xenobiotic compounds, including drugs and carcinogens, are metabolised by P450s
and other drug-metabolising enzymes. However, there is considerable evidence for
inter-individual variation of cytochrome P450 enzyme activities in humans, and these
differences may be either inherited or acquired. Consequently, the metabolic oxidation
of drugs and other alien chemicals can be highly variable from person to person. For
example, some patients may respond better than others to the same drug treatment. This
in part makes it difficult to produce a drug appropriate to everyone. In addition,
although cigarette smoking is considered to correlate with lung cancer, not every
smoker will definitely develop cancer because of a differential susceptibility to tobacco
smoke (Bascom, 1991). Therefore, the individual differences in the level of drug-
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Figure 1.6. P450-mediated metabolism of aflatoxin Bj (adapted from Yamazoe and
Kato, 1993).
Aflatoxin Bj
Aflatoxin Mi. Qi and other products
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metabolising enzyme activity may well be a factor in cancer susceptibility and in
environmentally linked disease. The understanding of P450s could supply important
information for medical treatment and cancer prevention.
In the past 15 years, tremendous progress has been made in the identification of
polymorphisms in P450 genes. By studying the metabolic phenotype, it has been found
that 5-10% of individuals from different racial groups cannot metabolise the
antihypertensive agent debrisoquine (Alvan et al., 1990). Levels of debrisoquine and
the 4-hydroxyl metabolite can be measured and used to calculate a metabolic ratio
(defined as debrisoquine/4-hydroxyl metabolite). Individuals with a metabolic ratio of
greater than 12.6 are classified as poor metabolisers of debrisoquine (PM) and others as
extensive metabolisers (EM) (Daly and Idle, 1993). Further studies indicate that
CYP2D1 (rat) and CYP2D6 (human) have high debrisoquine hydroxylase activity
(Larrey et al., 1984; Brosen and Gram, 1989), and this enzyme is absent from the liver
of poor metabolisers (Zanger et al., 1988). In addition, CYP2D is involved in the
metabolism of more than 30 clinically important drugs, including antidepressants,
neuroleptics, opioids and cardiovascular drugs.
Cloning and sequencing of CYP2D genes have assisted in the identification of
mutations which give rise to the Sebrisoquine polymorphisms in rat and human. The
results suggest that mutations in the CYP2D6 gene are common in poor metabolisers
and may be responsible for the absence of the CYP2D6 protein. To date, more than
90% of the mutations of CYP2D6 have been identified (Skoda et al., 1988; Kagimoto
et al., 1990; Gough et al.. 1990). The most common mutant alleles are characterised by
a point mutation or a 1 -bp deletion at a splice site recognition sequence that lead to a
frame shift.
The debrisoquine hydroxylase phenotype has important consequences both with regard
to response to drug therapy and exposure to xenobiotic. Both extensive and poor
metabolisers may suffer adverse effects due to low serum concentrations or toxic
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concentrations of xenobiotic, respectively (Broken and Gram, 1989). A well studied
case is the association between poor metaboliser status and susceptibility to Parkinson's
disease (Smith et al., 1992). It has been postulated that this disease may occur as a
result of environmental exposure to pesticides similar to MPP+, which can produce a
Parkinsonian syndrome in man (Davis et al., 1979). In vitro studies have shown that
MPP+ (l-methyl-4-phenylpyridinium ion) and its precursor MPTP (l-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) can competitively inhibit CYP2D6 and are possible
substrates (Fonne-Pfister et al., 1987).
Another disease related gene is CYP11B1 encoding an 1 lB-hydroxylase. It has been
found that inherited deficiency of 1 lB-hydroxylase can cause congenital adrenal
hyperplasia, a disorder of Cortisol biosynthesis (New et al., 1989). The missense
mutations reported to be associated with 1 lB-hydroxylase deficiency are four base pair
mutations and a base pair deletion in exon 2 of the CYP11B1 gene. The deletion causes
a frameshift and premature termination of the protein. Each of these point mutations has
been shown by in vitro transfection to abolish 1 lB-hydroxylase activity (Curnow et al.,
1993).
1.5 Aims of the Study
t
Our present knowledge of the P450 system already indicates that many factors
determine P450 levels in an individual, including genetic background, dietary habits,
hormonal level and exposure to foreign compounds that act as inducers or repressors.
The great inter-individual differences in activity of P450 can influence individual
susceptibility to clinical drug treatment, chemically induced disease and cancers. If we
can decide whether the level of a particular P450 in an individual is at a dangerously
high or low level, or the individual differences are associated with cancer susceptibility
and environmentally linked disease, it will be possible either to adjust the drug
exposure or to avoid the exposure to harmful substances. For instance, it may be
possible to predict whether a tobacco smoker is more or less susceptible to lung cancer.
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All of these approaches will be on the basis of a thorough understanding of the human
P450 system.
In addition, one of the most critical concerns of pharmacology is to define the dose-
response relationships of a drug. A large amount of information has clearly
demonstrated that drug metabolism and the regulation of drug-metabolising enzyme
activity are often different in man compared to experimental animals. Humans appear to
have their own unique set of P450 genes. The inability to correlate xenobiotic
metabolism in humans and in rodents stresses the importance of a thorough analysis of
human P450s. Therefore, human-like systems to study drug metabolism must be
developed.
The CYP2A subfamily is one of the important gene families involved in the metabolism
of xenobiotics, and has been extensively studied in rodents. In rat, three cDNAs have
been isolated and sequenced (Nebert et al., 1991). The enzymatic activity of CYP2A1
was found to specifically hydroxylate testosterone at the 7a position. Although
CYP2A2 is highly homologous to CYP2A1 by deduced amino acid sequence, it does
not have the same degree of specificity to testosterone hydroxylation. The expression
levels of both genes are also regulated differently during development and after
treatment with the carcinogen 3'-methylcholanthrene. Rat CYP2A3, appears to be
expressed only in lung, and the expression level is induced by 3'-methylcholanthrene
(Kimura-S. et al., 1989). In mice, two cDNAs, Cyp2a-4 and Cyp2a-5, have been
isolated (Burkhart et al., 1990). The sequences of both cDNAs exhibit 98% similarity,
however, the encoded enzyme activities depend on the three amino acids at positions
117, 209, and 365 (Lindberg et al., 1989). Interestingly, only one amino acid change
results in a high or low activity of coumarin 7-hydroxylase in different mouse strains
(Lindberg et al., 1992). This result indicates that during evolution, amino acid
substitutions have selectively occurred at positions which alter substrate specificity of
enzyme and increase enzymatic activity (Figure 1.8).
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Figure 1.8 Phylogeny of the CYP2A family. At the top is the most parsimonious
phylogeny. The numbers next to each branch are the inferred minimum numbers of
nonsynonymous/synonymous/noncoding substitutions that occurred in each branch.
The vertical bars depict the conceptual translations of the cDNAs. Sites that differ from
P450cohH are marked by open ticks. The amino acids at the three sites shown to effect
coumarin 7-hydroxylase and steroid 15oc-hydroxylase activities are also indicated.
P450Cohh, high coumarin 7-hydroxylase activity; P450Coh', low coumarin 7-
hydroxylase activity and P450i5a, steroid 15a-hydroxylase (adapted from Gonzalez,
1992; Lindberg and Negishi, 1992).
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Two distinct CYP2A cDNAs have been isolated from a human cDNA library (Yamano
et al., 1990), one of which (CYP2A6) has been identified as encoding a coumarin 7-
hydroxylase (Miles et al., 1990). The second one, designated CYP2A7, encodes a
protein containing a complete reading frame and exhibits 96% nucleotide sequence
similarity with CYP2A6. However, the catalytic activity of it is unknown.
It has been found that human liver samples exhibit a great inter-individual variability in
levels of CYP2A mRNAs, protein and coumarin 7-hydroxylase activity (Yamano et al.,
1990; Miles et al., 1990; Yun et al., 1991). Up to 144-fold variability of CYP2A
protein(s) was detected in human liver samples (Maurice et al., 1991). A possible
reason is that CYP2A genes are polymorphically expressed in humans, and the mutant
alleles in the population result in the marked inter-individual variability in the activity of
coumarin 7-hydroxylase. If polymorphisms of CYP2A genes exist indeed, it will be
important to determine whether the expressions of CYP2A genes are associated with an
increased risk for chemically induced cancer because the enzyme is involved in the
metabolic activity of aflatoxin Bi and N-nitrosodiethylamine (NDEA) (Crespi et al.,
1990; Yamazaki et al., 1992; Tiano et al., 1993)
However, the human CYP2A subfamily has not been extensively investigated, and no
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human CYP2A gene has ever been isolated. In order to characterise the genetic and
environmental factors involved in the inter-individual variability in the expression levels
of human CYP2A genes, and to study their transcriptional regulation, the CYP2A
genes need to be isolated and their structure and promoter element(s) need to be
thoroughly characterised. On the basis of studies relating to human P450 subfamilies
2A and 2B in this laboratory (Miles et al., 1989; 1990), the aims of this thesis were
therefore as follows:
1). To isolate human cytochrome P450 genes - in particular, to isolate the genes in the
CYP2A family.
29
2). To characterise the gene structure, including intron-exon junctions and promoter
region in order to understand the regulation of the CYP2A gene.
3). To define the factors involved in the transcriptional regulation of the CYP2A gene
and possible induction by xenobiotics.
4). To study the molecular mechanisms of inter-individual variation in the expression of
the CYP2A gene and the catalytic activity of the enzyme encoded by the gene.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Materials
2.1.1 Commercial material sources
Most chemicals were supplied by BDH limited, Burnfield Avenue, Thornliebank,
Glasgow, G46 7TP and Sigma Chemical Company Limited, Fancy Road, Poole,
Dorset, BH17 7NH. A list of chemicals including tissue culture materials and suppliers
is given in Appendix 1.
Human genomic library was supplied by CLONTECH Laboratories, Inc.
2.1.2 Non-commercial materials
Cytochrome P4502A antibody is a polyclonal antiserum to rat P450IIA1, supplied by
Prof. C.R. Wolf. The antiserum has been extensively characterised in this and other
laboratories, and cross-reacting protein was quantified for comparative purpose by
scanning the autoradiographs. Standard curves establishing the linearity of the method
were made by comparing the band intensities obtained on serial dilution of a
microsomal sample (Wolf et al., 1988; Miles et al., 1990; Forrester et al., 1992).
Cosmid library was a gift from Dr. D. Kioussis (Kioussis et al., 1987). It is a human




HepG2 cells were grown in Dulbecco's minimal essential medium supplemented with
15% (v/v) fetal calf serum and antibiotics (penicillin 50 IU/streptomycin 50 pg/ml). The
HepG2 cell line was derived from a childhood hepatoblastoma and has been shown to
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retain many of the different features of human liver including cytochrome P450-
dependent monooxygenase activity (Knowles et al., 1980).
COS-7 is a simian virus 40-transformed monkey kidney fibroblast cell line. The cells
were grown in Dulbecco's minimal essential medium supplemented with 10% (v/v)
fetal calf serum and antibiotics (penicillin 50 IU/streptomycin 50 (Xg/ml).
Human skin fibroblast cell line ("FEK41 was kindly donated by Dr. S. Keyse. The cells
were cultured in DMEM medium supplemented with 10% (v/v) fetal calf serum and
antibiotics (penicillin 50 IU/streptomycin 50 jig/ml).
2.2.2 Conditions for cell culture
The cell culture methods used were as described by Freshney (1987). All culture work
was conducted in a Class 2 Biological Safety Cabinet, MDH Ltd., Walworth Road,
Andover, Hampshire. The cabinet was U.V. sterilised when not in use and cleaned at
regular intervals.
2.2.3 Freezing cells for storage and retrieving stocks
Upon reaching about 80% of confluence, cells were harvested using a solution
containing 0.125% (w/v) trypsin and 0.01% (w/v) EDTA until the monolayer detached.
The trypsin was then quickly diluted out by adding growth medium containing 10%
(v/v) fetal calf serum (specific for each particular cell line) and the cells were spun
down for 5 min at 1500 rpm in a MSE Microcentaur centrifuge. The cell pellet was then
resuspended at a density of 0.5-1.0 x 106 cells/ml in 90% (v/v) fetal calf serum, 10%
(v/v) DMSO. Aliquots of 1 ml were frozen at -70°C overnight and then transferred to
liquid nitrogen for long-term storage. DMSO permeates cells rapidly and maintains
long-term viability of cell lines. To retrieve cells from storage, an aliquot was thawed at
37°C and carefully resuspended in the appropriate growth medium pre-warmed to
37°C. The cells were then seeded into a 80 cm2 tissue-culture flask. The cells were
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allowed to adhere overnight and re-fed the next morning to eliminate any dead cells or
other debris from the flask.
2.2.4 Feeding cells
Cells were fed with specific media as required by each cell line. Most cell lines required
re-feeding every 2 or 3 days to maintain optimal pH and essential growth requirements.
2.2.5 Sub-culture of cells
Just before reaching confluence, cells were sub-cultured by washing them twice in PBS
and harvesting them using a solution containing 0.125% (w/v) trypsin and 0.01%
(w/v) EDTA until the cells detached. Fresh medium with serum was then added to
inhibit the trypsin and the cell suspension was spun at 1500 rpm for 5 min. The cell
pellet was resuspended in fresh medium. To ensure accurate seeding, when required,
the cells were counted using a Neubauer haemocytometer and seeded into fresh flasks.
Most parental cell lines were sub-cultured every 3-4 days at a dilution of 1:10 to 1:15.
2.2.6 Sterility
Culturing of cells was carried out in a sterile cabinet and aseptic techniques were
employed at all times. Solutions were either sterilised in a Laboratory Thermal
Equipment 225 EH autoclave or filter-sterilised (0.2 pm pore size) before use. Testing
the sterility of media and other solutions was routinely done by inoculation of the test
solution into sterile L-broth [2%, (w/v) Bactotryptone, 1% (w/v) Bactoyeast extract,
2% (w/v) NaCl] and incubating for 4-7 days at 37°C. A turbid L-broth test was an
indication of some form of contamination and the solution could be discarded before
use. Regular mycoplasma tests were done by Mr. W. Christie, MRC Clinical and
Population Cytogenetics Unit, Western General Hospital, Crewe Road, Edinburgh.
The mycoplasma test involved staining with Hoescht 33258 fluorescent dye (Chen,
1987) and growth on selective broth (Taylor and Robinson, 1978).
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2.2.7 Preparation of fraction for cytochrome P450 estimation
Cells were grown in 80 cm2 flasks, seeded at 3 x 106 cells per flask. Following
treatment as before, the cells were washed twice in ice-cold PBS and harvested using a
solution containing 0.125% (v/v) trypsin, 0.01% (v/v) EDTA. Cold PBS was added to
the flasks following detachment of the cells and the cell suspension spun at 1500 rpm
for 5 min. The cell pellet was then resuspended in 0.5 ml cold, filter-sterilised
phosphate buffer, pH 7.4 (10 mM Na2HP04, 2 mM MgCl2, 2 mM DTT, 1 mM
EDTA). The cells were sonicated using an MSE Soniprep (amplitude 12 |im, 5 sec,
twice) with samples kept on ice. Cell disruption was assessed visually by checking an
aliquot under the microscope at 10 x magnification. The disrupted suspension was then
spun at 6000 rpm for 5 min in a microfuge. The supernatant was retained whilst the
pellet was re-suspended in 200 |il of the phosphate buffer. Both fractions were
assayed separately.
2.3 Analysis and Enzymatic Manipulation of DNA
2.3.1 Materials and solutions
Electrophoresis-grade agarose, and 1 kb DNA molecular weight markers (GIBCOBRL
Ltd). *
10 x loading buffer: 20% (w/v) Ficoll 400, 0.1M Na2EDTA, pH 8.0, 1.0% (w/v)
sodium dodecyl sulphate, 0.25% (w/v) Bromphenol Blue and 0.25% (w/v) Xylene.
TE buffer: 10 mM Tris-Cl (pH8.0), 1 mM EDTA.
5 x TBE buffer: 54 g Tris base, 27.5 g boric acid and 20 ml 0.5 M EDTA (pH 8.0).
20 x TAE buffer: 96.8 g Tris base, 22.8 ml glacial acetic acid and 40 ml 0.5 M EDTA
(pH 8.0).
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Electrophoresis working solution: 0.5 x TBE or 1 x TAE with 0.3 pg/ml ethidium
bromide.
20 x SSC: Dissolve 175.3 g of NaCl and 88.2 g sodium citrate in 800 ml of H2O.
Adjust the pH to 7.0 with a few drops of a 10N solution of NaOH, and then add water
to 1 litre.
10 x CIP buffer: 0.2 M Tris-Cl', pH 8.0, 10 mM MgCl2, 10 mM ZnCl2.
OLB (oligo-labelling buffer) consists of a mixture of solutions A, B and C mixed in a
ratio of 2:5:1 and was routinely stored at -20°C.
Solution A
2 M Tris-HCl, pH 8.0 625 pi
water 82 pi
2-mercaptoethanol (99% min) 18 pi
MgCl2 (1 M) 125 pi
10 mM dATP, dGTP, dTTP 50 pi (of each)
Solution B: 2 M Hepes, adjust pH to 6.6 with NaOH and stored at 4°C.
Solution C: Hexadeoxyribonucleotides suspended in 3 mM Tris-Cl 0.2 mM EDTA, pH
*
7.0 at a concentration of 90 A units/ml and stored at -20°C.
Denhardt's reagent: 0.02% (w/v) polyvinylpyrrolidine, 0.02% (w/v) bovine serum
albumin (BSA) and 0.02% (w/v) Ficoll 400.
2.3.2 Quantification of DNA by spectrophotometry measurement
DNA concentration was determined by measuring the UV absorption at 260 nm. For
double-stranded DNA, 5.0 pi sample was diluted to 1 ml with deionized water. For
single strand oligonucleotides, 2.0 pi sample was diluted to 1 ml and mixed
thoroughly. The absorption at 260 nm was read and the concentration was calculated
according to the following equation:
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DNA (pg) = A260x 10
where A260 *s the absorption at 260 nm. The above equation is based on the
assumption that 1 A260 corresponds to approximately 50 |lg/ml for double-stranded
DNA or 20 pg/ml for single-stranded oligonucleotides. To assess the purity of the
sample, the absorption at 280 nm is also obtained and the ratio between the readings at
A260 and A280 provides an estimate of the purity of the DNA. A pure preparation of
DNA sample has an A2go/A28o value of 1.8.
2.3.3 Agarose gel electrophoresis
The desired amount of agarose (0.8-2.0%, w/v) was added to a volume of
electrophoresis buffer and the agarose was melted in a microwave oven. The melted gel
was cooled to 50°C before pouring. DNA samples were prepared by adding 1/10
volume of 10 x loading buffer and loaded into the wells with a pipette. 1 kb DNA
molecular weight standards were used and gel electrophoresis carried out at 2 to 8
V/cm. Separation was monitored by the migration of the dyes, and the DNA visualised
using UV light and photographed.
2.3.4 Isolation and purification of DNA restriction fragment from low
i
melting agarose gel
DNA was digested with appropriate restriction enzyme(s), digested DNA fragments
were loaded onto a 1% to 2% (w/v) low melting gel (dependent on the size of DNA
fragment), and electrophoresed in 1 x TAE buffer (see Section 2.3.3). After
electrophoresis, the target band was carefully cut out and purified using a GlassMAX
DNA Isolation Spin Cartridge System (GIBCO BRL Ltd). In detail, for 0.1 g
recovered gel 450 pi of binding solution (6M sodium iodide, Nal) was added, and the
mixture was heated at 65°C until the agarose gel was fully dissolved. The 550 pi of
DNA/Nal mixture was added to the spin cartridge, centrifuged at 13,000g for 20
seconds. The spin cartridge was washed by 0.4 ml washing solution for three times,
36
then moved to a fresh tube. 40 pi of the TE buffer preheated to 65°C was added into
the spin cartridge, and then the spin cartridge with the tube was centrifuged at 13,000
rpm for 20 seconds to elute the DNA. The purified DNA was used in subsequent
manipulations.
2.3.5 Subcloning of DNA fragment
Ligation: vector and insert DNA (5 to 10 pg) was digested with appropriate restriction
enzyme(s), then the target DNA fragment was isolated and purified by low melting
agarose gel (section 2.3.4). For dephosphorylation of 5' phosphate 1/10 volume of 10
x CIP buffer and 1U CIP (Promega) was added and incubated 60 min at 37°C. For
blunt end conversion 1/10 volume of a solution containing all 4 dNTPs (0.1 mM) and
2-5 U Klenow large fragment of E.coli DNA polymerase was added and incubated 30-
60 min at 22°C. After the reaction was complete, the DNA fragment was purified by
GlassMAX DNA Isolation Spin Cartridge System (section 2.3.4). Ligation reactions
were set up as follows and incubated at 15°C water bath overnight. The ligated
recombinant plasmid DNA was transformed into competent cells according to the
protocol in section 2.4.5.
Vector DNA 100 ng
Insert DNA X ng
T4 DNA ligase lu (Weiss units)
10 x ligation buffer* 1.0 pi
H20 to final volume 10 pi
X: the calculated amount for the molar ratio of vector to insert, 1:1 to 1:3.




The amount of DNA in a Southern blotting (Southern, 1975) depends both on the
complexity of the DNA and the probe to which it will be hybridised. An amount of 1 ng
or less of a plasmid DNA will be sufficient to yield a signal that can be detected within
hours. However, 10 to 20 p,g of mammalian total genomic DNA is usually required to
yield a signal that can detected within 1 to 2 days.
DNA (10 ng to 20 |ig) was digested completely, loaded onto an agarose gel and
electrophoresed for 4 to 12 hr. Following electrophoresis the gel was photographed,
transferred to a tray containing 500 ml denaturation solution (1.5 M NaCl, 0.5 M
NaOH) with constant, gentle agitation for 60 min. The gel was rinsed twice in water
after pouring off the denaturation solution, and then 500 ml neutralisation solution (0.5
M Tris-Cl, pH8.0, 1.5 M NaCl) was added and the tray was rocked again for 60 min.
Transfer to Amersham Hybond N membrane was achieved by capillary action in 10 x
SSC for 16-20 h, and the DNA was fixed to the nylon membrane by exposing the filter
to ultra-violet irradiation (254 nm) for 30 seconds using a Stratalinker 2400. This
method is time saving and enhances the hybridisation signal compared to conventional
oven-baking (Khandjian, 1987).
2.3.7 Preparation of radiolabelled probes and hybridisation
The DNA or cDNA fragment used as a probe was isolated and purified according to the
protocols in Section 2.3.4. A small amount of a DNA fragment (50-100 ng) was
labelled to high specificity using the method of Feinberg and Vogelstein (1983). This
method was used to generate probes from denatured double-stranded DNA. The
purified DNA, mixed with a molar excess of random primers, was denatured and
synthesis was carried out using the Klenow polymerase I. This enzyme lacks 5'-3'
exonuclease activity so that the product is synthesised exclusively by primer extension.
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DNA (0.1 |lg) in a volume of 10 |il was denatured by boiling for 5 min and then 3 gil
OLB buffer was added. The reaction was kept at room temperature for 10 min, then 3
|ll of BSA (Fraction 5, Sigma, 10 mg/ml), 4 p.1 H20, 2 fil Klenow polymerase I (4
units), and 3 ptl (a-32P)-dCTP (sp. act. >3000 Ci/mmol) were added and mixed. The
radiolabelling reaction was allowed to proceed for 5 h to 16 h. Following incorporation
of radiolabel, the DNA was diluted to 100 (J.1 with TE buffer containing 15 mM EDTA
and denatured for 5 min at 100°C. 1/3 volume of reaction mixture was added to the
hybridisation solution as quickly as possible. To estimate the percentage of radioactivity
incorporated into the DNA, a 2 |il aliquot was removed from the diluted reaction
mixture and spotted onto DE 81 Whatman filter paper. A chromatography experiment
was run in 0.3 M ammonium formate, pH 8.0 for 20-60 min. The filter paper was
wrapped in Saran parafilm and exposed to Kodak X-Omat AR-5 film for 10 to 60 min.
Radioactivity incorporated into the DNA appeared as a spot at the origin whereas
unincorporated nucleotides was eluted up the paper with the solvent front.
Incorporation is routinely between 50-70%.
The membrane with DNA was placed in a glass tube with prehybridisation mixture (5 x
SSC, 5 x Denhardt's solution, 0.1% (w/v) SDS, 150-200 ]ig denatured salmon sperm
DNA) for 2-4 h at 65°C. Denhardt's reagent was used to block non-specific attachment
of the probe to the membrane surface. Following prehybridisation, denatured probe
was added directly to the prehybridisation solution and allowed to hybridise to the DNA
for 16-18 h at 65°C. After hybridisation, the membrane was washed several times in
0.1 x SSC, 0.1% (w/v) SDS at room temperature, then at 65°C for 30-60 min to
eliminate cross-reactivity to similar DNA sequences. The filter was wrapped in Saran
wrap and exposed to Kodak X-Omat AR-5 film at -70°C with intensifying screens.
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2.4 Culture of Escherichia coli and Preparation of Plasmid DNA
Initially the procedure used for large-scale and small-scale preparation of plasmid DNA
was a modification of the methods of Birmboin and Doly, (1979), Ish-Horowicz and
Burke, (1981). Qiagen kits were later employed.
2.4.1 Materials and solutions
L-broth medium (LB):
Difco bactotryptone 10 g/1
Difco yeast extract 5 g/1
NaCl 5 g/1
L-broth-agar: As for L-broth but including 12 g/1 Difco agar.
Solution I: 50 mM glucose, 25 mM Tris-Cl (pH8.0), 10 mM EDTA (pH8.0).
Solution II: 0.2 N NaOH (freshly diluted from a 10 N stock) and 1% (w/v) SDS.
Solution III:
The resulting solution is 3 M with respect to potassium and 5M with respect to acetate.
CsCl/ethidium bromide solution (Density is between 1.55 and 1.59 g/ml):
i










ethidium bromide (10 mg/rnl) 10 ml
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Buffer 1 (for competent cells preparation): 30 raM Potassium Acetate, 100 mM RbCl2,
10 mM CaCl2, 50 mM MnCl2 and 15% (v/v) glycerol. This solution should be
prepared fresh and filter-sterilised for each use.
Buffer 2 (for competent cells preparation): 10 mM MOPS, 75 mM CaCl2, 10 mM
RbCl2 and 15% (v/v) glycerol.
2.4.2 Media used for bacterial culture
L-broth and L-agar were used for the culture of DH5a in liquid and solid phase
respectively. L-agar plates with streaked out colonies were stored at 4°C for up to 4
weeks.
2.4.3 Storage of bacteria
Bacterial cells were grown in L-broth overnight with appropriate antibiotic selection.
Glycerol was added in the overnight culture to a final concentration of 15% (v/v) and 1
ml aliquots were frozen at -70°C.
2.4.4 Preparation of competent cells
The following procedure is a variation of the Hanahan method (1983), and all culture
media contain the appropriate antibiotic. A single colony from an L-agar plate was
inoculated into 10 ml LB medium and cultured overnight at 37°C with vigorous
shaking. Inoculate 200 ml of LB medium with 2 ml of overnight cultured cells in a 1.0
litre flask, shake the culture at 37°C until the OD600 reaches 0.35, chill the cells in ice
water for 1 h and collect the cells by centrifugation at 2,500 rpm for 12 min at 0°C.
Resuspend the cells in 100 ml of ice-cold buffer 1, then keep the cells on ice for 15
min, centrifuge at 2,500 rpm at 0°C for 12 min and gently resuspend the pellet in 20 ml
of ice cold buffer 2. Chill the resuspended solution on ice for 15 min. Aliquot the cells
in 0.2-1.0 ml quantities, freeze in dry ice and store at -80°C.
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2.4.5 Transformation of competent cells
An aliquot (0.2 ml) of competent cell was thawed on ice. Ligated plasmid DNA (10 to
200 ng) was added, and the cells was incubated on ice for 30 min, and heat shocked at
42°C water bath for 1.5 min. For some strains, this treatment has been reported to
increase transformation efficiency. Following the heat shock, cool the tube on ice for 1
minute, add 0.8 ml of LB medium and shake at 37°C for 1 hr to allow the cells to
recover. The cells could be plated directly or concentrated (centrifuge and resuspend the
cells in 100-200 p.1 of LB medium) before plating on an LB plate containing appropriate
antibiotic and incubated at 37°C for 12-16 h.
2.4.6 Preparation of plasmid DNA
(A) Large-scale preparation of plasmid DNA or cosmid DNA
A single colony from an L-agar plate was inoculated into 10 ml of L-broth plus
appropriate antibiotic and incubated overnight at 37°C with shaking. The culture was
seeded into 200 ml of pre-warmed L-broth plus appropriate antibiotic in a 1 litre conical
flask and incubated overnight at 37°C with vigorous shaking. The cell suspension was
spun at 5,000 rpm at 4°C for 10 min in a Sorvall RC 5B rotor. The bacterial pellet was
then resuspended in 20 ml of solution I with 2 mg/ml lysozyme, and kept on ice for 30
min to lyse the bacterial cell wall. Solution II was then added, mixed and left on ice for
5 min to further disrupt the bacterial cell membrane. To remove the SDS and the
proteins, solution III was added and the mixture was left on ice for a further 20 min.
The white precipitate was pelleted by centrifugation at 10,000 g, 4°C, for 15 min. The
supernatant, containing the plasmid DNA, was retained and isopropanol (0.7 volumes)
was added. The DNA was precipitated by keeping the solution for 30 min at room
temperature followed by a 10 min spin (10,000 g, 4°C).
The DNA pellet was resuspended in 15.5 ml of TE (10 mM Tris-Cl, pH 8.0, 1 mM
EDTA), to which caesium chloride (14.4 g) and ethidium bromide (10 mg/ml, 2.3 ml)
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were added. After the suspension was centrifuged (200,000g, 16 hour, 15°C), the
DNA bands were visualised using a short-wave transilluminator. Using a hypodermic
needle inserted into the side of the ultracentrifuge tube, the band of circular plasmid
DNA was collected as described by Maniatis (1989). For transfection, the plasmid
DNA was centrifuged a second time. The ethidium bromide was extracted using water-
saturated butanol and the DNA solution dialysed against three changes of 1,000
volumes of TE at 4°C for 16 h with stirring. The DNA was precipitated at -70°C for 60
min by adding 2 volumes cold ethanol, 0.1 volume 3 M sodium acetate, pH 4.8 and
spinning at 10,000g, 4°C for 30 min. The DNA pellet was finally washed in 70% (v/v)
ethanol, dried briefly by desiccation and redissolved in a suitable volume of TE buffer
and kept at 4°C.
IB) Plasmid DNA preparation by OIAGENE column method
The initial steps of the protocol were essentially the same as for part A. Following
addition of solution III to precipitate SDS, the mixture was centrifuged at 4°C for 30
min, 20,000g. The supernatant was carefully but promptly removed to obtain a particle-
free clear lysate. A QIAGENE column was equilibrated with 10 ml of buffer QBT (750
mM NaCl, 50 mM MOPS, 15% (v/v) ethanol, pH 7.0, 0.15% (v/v) Triton X-100) and
allowed to empty by gravity flow. The supernatant containing plasmid DNA was then
applied to the column and allowed to enter the resin by gravity flow. The column was
then washed with 2 x 30 ml buffer QC (1.0 M NaCl, 50 inM MOPS, 15% (v/v)
ethanol, pH 7.0). At pH 7.0, the solubility of DNA is reduced and it will bind to the
resin. The DNA was eluted with 15 ml of buffer QF (1.25 M NaCl, 50 mM MOPS,
15% (v/v) ethanol, pH 8.2). The DNA was then precipitated with iso-propanol ( 0.7
volumes) and centrifuged at 4°C for 30 min, 10,000g. The DNA pellet was finally
washed in 70% (v/v) ethanol, dried briefly by desiccation and redissolved in a suitable
volume of buffer and kept at 4°C.
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(C) Small-scale preparation of plasmid DNA
1.5 ml of overnight culture was poured into a microfuge tube, and centrifuged at
12,000g for 2 min at room temperature. The supernatant was removed by aspiration,
and the pellet was resuspended in 100 pi ice-cold Solution I by vigorous vortexing.
200 pi solution II was added, mixed by inverting the tube several times, then 150 pi of
solution III was added to the tube and the contents were quickly mixed by inverting the
tube several times. 450 pi phenokchloroform (1:1) solution was added, mixed by
vortexing and centrifuged at 13,000 rpm for 2 min. The supernatant was transferred to
a fresh tube. Then 2 volumes of ethanol at room temperature were added and mixed to
precipitate the plasmid DNA for 2 min. After centrifuging at 13,000 rpm for 10 min,
the supernatant was removed and the pellet was washed with 1 ml of 70% ethanol. The
pellet was allowed to dry at room temperature, and redissolved in 50 pi of TE buffer
containing DNase-free pancreatic RNase (50 pg/ml). The plasmid DNA prepared in this
method can be used in the restriction enzyme analysis.
2.5 Screening of Human Genomic Library
2.5.1 Human genomic cosmid library
*
A human genomic DNA library was constructed by Dr. Kioussis et al. (1987). Figure
2.1 shows the structure of the EBV-based shuttle cosmid vector cos202. The human
genomic DNA fragments (25-40 kb) were inserted into the Bglll site.
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Figure 2.1 Structure of cosmid vector cos202. The EB-Bam K and EB-Bam C are
fragments from Epstein-Barr virus (EBV). Amp, the ampicillin resistance gene, and RI
(.EcoRl), Cla (Cla I) and Bglll, the restriction enzyme sites.
2.5.2 Screening the library for CYP2A genes
(A) Screening of cosmid library:
The cosmid library was plated onto Hybond-N filters at a density of 100,000 colonies
per plate as follows: a dry Hybond filter was layered on to a surface of freshly made
LB-ampicillin plate to wet it. Cells were spread over the filter in a volume of 0.5 ml per
plate using a bent glass rod and then incubated at 37°C until colonies were just visible
and then stored in a refrigerator.
To make replicas, the master filter was lifted from its plate and placed colony side up on
several layers of Whatman filter paper on a flat rigid surface. A new piece of Hybond
filter was placed on a freshly made LB-ampicillin plate to allow it to become damp, then
lifted from the plate and placed on the top of the master filter and pressed hard over the
surface of the filter using the palm of the hand. A series of key holes were made
through the filters in an irregular pattern using a syringe needle dipped in water-proof
ink. The filter was peeled apart, replaced on its plate and incubated at 37°C. The master
plate was incubated at 37°C until the colonies reappeared, and then the next replica was
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made. Duplicate replicas were used for screening. For screening, the replica was laid
on a piece of 3 MM paper soaked in 0.5 M NaOH for 4 min, transferred to a similar
piece of filter paper soaked in 1 M Tris-Cl pH 7.6, left for 4 min, and then transferred
to a further piece of filter paper soaked in 1.5 M NaCl, 0.5 M Tris pH 7.6, for 4 min.
Following vigorous removal of bacterial debris from one side to the other by using
tissue paper soaked in 2 x SSC, 0.1% (w/v) SDS, the replica was washed briefly in 2 x
SSC, air dried and DNA was fixed by U.V.
(B) Screening of bacteriophage library
Place 50 ml LB supplemented with 0.2% (w/v) maltose in a sterile 250 ml flask and
inoculate with a single bacteria colony. Grow the culture overnight at 37°C with
shaking. Pellet the cells by centrifugation at 4000 rpm for 10 min at room temperature
and resuspend the cells in 20 ml of 10 mM MgSCL. Store the cell suspension at 4°C.
Mix an aliquot of the recombinant phage and an aliquot of the plating bacteria (see Table
2.1) in a culture tube and incubate 20 min at 37°C. Add molten (47°C) top agarose
(0.7%) to the tube and pour the mixture to a LB plate. Disperse bacteria and agarose on
the plate by tilting the plate back and forth. Incubate the plate at 37°C until plaques
cover the plate but were not confluent, chill the plate at 4°C for at least 1 h before
applying filter. Remove the plate from refrigerator and place a nylon filter neatly onto
the surface of the top agarose. This was accomplished by touching first one edge of the
filter to the agarose and progressively laying down more of the filter as it wets. Bubbles
should be avoided. Mark the filter in three or more asymmetric locations by stabbing
through it and into the agar beneath with an 18-gauge needle attached to a syringe
containing waterproof black drawing ink. After 30-60 seconds, remove the filter
carefully from the plate with blunt, flat forceps. Place the filter, DNA side up, on a
Whatman 3MM paper saturated with 0.5 M NaOH, 1.5 M NaCl for 5 min, then
transfer the filter, DNA side up, to another 3MM paper saturated with 0.5 M Tris (8.0),
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1.5 M NaCl for 5 min. Rinse the filter in 2 x SSC, and place it, DNA side up, on paper
towers to dry for 30 min. Up to 5 replicas can be made from each plate.
The human genomic DNA libraries were screened using a 0.7 kb CYP2A6 cDNA
(Miles et al., 1988) as a probe. The hybridisation and washing conditions were as
described for Southern blotting in section 2.3.6.
Table 2.1 Recommended mixtures for plating bacteriophage libraries (Adapted from
Ausubel et al., 1987)
Plate Size
LB plate ingredient 82 mm 150 mm 245 x 245 mm
Plating Bacteria (ml) 0.2 0.5 2.0
Phage, pfu 5000 20,000-30,000 150,000
Top agarose (ml) 3.0 7.0 30
2.6 DNA Sequencing
The dideoxy chain-termination method (Sanger et al., 1977) was used with (a-35S)-
i
dATP (400 Ci mmoH) to sequence double-strand DNA cloned in pUC18, pCAT-basic
plasmid (Promega) or other vectors. Sequences were compiled and analysed using
Gene Jockey software. The sequencing procedure was as follows.
Plasmid DNA was made from 10 ml overnight culture according to the small-scale
preparation of plasmid DNA in section 2.4.4.C. Following ethanol precipitation,
redissolve the DNA pellet in 150 |il TE buffer, transfer an aliquot of 50 pi to a fresh
tube, then add RNase A to 100 pg/ml. Keep the tube at 37°C overnight, then add 30 pi
of PEG solution [20% (w/v) polyethylene glycol 6000/ 2.5 M NaCl], mix and chill the
tube on ice for at least lh to precipitate DNA. The aim of PEG precipitation is to
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remove the digested RNA from the DNA pellet. After centrifugation, wash the DNA
pellet with 70% (v/v) ethanol at room temperature and redissolve the DNA in 54 pi TE
buffer (for three sequence reactions). Transfer an aliquot of 18 pi to a fresh tube, add 2
Hi of 2 N NaOH to denature the DNA at room temperature for 5 min, and then add 8 pi
of 5M ammonium acetate (pH 7.5) to neutralise the reaction. Add 4 volumes of ethanol
at 0°C to the tube, mix, and store the solution at -80°C for 30 min. Recover the
denatured plasmid DNA by centrifugation at 13000 rpm for 12 min in a microfuge.
Carefully remove and discard the ethanol. Leave the tube open on the bench until the
last traces of ethanol have evaporated. Dissolve the DNA in 7 pi of water. The
sequencing reaction is carried out using a Sequenase Version 2.0 DNA Sequencing Kit
and according to the protocols supplied by United States Biochemical.
Briefly, add 2 pi reaction buffer, 1 pi primer, anneal by heating 2 min at 65°C and then
cool slowly to below 35°C over 30 min. While cooling, dilute the Labelling Mix 10-
fold with distilled water (e.g. 1 pi of Mix combined with 9 pi of water). Dilute the
sequenase 2.0 enzyme 1:8 in ice-cold enzyme dilution buffer. To the annealed template-
primer (10 pi) mixture, add diluted Labelling solution 2 pi, DTT 1 pi, (a-35S)dATP
(>400Ci/mmol) 0.5 to 1 pi and diluted sequenase 2 pi (3 units). Mix the reaction
thoroughly and incubate for 2-5^min at room temperature. Remove 3.5 pi reaction
mixture to the tube labelled G, in which 2.5 pi ddGTP has been added and prewarmed
at 37°C. Similarly transfer 3.5 ml reaction mixture to A, T and C tubes with 2.5 pi
ddATP, ddTTP and ddCTP, respectively. Mix and return them to the 37°C water bath.
After incubation for 2-5 min, add 4 pi of stop solution to each of the termination
reactions and mix. When the 6% denaturing gel was ready for loading, heat the samples
to 75-85°C for 2 min and load immediately on the gel with 2-4 pi in each lane.
2.7 Strategies for Studying Gene Regulation and Expression
The DNAs for transfection were prepared by the alkaline lysis method and purified
either by filtration (QIAGENE), or CsCl density gradient centrifugation (Section 2.4.6,
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Figure 2.2 Comparison of plasmid DNA prepared by caesium
chloride/ultracentrifugation or by QIAGEN filtration.









B: Comparison of transfection efficiency. NIH3T3 cells were transfected with the
plasmid pRSVlacZ which were prepared with QIAGEN or by CsCl. Data from Ehlert et




A and B). The transfection efficiencies of DNAs prepared by different methods is
shown in Figure 2.2.
2.7.1 Buffers
All buffers used in transfection were sterilised by autoclaving or filtration with a 0.2 p
filter.




Adjust the solution to pH 7.08 (at room temperature) with about 6 ml of IN NaOH.
DEAE-dextran: 10 mg/ml in PBS (Ca2+-Mg2+-free; GEBCO).
6-Galactosidase assay 2 x buffer (Promega Corporation, Madison):





2.7.2 Introduction of fused genes into mammalian cells by calcium
phosphate co-precipitation
For preparation of the constructs containing the deleted 5' flanking sequence of the
CYP2A7A, the DNA of pCAT2A7A5'-3.0 was double digested with Hindlll and
another enzyme which only digests the 3 kb insert of pCAT2A7A5'-3.0. Digested
DNA fragments which contained a pCAT-basic vector and different sizes of 5'
truncated insert were isolated, blunted and re-ligated to form the various constructs:
pCAT2A7A5'-2.2 (Hindlll-Sstl), pCAT2A7A5'-1.5 (Hindlll-EcoRY), pCAT2A7A5'-
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1.0 (Hindlll-BgllY), and pCAT2A7A5'-0.5 {Hindlll-Aval) (See chapter 3, Figure
3.12A).
The other series of constructs containing a 5' truncated promoter of CYP2A7A were
obtained by digesting the plasmid pCAT2A7A5'-0.5 DNA with Bal31 as follows: 20
pg pCAT2A7A5'-0.5 DNA was cleaved with Hindlll, and then treated with 5 units
Bal3l (BRL) for 15-30 min. Xhe aliquots were removed at different time points and
instantly chilled on ice. All aliquots were combined, purified by phenol/chloroform
extraction and ethanol precipitation. The pellet was redissolved in water, blunted using
Klenow polymerase I. BamHl digestion was carried out to remove the part of the
vector which was also deleted during the Bal31 digestion. The fragments containing the
progressively deleted insert and the vector (the part from insert to BamHl site) were
purified. These fragments were then ligated into the previously prepared part of pCAT-
basic vector having a blunted Hindlll end and a BamHl sticky end to form a series of
constructs (See chapter 3, Figure 3.12B).
The cultured cells were seeded as described by Chen and Okayama (1987) at a density
of 0.5-1.0 x 106 cells per 100-mm petri dish the day before transfection (See section
2.2.2). On the day of transfection, the cells were re-fed with fresh medium and
continually cultured for 3 h. The 6NA-calcium phosphate coprecipitate were prepared
as follows: 10 pg of test plasmid DNA and 5 jig of the standard plasmid DNA (pSV-B-
Galactosidase plasmid, Promega Corporation, Madison) in a volume of 438 pi were
mixed with 62 pi of 2 M CaCb solution. The mixture was dropped slowly into another
tube containing 500 pi of 2 x HBS solution with shaking and then allowed to stand at
room temperature for 20 to 30 min. The calcium phosphate-DNA suspension was
mixed gently and added directly to the medium on top of the cell monolayer. Four
hours later, the cells were subjected to a 15% (v/v) glycerol/1 x HBS shock for 2 min.
Cells were harvested 48 to 60 hr after transfection .









2.7.3 DEAE-dextran-mediated DNA transfection
DEAE-Dextran-mediated DNA transfection (Cullen, 1986) is a simple and efficient
procedure which is specifically tailored for transient expression in COS cells. This
protocol has been reported to yield transfection frequencies as high as 80%.
The COS cells were seeded at a density of 0.5 x 106 cells per 100-mm petri dish and
incubated at 37°C for overnight. Next day, the plate should be just subconfluent.
Prepare transfection cocktail in a Eppendorf tube as follows: Add plasmid DNA into
PBS solution (1.9 ml), vortex. Add 100 Hi of DEAE-dextran into the DNA solution
and mix. Aspirate culture medium from culture dish and rinse cells with 2 ml of PBS
warmed to 37°C and aspirate the PBS. Add transfection cocktail on top of the cell
momolayer and distribute evenly by tilting plate. Incubate at 37°C for 30 min with
occasional gentle shaking to prevent drying. Add 5 ml of culture medium supplemented
with 80 hM chloroquine and incubate at 37°C for 2.5 h. Aspirate supernatant medium
and replace with 3 ml culture medium containing 10% DMSO for 2.5 min. Remove the
medium and add 10 ml of fresh medium. Incubate the cells at 37°C for 48-60 h.
2.7.4 CAT activity assay
The CAT assay was carried out as follows ((Promega, protocols and applications
guide): Transfected cells were washed 5 times with phosphate-buffered saline (PBS,
Ca2+' Mg2+-free; GIBCO) and resuspended in 100 ul of 250 mM Tris-Cl, pH7.5. Cell
lysates were prepared by freezing (-70°C) and thawing (37°C) for four cycles with
vortexing after each freezing-thawing cycle, incubated at 60°C for 10 min to inactivate
*
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the endogenous acetylase and then centrifuged in a microfuge for 10 min. The reaction
mixture is prepared as follows:
0.25M Tris-HCl, pH8.0
(14C) chloramphenicol
n-butyryl coenzyme A (5 mg/ml)
cell extract 50 pi
60 pi
10 jil*
5 pi (final volume 125 pi)
* l|ll (14C) chloramphenicol was diluted to 50 pi (0.5 pCi/ml)
Incubate the reaction at 37°C for two hours. Terminate the reaction by adding 300 pi of
xylene to each tube and shake by vortex for 30 seconds. Following centrifugation for 3
min, transfer 270 pi the upper phase (xylene) to a fresh tube. Add another 100 pi of
fresh 0.25 M Tris buffer, pH 8.0, to wash the xylene phase by repeating the vortex and
centrifugation. Carefully remove 200 pi of the upper, xylene phase and transfer it to a
scintillation vial. Add 5 ml scintillation fluid and count the samples in a liquid
scintillation counter.
For B-galactosidase assay, add the following reaction mixtures directly to the wells of
microtiter plates which has a maximum well volume of approximately 300 pi:
Positive control: *
G-galactosidase assay 2 x buffer 50 pi
G-galactosidase 0.025 u*
water to final volume 100 pi
* diluted in water on ice from 1 u/lpl stock, prepared immediately before use.
Negative control:
B-galactosidase assay 2x buffer 50 pi
non-transfected cell extract 30 pi
water to final volume 100 pi
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Sample reaction:
G-galactosidase assay 2x buffer 50 pi
transfected cell extract 30 pi
water to final volume 100 pi
Mix all samples by pipetting well contents up and down, and incubate the reaction at
37°C for 2 h until a yellow colqur is present. Stop the reaction by adding 150 pi of 1M
sodium carbonate and mix by pipetting the contents of each well up and down.
Absorption at 420 nm was measured.
2.8 Preparation and Analysis of RNA
2.8.1 Materials and buffers
4 M guanidinium solution (500 ml): 236.5 g guanidinium thiocyanate, 3.23 g (25 mM)
NaCitrate, 0.5% (w/v) Sodium lauryl sarcosinate. Add deionized water to 500 ml and
adjust pH to 7.0 with NaOH solution.
5.7 M CsCl solution (100 ml): 96 g CsCl, 37.2 g EDTA (0.1 M). Add ddH20 to 100
ml and adjust pH to 7.0 with NaOH solution.
solution D: 4 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0; 0.5% (v/v)
sarcosyl and 0.1 mM 2-mercaptoethanol.
10 x MOPS (1000 ml): 40.86 g MOPES, 6.8 g Na-acetate 3 H20 and 50 ml of 0.2 M
EDTA. Add H20 to 800 ml, adjust pH to 7.0 with NaOH solution and then add H20 to
1000 ml. Keep the solution in cold (4 °C) and in dark place.
2.8.2 Guanidinium method for total RNA preparation from tissue culture
cells
RNA preparation was carried as described by Ausubel et al. (1987). The cultured
monolayer cells were washed twice, each time with 5 ml PBS. 5 ml 4 M guanidinium
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solution was added to the cells (150 mm culture dish) and the cells should immediately
lyse. The resultant extremely viscous solution was recovered by scraping the culture
dish with a rubber policeman, transferred to a clean tube and homogenised with a
whole glass homogeniser and a pestle (type A). The resulting homogenate was drawn
up and down five times through a 20-G needle. It is critical that chromosomal DNA is
sheared in this step in order to reduce viscosity and remove complete in the following
centrifugation step. The cell lysate (5 ml) was carefully layered on top of CsCl cushion
(5 ml 5.7 M CsCl ) to create a step gradient and the interface should be visible. The
sample was centrifuged at 35,000 rpm in a Beckman SW-55 rotor (or equivalent) 12 to
18 hr at 15°C. after centrifugation the supernatant was carefully removed. The pellet
was drained for 5 to 10 min, then resuspend it in 300 (il water and transferred to a clean
tube. The RNA solution was extracted twice with same volume of phenol/chloroform,
one time with chloroform/butanol and then precipitated with 1/10 volume of 3 M
sodium acetate and 3 volume of cold ethanol at -20°C for at least 1 hr. After
centrifugation the RNA pellet was resuspended in a minimum volume of water and
stored at -70°C until required.
2.8.3 Single-step preparation of RNA from tissues and cells
The single-step method of RNA preparation (Chomczynski et al ,1987) allows isolation
of RNA in 4 hr and provides both high yield and purity of undegraded RNA
preparation. In addition, this procedure permits recovery of total RNA from small
quantities of tissue as well as cultured cells
0.1 g frozen tissue was minced on ice and homogenised (at room temperature) with 1
ml of solution D in a glass-Teflon homogeniser and subsequently transferred to a clean
tube. Sequentially, 0.1 ml of 2 M sodium acetate, pH 4, 1 ml of phenol (water
saturated), and 0.2 ml of chloroform-isoamyl alcohol mixture (49:1) were added to the
homogenate, with thorough mixing by inversion after the addition of each reagent. The
final suspension was shaken vigorously for 10 seconds and cooled on ice for 15 min.
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The mixture was centrifuged at 10,000g for 20 min at 4°C. After centrifugation, RNA
was present in the aqueous phase whereas DNA and proteins were present in the
interface and phenol phase. The aqueous phase was transferred to a fresh tube, mixed
with 1 ml of isopropanol, and then placed at -20°C for at least 1 hr to precipitate RNA.
Sedimentation at 10,000g for 20 min was performed and the resulting RNA pellet was
dissolved in 0.3 ml of solution D, the solution was transferred into a 1.5 ml Eppendorf
tube, and precipitated with 1 vol. of isopropanol at -20°C for 1 hour. After
centrifugation for 10 min at 4°C the RNA pellet was washed with 75% ethanol,
pelleted, dried, and dissolved in a minimum volume of water and stored at -70°C until
required. The purity of the RNA was further increased by repeating precipitation steps
once or twice. Isopropanol precipitation can be replaced by precipitation with three
volumes of ethanol.
2.8.4 Quantification of RNA
RNA concentration is determined like the DNA determination described in section
2.3.2. 3.3 pi of RNA solution was diluted to 1 ml with ddP^O and mixed thoroughly.
The absorption at 260 nm was read and the concentration was calculated according to
the following equation:
RNA (pg)= A260 x 10
The above equation is based on the assumption that 1 A260 = 33 pg RNA. A pure RNA
sample has an A260/A280 ratio of 2.0
2.8.5 Primer extension analysis
Primer extension analysis (Ausubel, et al., 1987) was carried out as follows: A 22-mer
oligonucleotide was synthesised corresponding to positions 52-73 bp of the CYP2A7
cDNA in the antisense orientation, 5'-GCCAGACAGACATCAAGACCAT-3'. Total
RNA (50 pg) was coprecipitated with the (y-32P)ATP end-labelled oligonucleotide
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prepared using T4 polynucleotide kinase and the pellet was then resuspended in
hybridisation buffer [80% (v/v) formamide, 40 mM PIPES, pH 6.4, 400 mM NaCl
and 1 mM EDTA] and hybridised at 30°C for overnight. The mixture was ethanol-
precipitated and resuspended in 50 mM Tris-Cl, pH 8.3, 5 mM MgCl2, 50 mM KC1,
10 mM dithiothreitol, 0.8 mM each of dNTPs, 0.5 unit RNasin and 40 units of avian
myeloblastosis virus reverse transcriptase (BRL), in a reaction volume of 25 jxl.
Extension reaction was carried out for 1.5 hour at 42°C, and terminated by adding 1 pi
0.5 M EDTA and 1 pi RNase A (1 mg/ml) at 37°C for 30 min. Following ethanol-
precipitation and resuspension in 8 pi of denaturing dye buffer, the reaction products
were run on a 6% polyacrylamide, urea gel. Labelled products were sized by a standard
DNA sequencing reaction.
2.8.6 Amplification of RNA (RT-PCR reaction)
(A) Reverse transcription reaction
The following reagents were assembled in a final volume of 20 pi: 2 pi of 10 x PCR
buffer (Promega Ltd.), 10 pi of 2 mM each dNTP solution, 0.5 pi of RNasin (40
unit/pl, Promega Ltd.), 1 pi of oligo(dT)6-8 solution (0.1 pg/ pi), 1 pi of 100 mM
MgCl2 solution, 1-5 pi of total.^RNA sample (5-10 pg), and 200 to 400 units of
MoMuLV reverse transcriptase. The reaction was incubated 15 min at 23°C, then 60
min at 43°C, and transferred to 95°C water bath for 10 min. After heat treatment the
reaction was quick-chill on ice.
(B) PCR amplification
To the heat-treated reverse transcription reaction, 80 pi of 1 x PCR buffer was added
containing 10 to 50 pmol each of upstream and downstream primer and 2.5 units of
Taq polymerase. Then 100 pi of mineral oil was added on the top of the PCR solution
to prevent evaporation of liquid during thermal cycling. A thermal cycle profile was: (1)
denaturing for 1 minute at 94°C, (2) annealing primers for 1 minute at 55°C, (3)
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extending the primers for 2 min at 72°C. After 30 to 35 cycles the reaction was
incubated at 72°C for 8 min, then 5 to 10 pi was used for analysis in a 1% (w/v)
agarose gel.
2.8.7 Northern blot and hybridisation analysis
The following mixture should be prepared for each RNA sample to be analysed
(Ausubel, et al., 1987):
formamide 4 pi
formaldehyde 1.6 pi
10 x MOPS 1.2 pi
RNA (10-15 pg) 3.2 pi
Mix the samples well by vortexing, and incubate at 65°C for 20 min. Add 2 pi loading
buffer (same as that used in DNA electrophoresis) to each sample and load the samples
along with 3 pi of an RNA ladder (0.24-9.5 kb derived from bacteriophage T7, yeast 2
p circle and bacteriophage lambda DNA. BRL, Paisley, UK.) onto gel. Run the gel in
lx MOPS at a constant voltage of 5 V/cm for 3-5 h. The transfer of the RNA from gel
to a Hybond-N filter was same to the procedure in Southern blot (Section 2.3.6) except
that there was no denaturing and neutralising treatment.
*
After the transfer was completed, the filter was placed in hybridisation mixture [50%
(v/v) formamide, 5 x SSC, 5 x Denhardt's solution, 0.1% (w/v) SDS, 50 mM sodium
phosphate, pH 6.5 and 50-100 pg/ml denatured salmon sperm DNA] for at least 4 h at
42°C in a glass tube in a preheated oven. Probe, prepared and radiolabeled as
described in Sections 2.3.4 and 2.3.7, was added directly to the hybridisation solution
following denaturation. The reaction was incubated for 16-18 h at 42°C. The filter was
washed 3 times in 2 x SSC, 0.1% (w/v) SDS. Higher stringency washes of 0.2 x
SSC, 0.1% (w/v) SDS at room temperature were carried out for 15 min. After washing
the filter was wrapped in Saran wrap and exposed to Kodak X-Omat AR-5 film at
-70°C in a cassette with intensifying screens.
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2.9 Analysis of Proteins
2.9.1 Protein estimation
Protein concentration was determined spectrophotometrically according to Lowry et al
(1951), using serial dilution of bovine serum albumin (BSA) to generate a standard
curve for each assay. The absorption obtained at 600 nm was linear over the range 0-
200 pg/ml, and all samples were therefore diluted (0.1 M NaOH) to lie within this
range.
2.9.2 Denaturing gel electrophoresis (SDS-PAGE)
SDS-PAGE gel electrophoresis was carried out according to the method of Laemmli
(1970). All protein samples were analysed by SDS-PAGE prior to immunoblotting to
demonstrate equivalence of loading and to ensure that the samples were not degraded.
Samples were prepared for electrophoresis by dilution in distilled deionised water to a
concentration of 3 mg/ml of total protein, before the addition of an equal volume of
"boiling mix" (0.05 M Tris-HCl pH 8.0, 2% (w/v) SDS, 5% (v/v) G-mercaptoethanol,
10% (v/v) glycerol, 0.005% (w/v) bromphenol blue) to give a final protein
concentration of 1.5 mg/ml. Proteins were denatured by heating to 100 °C for 5 min.
For Coomassie Brilliant Blue stairifed gels, 15 jig of total cellular protein was loaded per
track. Molecular weight markers containing alpha-lactalbumin (Mr= 14200), soybean
trypsin inhibitor (Mr=20100), trypsinogen (Mr=24000), bovine erythrocyte carbonic
anhydrase (Mr=29000), rabbit muscle glyceraldehyde-3-phosphate dehydrogenase
(Mr=36000), chicken egg albumin (Mr=45000) and bovine serum albumin
(Mr=66000) were prepared according to the manufacturer's instructions and were
loaded at 10 pi per track. SDS-PAGE gel (0.15 cm) was cast using Biorad Protean II
electrophoresis apparatus. Separating gel composition was dependent on the particular
protein, for example P4502A proteins were separated by electrophoresis in a 10% gel.
The gel composition is given as below:
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10% Separating gel: 9.65 ml 40% (w/v) acrylamide, 6.65 ml 2% (w/v) bis-acrylamide,
10 ml 1.5 M Tris (pH8.8), 0.8 ml 10% (w/v) SDS, 13 ml ddH20, 400 p.1 10% (w/v)
APS, 20 [ll TEMED.
4.5% Stacking gel: 1.23 ml 40% (w/v) acrylamide, 0.85 ml 2% (w/v) bisacrylamide,
1.25 ml 1.0 M Tris-Cl (pH6.8), 0.1 ml 10% (w/v) SDS, 6.4 ml dH20, lOOjll 10%
(w/v) APS, 10 ^tl TEMED.
Gels were poured to a height of 12 cm and immediately overlaid with the water
saturated isobutanol. The rapid separation of this mixture into organic and aqueous
phases resulted in an even boundary forming at the interface with the gel. Once set, the
butanol overlay was removed and the gel rinsed several times with dH20, before a
stacking gel was poured to the top of the separating gel and a well-forming comb (15
tracks) inserted. When the stacking gel had set, the plate assemblies were securely
attached to the central cooling reservoir of the Protean II apparatus and the position of
the wells clearly marked. The top buffer chamber was filled with freshly prepared
electrophoresis buffer [5 mM Tris, 50 mM glycine, pH 8.3 and 0.02% (w/v) SDS],
and the combs carefully removed. Samples were loaded before the entire apparatus was
placed in a gel tank containing 3 litres of electrophoresis buffer. Gels were run (60
mA/gel stacking, 30 mA/gel separating) with cold water cooling and with continuous
mixing of the electrophoresis buffer to minimise any build-up of buffer gradients.
When the dye front was approximately 1 cm from the bottom of the plates,
electrophoresis was stopped, and the gels removed from the glass plates. The gel can
be stained with Coomassie Brilliant Blue , or used for a western blot.
(A) Staining SDS-PAGE gel with coomassie brilliant blue
The gel was immersed in staining solution [0.25% (w/v) Coomassie Brilliant Blue in
45.5% (v/v) methanol, 9% (v/v) acetic acid] with slow shaking for 4 h at room
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temperature, then destained in the solution of 10% (v/v) methanol, 9% (v/v) acetic acid
to visualise the protein bands.
(B) Immunoblotting (Western blotting)
Immunoblotting was performed essentially as described by Lewis et al. (1988). After
electrophoresis, the gel was removed from the glass plates, and then a gel/membrane
"sandwich" was assembled as follows: A large basin was filled with transfer buffer [20
mM sodium orthophosphate 12 H20, 20% (v/v) methanol], into which was placed a
plastic cassette containing a nylon "Scotchbrite" pad, a sheet of 3 mm filter paper cut to
a size slightly larger than the gel was put on top of the nitrocellulose filter, covered with
another sheet of filter paper, a further nylon pad and the cassette were closed, thus
clamping the gel sandwich firmly together. Each gel was assembled in a similar
manner, and the cassette(s) was placed in a Biorad transblot apparatus containing
freshly prepared transfer buffer. Proteins were then transferred electrophoretically (250
mA, overnight) from the gel to the nitrocellulose sheet. Following transfer, the
nitrocellulose filter was cut to an exact replica of the gel and was placed in a plastic
container containing sufficient TBST [0.9% (w/v) NaCl, 0.6% (w/v) Tris-Cl, pH 7.9
and 0.05% (v/v) Tween-20] to cover the filter. The filter was washed twice with TBST
for 5 min, and then incubated with the blocking solution [5% (w/v) low-fat dried milk
in TBST] for 1-2 h. The filter was further washed with TBST (1x15 min, 2x5 min),
before being incubated with the first antibody (rabbit anti-CYP2A antibody, diluted
1:500 to 1:1000 in TBST) for 1 hour. After washing with TBST (3 x 10 min) to
remove excess unbound first antibody, the filter was placed in the HRP-labelled second
antibody (donkey anti-rabbit IgG-HRP for monoclonal primary, diluted 1:1000 in
TBST) for 1 hour. After washing with TBST (3 x 10 min), freshly prepared substrate
solution [0.05% (w/v) 4-chloro-l-naphthol, 17% (v/v) methanol, 0.01% (v/v)
hydrogen peroxide in TBS] was added, and the immunoreactive polypeptides were
visualised by the appearance of purple bands on the filter. For higher sensitivity, the
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filter was washed in distilled water for 15 min with shaking and then placed in 50 ml
TBST containing 50 flCi (0.19 MBq) 125I-protein A (Amersham International, pic).
After 30-60 min, the filter was exhaustively washed with TBST and subsequently
exposed (Kodak X-Omat AR5 X-ray film) 1-3 days with intensifying screens at -70°C
in an autoradiography cassette. When the amount of the protein of interest was
particularly low, enhanced chemiluminescent detection (ECL) was used (Amersham
International, pic). This technique relies on the generation of an unstable photodynamic
complex on reaction of H202, HRP-labelled secondary antibody and the cyclic
diacylhydrazine luminol. Dissociation of this complex results in luminol returning to its
ground state with associated light emission. The amount of light emitted is directly
proportional to the amount of immobilised protein bound to the HRP-labelled
secondary antibody.
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CHAPTER 3: ISOLATION AND CHARACTERISATION OF THE
HUMAN CYP2A7A GENE
3.1 The Background of CYP2 Gene Family: Structure and Regulation
3.1.1. The methods used for isolation of CYP genes
Since DNA was found as the active genetic principle, studies in the field of molecular
biology have made rapid progress catalysed by many theoretical and technical
advances. During this period the technique of DNA cloning also developed rapidly, and
it became possible to construct genomic DNA or cDNA libraries in the late 1970s when
Maniatis et al. (1978) devised a strategy to generate and clone large numbers of random
fragments of mammalian genomic DNA. This progress gave a vigorous push to the
understanding of cytochrome P450s at the molecular level. More than 220 genes of
cytochrome P450 have been isolated during the last decade. The strategy of isolating
and characterising P450 genes is illustrated in Figure 3.1.
Briefly, RNA is isolated from the appropriate tissue, usually from liver in which there
are high levels of P450 except for those with a tissue-specific manner of expression.
The double-stranded cDNA is synthesised from the isolated mRNA and inserted into a
vector which allows the inserted cDNA to generate a protein product. The protein can
be detected with a specific antibody, or the clone containing an interesting cDNA
fragment can be isolated from a population of thousands of diverse cDNAs by
screening with an oligonucleotide probe.
After the cDNA has been isolated, it can be used as a probe to screen a genomic DNA
library to get its corresponding genomic clone. The genomic library is constructed from
total DNA isolated from cultured cells or tissues. Total DNA is partially digested with a
restriction enzyme and then fragments ranging from 15-20 kb in size are inserted into a
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Figure 3.1 The basic strategy of isolating a P450 gene.
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Lambda phage cloning vector, or fragments ranging from 30-45 kb in size are inserted
into a cosmid vector which is suitable to isolate a full length of gene in one clone
(Figure 3.2).
The cDNA and genomic DNA clones of P450 can be used in a variety of studies in
pharmacology and molecular biology. The cDNA can be used to determine the amino
acid sequence of an enzyme. The human P450 can be heterologously expressed in E.
coli or yeast cells to obtain a protein for further studies. The genomic DNA can be used
to determine the structure of a P450 gene and to identify the important regulatory
domains which can be used to isolate and characterise receptors and factors required for
control of gene expression.
3.1.2 The structural features of CYP2A subfamily genes
The CYP2A subfamily has been extensively studied in the rat and the mouse. Three
genes of rat CYP2A subfamily have been isolated and sequenced recently, and the
genomic structures of the CYP2A1 and CYP2A2 genes have been described
(Matsunaga et al., 1990). These genes contain nine exons, in common with other
CYP2 family genes. The size of the CYP2A1 gene is almost twice as long as CYP2A2
or CYP2A3 due to a 14 kb fifth intron in CYP2A1. The 5'-flanking region of CYP2A1
t
contains a typical TATA box at -27 to -24 bp and a reverse CCAAT box at -85 to -90
bp upstream of the transcription start site. The CYP2A2 gene also has a typical TATA
box at -24 bp, but contains no CCAAT box. In vitro transcription of the CYP2A1 and
CYP2A2, both genes were accurately transcribed in extracts prepared from livers of
male and female rats. This result is surprising in view of the fact that the CYP2A1 is
expressed only in adult female rats while the CYP2A2 is expressed in adult males
(Nagada et al, 1987).
Two genes of the mouse Cyp2a subfamily, designated Cyp2a-4 and Cyp2a-5, have
been isolated and sequenced (Lindberg et al., 1989). The comparison between the two
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Table 3.1 The genes in CYP2A subfamily and their chromosomal location
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Ueno and Gonzalez 1990
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Yamano et al., 1990
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Yamano et al., 1990
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Nelson et al., 1993
Nelson et al., 1993
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genes, each about 8 kb in size, exhibits virtually identical exon-intron organisation and
over 96% nucleotide sequence homology, including both 5'- and 3'-regions. Both
genes have TATA boxes at 30 bp and CAAT boxes at 100 bp upstream from the
transcription start site. The Cyp2a-4 is expressed predominately in female liver, male
kidney, and the Cyp2a-5 is mainly activated in female liver and kidney (Squires et al.,
1988). In order to gain some insight into the sex-specific transcriptional of these Cyp2a
genes, the mRNAs from these' different tissues were used as templates to determine
transcription start site. The results demonstrated that there was not sex-specific
transcriptional start site and both genes have similar multiple start sites in all tested
tissues even after digestion with the highest tested amount of mung bean nuclease (400
units). The high amount of nuclease was used to avoid incomplete digestion. Two
major start sites were at 24 bp and 14 bp upstream from the initiation codon,
respectively.
Up to date, there is no report about the structure of the human CYP2A gene. It was the
aim of this study to characterise structure and regulation of the human CYP2A genes.
3.1.3 The multiple control of CYP2 gene expression
Eukaryotic genes are under the control of transcription factors which bind to
♦
promoter/enhancer elements to regulate transcription. Some of these factors are active
only in the presence of an inducing stimulus or in a specific tissue, thereby producing a
specific pattern of inducible or tissue-specific gene expression. In addition, some
factors are constitutively active binding to specific upstream sequences. The binding of
these factors and their interaction with basal transcriptional complex result in normal
levels of transcription in all tissues. In the absence of such factors, therefore, the basal
transcriptional complex can produce only a very low level of transcription.
The expression of genes in CYP2 family is under the control of different regulation
mechanisms, probably including receptors which are responsible for the induction of
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foreign chemical and some tissue-enriched transcriptional factors that control
constitutive expression. Developmental and sex-dependent regulations have also been
described (Gonzalez, 1990). Although a suitable cell culture system is lacking for
defining the regulatory elements of the inducible CYP2 genes, especially the human
inducible CYP2 genes, recent studies on rodent CYP2 genes and bacterial CYP102
genes have made some progress for understanding cis-regulatory mechanism(s).
Several models for the expression of these genes are reviewed below:
(A) Induction response of CYP2 genes
Of great interest are the mechanisms by which large numbers of foreign chemicals can
induce specific CYP genes to increase transcription. A well studied case is induction by
barbiturates. A number of genes in CYP2 and CYP3A subfamilies are induced by
phenobarbital and the induction occurs at the level of transcriptional activation,
involving an increase in the synthesis ofmRNA and in the rate of transcription initiation
(Omiecinski et al., 1985; Honkakoski et ai, 1992; Hahn et al., 1991). The two major
phenobarbital-inducible forms are rat CYP2B1 and CYP2B2 genes (Hardwick et al.,
1983). Phenobarbital administration to rat causes a dramatic increase in the level of
CYP2B mRNA (Omiecinski et al., 1986). Another phenobarbital-inducible gene is
rabbit CYP2C which is induced b^ a similar mechanism as CYP2B (Zhao et al., 1990).
Unfortunately, to date, the kind of factors or receptors are involved in the phenobarbital
induced expression of CYP2 genes in mammals still remains to be elucidated because
expression is not phenobarbital-inducible in cultured cell lines. However, progress has
been made recently in the bacterium Bacillus megaterium (He and Fulco, 1991).
CYP102 (P450bm3) is one of the barbiturate inducible genes in this bacterium which
incorporates both P450 and P450 reductase in a single soluble 119-KDa polypeptide.
CYP102 is involved in the metabolism of fatty acids, and the mechanism of barbiturate
inducible expression of CYP102 has been partially characterised (Shaw and Fulco,
1993). Comparing the sequences between the CYP 102 gene and other barbiturate
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inducible genes, a 15 bp element, ATCAAAAGCTGGAGG, was found existing in the
rat CYP2B1 and CYP2B2 genes. A protein in the extracts prepared from normal
Bacillus megaterium cells binds strongly to the 15 bp element, but this binding is
dramatically blocked with protein extracts from phenobarbital treated cells. Conversely,
the 15 bp homologues in rat CYP2B1 and CYP2B2 genes are weakly bound by a
protein in untreated nuclear extracts of rat, but the binding is much stronger with the
protein from phenobarbital treated rats, suggesting a different regulation mechanism
with that of bacterial CYP102 gene.
The protein binding to the 15 bp element in Bacillus megaterium is identified as the
Bm3Rl repressor, and the gene encoding the protein is located upstream of the
CYP102 gene (Shaw and Fulco, 1993). The Bm3Rl repressor binds specifically to a
palindromic 20-bp site in the promoter-operator region of the Bm3Rl gene to inhibit
transcription of the gene. The binding between Bm3Rl repressor and its operator,
identified by in vitro gel retardation studies, is strongly blocked by addition of 2 mM
phenobarbital, but not by addition of non-inducer. However, it is still unclear whether
the phenobarbital acts directly as depicted in Figure 3.3 or indirectly to release the
repressor from the operator.
Figure 3.3 shows the elements Which have been proposed for this regulation. A
palindromic 20-bp site is located upstream of the open reading frame of Bm3Rl and
interacts with the Bm3Rl protein. It is believed that Bm3Rl repressor binds tightly to
this motif to inhibit transcriptional initiation.
In addition, rat CYP2B1 and CYP2B2 are also regulated by a synthetic glucocorticoid
dexamethasone (DEX). After DEX injection, rat CYP2B1/CYP2B2 mRNAs increased
twelve fold (Simmons et al., 1987). Jaiswal et al., (1990) inserted the 5'-flanking
segment of CYP2B2 gene into the vector pBLCAT which contains a 'basal' thymidine
kinase gene promoter (including a TATA element, but no other upstream promoter
elements) and a reporter gene CAT. The expression of CAT is under the control of this
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Figure 3.3 Model of transcriptional activation of the CYP102 gene. Schematic
diagram of barbiturate and peroxisome proliferator-mediated induction in Bacillus
megaterium. In the absence of inducer, the repressor (Bm3Rl) binds to the operator,
and prevents initiation of transcription. Barbiturate or peroxisome proliferator interact
with Bm3Rl and inhibit its binding to the opreator. Transcription is then initiated with
formation of a bi-cistronic message encoding Bm3Rl and CYP102 (Adapted from
English et al., 1994).
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fused promoter-enhancer segment and the expression level of CAT can be determined
in transfected cells. Using this technique, it was found that transfected rat hepatoma
H4II cells show only a low level CAT expression in absence of DEX. Addition of DEX
leads to an approximately 20 fold increase in CAT expression. The sequence analysis
of 5'-flanking regions shows that there is a putative glucocorticoid response element
(GRE) in the rat CYP2B2 gene and in the rat CYP2B1 gene as well (Ding and Wolf,
unpublished result). The GRE is clustered together with CACCC and CCAAT binding
sites (Figure 3.4A). It has been found that duplication of GRE, or the combination of
GRE with either a CACCC, CCAAT or Spl motif increases the transcriptional activity
in responding to steroid hormone induction, while GRE itself mediates a very low
induction upon treatment with dexamethasone (Strahle et al., 1989; Jantzen et al., 1987;
Schiile and Muller, 1988). A study on the cooperation of GRE with other transcription
factor binding sites is shown in Figure 3.4B. All of these results suggest that the GRE
in rat CYP2B1/2B2 can function as an enhancer and may cooperate with the CACCC or
CCAAT motif to increase heterologous thymidine kinase gene promoter activity in cells
transfected by a CYP2B1FTK fusion gene.
(B) Constitutive expression of CYP2 genes
Many CYP genes are constitutively expressed in the absence of exogenous inducers.
Although extrahepatic tissues, such as lung, kidney, intestine and skin, have lower
levels of expression, the basal activity of CYP gene is mainly in liver. The liver-specific
gene expression is due to factors which are enriched in liver tissue. Hepatocyte
transcriptional factors have been extensively studied (Lai and Darnell, 1991; Kuo et al.,
1992), and eleven genes (Sladek et al., 1990; Gonzalez et al., 1993) encoding
positively-acting transcription factors have been cloned. These factors, which have
limited tissue distribution and appear to regulate many important liver-specific genes,
are all members of gene families: C/EBP, HNF-l, HNF-3, HNF-4 and albumin gene D
region-binding protein (DBP) (Johnson et al., 1987; Costa et al., 1989; Frain et al.,
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Figure 3.4
A: The sequence of rat CYP2B1/2B2-GRE (Jaiswal et al., 1990).
5'--1376CCACCCCAATAATATCAGTTAGGGTACAAAGTGTTCAAAO1346 -3'
GRE Consensus GGTACANNNTGTTCT
The CACCC-box is in bold letters and the CCAAT is underlined.
B: Cooperation of PRE/GRE with CACCC-box and other promoter elements (Strahle
et al., 1989; Jantzen et al., 1987; Schiile et al., 1988b). The plasmids containing
several binding site combinations were transfected into recipient cells. The activities
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1989; Baumhueter et al., 1990). Tables 3.2 (Lai and Darnell, 1991) and 3.3 (Sladek
and Darnell, 1992) summarise tissue distribution and some basic information on the
members of these transcription factor families.
In an in vitro transcription assay with cell-free liver extract as well as in a DNA
binding study, Ueno and Gonzalez (1990) found a positive control element located
between -127 and -89 bp of the rat CYP2E1 promoter. Deletion of the element results
in a 90% decrease of the in vitro transcriptional activity of adult liver extract. This ex¬
acting element exhibits significant sequence similarity with the core HNF-1 binding
motif which is involved in regulation of other liver-specific genes. The DNA binding
results also reveal that this element can be bound by HNF-1, suggesting that rat
CYP2E1 gene is positively regulated in adult rats by HNF-1 or a HNF-1 related factor.
However, CYP2E1 gene is not expressed in cultured cells, despite the presence of
HNF-1 mRNA and protein (Baumhueter et al., 1988). This demonstrates that the liver-
enriched transcription factor HNF-1 is not sufficient for expression of CYP2E1, other
factors which do not directly bind to the DNA may also be involved in the regulation of
CYP2E1 expression.
The transcription of CYP2C6 ger^e is maximally activated when male and female rats
reach puberty, and this activation coincides with the expression of the DBP (albumin
gene D region binding protein) which is believed to control albumin gene expression in
adult rats at a high level. Yano et al. (1992) found that DBP can activate transcription of
CYP2C6 by binding to a promoter element of the gene, and this binding affinity is 17-
fold higher than to the albumin promoter. Both of the DBP-binding regions of albumin
and CYP2C6 genes have a size of 20 base pairs, but have no sequence similarity.
Another factor (C/EBPa, a CAATT/enhancer binding protein) can bind to the DBP-
binding regions of the albumin and CYP2C6 , but only activates transcription of the






























































































































































































































































































































































































In rabbits, five genes of the CYP2C subfamily have been sequenced (Zhao et al., 1990;
Chan and Kemper, 1990; Pendurthi et al., 1990). Study (Venepally et al., 1992) of
rabbit CYP2C1/CYP2C2 genes shows that several promoter elements including
binding sites of liver-enriched factors such as HNF-1 and HNF-4 are present on the 5'-
flanking region of CYP2C1/CYP2C2 genes. In order to characterise the functional
significance of these regulatory elements, the 5'-flanking regions of both genes were
progressively truncated from the 5' end and subcloned upstream of the CAT reporter
gene. The promoter activities were analysed by transfecting these fused constructs into
human hepatoma cells (HepG2) and monkey kidney cells (COS-1), separately. The
results showed that the promoter activity in COS-1 cells was much lower than that in
HepG2 cells. Deletion of the sequence from -116 to -67 resulted in a 90% reduction of
promoter activity in HepG2, but had little effect on the promoter activity in COS-1
cells. In a further gel retardation study, one protein has been identified in the nuclear
extracts of HepG2 cells that can bind to the sequence between -116 and -67, but there
was not a similar protein in COS-1 cells. These results demonstrated that a hepatic-
specific factor functions in the regulation of CYP2C1/CYP2C2 genes. This conserved
protein binding sequence, designated as HPF1 (HepG2-specific P450 2C factor-1,
Venepally et al., 1992), has been found in the genes of rodent CYP2A, CYP2C and
CYP2D subfamilies and also been found in the human CYP2A7A gene in my study
(For details, see Section 3.3.4).
(C) Sex-specific expression of rodent CYP2 genes
The sex-specific expression of the CYP2A genes varies among different rodent models
and has not been found in humans. The best studied sex-specific CYP2 genes are male
rat specific CYP2C11 and female-specific CYP2C12 (Ryan et al, 1982; 1984). The
enzymatic activity of the CYP2C11 is only present in adult male rats, and is dependent
on androgen exposure both during the neonatal and adulthood stage of development
(Gonzalez, 1989). The Northern hybridisation with a CYP2CJ1 specific
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oligonucleotide probe establishes that CYP2C11 mRNA is exclusively expressed in the
liver of adult male rats and is absent in female liver (Morishima et al., 1987;
Zaphiropoulos et al., 1988). The high level of expression probably results from
transcriptional activation of this gene.
Rat CYP2A1/CYP2A2 genes are also sex-specifically regulated (Matsunaga et al.,
1988). The CYP2A1 gene is activated soon after birth in both males and females and is
specifically suppressed in postpubertal males but remains active in females (Nagata et
al., 1987). In contrast, the CYP2A2 gene is activated when males reach puberty but is
inactive through the life of females (Matsunaga et al., 1988). To determine the
mechanisms of sex-specific regulation, both rat genes have been isolated and sequenced
(Matsunaga et al., 1990). Both genes have nine exons that display 93% nucleotide
similarity. In vitro transcription studies were carried out using two plasmid constructs
as templates, each of them contained -6 kb to +1.5 kb from the transcription start site of
the rat CYP2A1 or CYP2A2 genes, separately. The constructs were transcribed in an in
vitro system with nuclear extracts derived from adult male liver, or female liver. The
results showed that there was not a sex-specific transcription site. This study,
therefore, did not explain the in vivo sex-specific activities of CYP2A rat genes
(Matsunaga et al., 1990).
Lindberg et al. (1989) recently described the structures of the mouse Cyp2a genes. In
spite of their high sequence homology, the transcriptions of Cyp2a4 and Cyp2a5 are
regulated differently. Both genes are expressed in female liver, whereas only Cyp2a4 is
expressed in castrated male liver. Mung bean nuclease digestion assays reveal that there
is not a sex-specific or tissue-specific transcription start site (See Section 3.3.3).
Taken together, the investigation on sex-specific expression of the CYP2A gene,
including the gene structure and the transcription start site failed to show a significant
difference between the male-specific and female-specific CYP2A (Cyp2a) genes. The in
vitro transcription assay does not reflect the in vivo sex-specific expressions of these
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genes either (Matsunaga et al., 1990; Lindberg et al., 1989). The possible explanations
are :1) The method of extract preparation is not satisfactory enough, and some
necessary factors such as hormone receptors may be lost or deactivated during the
preparation; 2) Different regulation pathways such as post-transcriptional level
regulation exist in rat or mice which can not be picked up in in vitro assays; and 3) The
different tissue-specific control elements which can enhance or suppress each other are
not included in the constructs used for the in vitro experiments.
3.2 Purpose of This Study
The increasing body of information about the structure, evolution and regulation of
P450s makes it obvious that the enzyme activities of P450s are controlled by a variety
of regulating mechanisms, many of which are species-specific and tissue-specific. The
studies with human P450s clearly demonstrate that drug metabolism and the regulation
of the drug-metabolising enzymes gene expression are often different in man compared
to these in experimental animals. Three basic differences are identified. First, even
highly structurally related P450s in rodents and humans, especially those in the CYP2
family, may have variable catalytic activity (Wrighton et al., 1992). For example, a well
studied case is the metabolism of coumarin, which is a product of certain plants and
fungi. Coumarin is metabolised in humans (Raunio et al., 1988) and in mice (Lindberg
and Negishi, 1989b) by CYP2A-mediated hydroxylation at the 7 position. The
coumarin 7-hydroxylase activity is higher in human liver than that in mice (Lindberg
and Negishi, 1989b; Raunio et al., 1988). In rat, however, the coumarin 7-hydroxylase
is very low, and the amount of excreted 7-hydroxycoumarin is less than 1% of the dose
administered (Pearce et al., 1992). Second, the expression of related P450 genes in
varied species are regulated differently. A case of this is the sexual dimorphism which
is observed in the metabolism of some compounds by rats and mice, but is not
observed in humans (Wrighton and Stevens, 1992). Third, through gene duplication,
species-specific CYP genes have evolved (Nebert, 1987). For example, rat CYP2A3 is
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found to be specifically expressed in lung tissue, but no similar gene is found existing
in mice and humans. These differences among rodent species and man have made it
difficult to extrapolate the conclusions drawn from the P450-mediated metabolism
studies performed in rodent to human. Therefore, it is becoming increasingly important
to characterise P450s and genes in the human CYP2A subfamily.
The human CYP2A subfamily is composed, at least, of two members, designated
CYP2A6 and CYP2A7 (Miles et al., 1989; Yamano et al., 1990). Both genes are
expressed in human liver and share 96% similarity of nucleotide sequences and 94%
similarity of amino acid sequences. Several lines of evidence suggest that enzymes of
the CYP2A subfamily play a role in the metabolic activation of promutagens, such as
smoking related nitrosamine 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK),
N-nitrosodiethylamine (NDEA) (Yamazaki et al., 1992; Crespi et al., 1990),
benzo[a]pyrene and the hepato-carcinogen aflatoxin B1 (Aoyama et al., 1991; Crespi et
al., 1991).
This project aims at characterising the function and regulation of the human CYP2A
gene. The strategy towards this aim includes:
a) Isolation of human CYP2A genes from human genomic libraries.
b) Analysis of the gene structure, including intron-exon junctions and mutations in the
gene.
c) Characterisation of promoter/enhancer elements in CYP2A genes by DNA
sequencing and transfection assay.
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3.3 Results
3.3.1 Isolation of the clones containing human CYP2A genes
Screening of human genomic DNA libraries in cosmid and in bacteriophage EMBL3
vectors was carried out as described in "Materials and Methods" (Chapter 2) with a 0.7
kb CYP2A6 cDNA fragment used as a probe. In order to isolate a complete gene, a
human genomic cosmid library (Kioussis et al., 1987) was screened. One clone,
designated CoIIA, was isolated, and then purified by spreading the cosmid clone on an
agar plate and repeating the colony hybridisation (Figure 3.5A). Restriction enzyme
digestion and Southern hybridisation analyses using three different CYP2A6 cDNA
probes, a 150 bp Sall-Pstl fragment containing part of exon 1 (Miles et al., 1989a), a
400 bp and a 300 bp PCR fragment containing exon 6 to 7, and exon 8 to 9,
respectively, suggested that the CoIIA contained an entire coding region and, at least, a
3 kb 5'-flanking fragment of a gene in the CYP2A subfamily (Figure 3.5B). Only one
CYP2A gene appeared to be contained within the 35 kb insert. A schematic gene
structure is shown in Figure 3.6.
3.3.2 Gene structure
i
(A) Comparisons of CoIIA sequence with those of other CYP2A genes
An 8 kb (pCoIIA, H8) and a 2.8 kb (pCoIIA, H2.8) Hindlll fragment, and a 4.8 kb
(pCoIIA, E/H4.8) Hindlll/EcoRl fragment were subcloned into the vector pUC18,
respectively. The restriction enzyme sites in these clones (shown in Figure 3.6) were
used to generate different subclones for sequencing and for further analysis. In
addition, oligonucleotides based on the intron/exon organisation of CYP2A subfamily
genes were used to sequence all exons and parts of the introns. The exons were
sequenced completely and the introns were partially sequenced. Comparison of the
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Figure 3.5, A: The isolated cosmid clone CoIIA by repeating the colony




Figure 3.5, B: Southern blot analyses of the CoIIA DNA. The DNA was digested
with EcoRl (E), HindlW (H) and double digested with EcoRMHindlW (E/H). The blots
were hybridised with random labelled CYP2A6 cDNA probes; A, with a probe of exon
8 to 9; B, with a probe of exons 6 to 7 and C, with a probe of part exon 1.
E E/H H
B







Figure 3.6 Schematic representation of the human CYP2A7A gene. The structure of
the gene was elucidated by DNA sequencing and restriction analysis. The following
restriction sites are shown BamHl (B); EcoRl (E); Apal (A); Bglll (G); HindlW (H);
BstXI (X); EcoRW (R); Ncol (N); NdeI (D); Sstl (S) and Aval (V). A: Exons are
represented by solid boxes, and arrows under the exons indicate the sequencing
direction from both ends for at least twice. The connecting line represents introns and
the 5'-flanking region. B: The 5'-region of CYP2A7A gene. Arrows indicate the
































exon sequences in CoIIA with the published sequence of the human CYP2A6 and
CYP2A7 cDNAs (Yamano et ai, 1990) revealed that there were 54 bp (3.6%), and 34
deduced amino acid (6.9%) differences between CoIIA and CYP2A6. There were 13
base changes (0.9%) resulting in 5 amino acid (1 %) differences between CoIIA and
CYP2A7 (Table 3.4).
It has been shown that there are two hypervariable regions between CYP2A6 and
CYP2A7: Six amino acid differences between residues 53 to 64, and five differences
between residues 158 and 164 (Yamano et al., 1990). Comparison of the deduced
amino acid sequences of CoIIA with that of CYP2A6 showed this was also the case
here, but seven amino acid differences were found in the region between residues 53 to
64, and only four amino acid differences between amino acids 158 to 164. In addition,
the proteins encoded by CoIIA and by CYP2A7 showed a common difference to
CYP2A6, namely, two base pair changes (GTA to GCG) in the codon 117, resulting in
a substitution of alanine for valine. These data indicated that proteins encoded by
CYP2A7 and CoIIA could be alleles. The gene in CoIIA was termed CYP2A7A.
Sequences of the exons, part of the introns and 5'-flanking region of the CYP2A7A
are shown in Figure 3.7.
*
(B) Structure of CYP2A7A
The intron-exon organisation of the CYP2A7A gene is shown in Table 3.5. The intron-
exon junctions were initially predicted by comparing CoIIA sequence with that of a
murine Cyp2a gene (Lindberg et al., 1989a) and confirmed by sequencing and by
comparing with the CYP2A7 cDNA sequence. The approximate lengths of introns,
except intron 1 which was completely sequenced, were established by PCR
amplification followed by agarose gel electrophoresis and comparison to a 1 kb DNA
ladder marker. Similar to the mouse genes in the Cyp2a subfamily, human CYP2A7A
was 8 kb in size, and contained nine exons, interrupted by eight introns ranging in size
85
Table 3.4 Differences of nucleotide and deduced amino acid sequences between
human CYP2A7 and CYP2A7A. (B) and (C) show encoding sequences of the
CYP2A7A . Asterisks indicate the nucleotide differences at the positions 610 (B) and
1423 (C).
CYP2A7 CYP2A7A
488-489 G-C (Ser1") C-G (Thr163)
610 A (Met204) G (Val204)
821 A (His274) G (Arg274)
909 G C
915 C G






1423 T (Ser475) C (Pro475)
t
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between 273 bp and 1.1 kb. All the intron-exon junctions followed the GT-AG
donor/acceptor rule.
Primer extension analysis was employed to identify the transcription initiation site using
a 22-mer synthetic oligonucleotide complementary to the sequence 73 to 51 bp
downstream from the first codon as the primer. Multiple extended fragments were
identified, corresponding to initiation at various sites between 14 to 87 bp upstream of
the initial methionine (Figure 3.8). Several smaller fragments (for example, 62 and 65
bp) were likely to reflect incomplete strand synthesis by the reverse transcriptase due to
local secondary structure. Due to homology of exon 1 among CYP2A genes, the primer
used in the extension analysis was not specific to CYP2A7A. Therefore, the
transcription initiation site of CYP2A7A can not be clearly defined by the result of the
primer extension analysis.
3.3.3 Alleles of CYP2A7
In addition to CYP2A7A, a second clone, LIIA, was isolated from a human EMBL3
genomic library by screening a total of 1.0 X 106 pfu (plaque forming unit) with a
CYP2A6 cDNA probe. Two more rounds of screening were carried out to purify the
positive phage away from contaminating phage. In order to compare this clone with
CYP2A7A, the DNAs of LIIA and CYP2A7A were separately digested with different
restriction enzymes, and hybridised to a 5'-end specific probe (a 150 bp Sall/Pstl
fragment containing partial exon 1 of CYP2A6) and a 3'-end specific probe (a 900 bp
BamHMEcoRl fragments containing exon 5 to 9). The results showed that LIIA
hybridised with the 3'-end probe, but not with the 5'-end probe (Figure 3.9A),
suggesting that it was a member of the CYP2A subfamily gene missing exon 1. The
restriction maps, using Hindlll or EcoRl and double digestion with EcoRl/Hindlll,
indicated several differences between the gene in LIIA and CYP2A7A. For example,
Hindlll digestion generated 2.8 kb and an 8.0 kb fragment for the CYP2A7A\ a 2.8 kb
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Figure 3.7 Nucleotide sequences of human CYP2A7A gene. The genomic clone
CoIIA was digested with restriction enzymes and the fragments were subcloned into
vector pUC18/19. The subcloned fragments containing the exons were sequenced
from both ends. Exonic sequences are denoted by bold letters, sequences of the
introns and the 5' flanking region by plain letters.
-12 6 3 CTGCCTCTGTGCCTAACACTGGAGTTACCCCAATCTCTTCTGCCACTGTTCCCTCTGCCT
-12 0 3 GCTAATAGTAGTAGCCCC.TGACAAAGCAGGAATCGCCCTTAAAGGAGACTTAACTCACCC
-114 3 TCAAATGTGATCTTCTCTTCCCAACACTCCCTTTCCACTGGCAGAAAACCAAATCCAGAA
-10 8 3 AGGGAACTAAGTACACAGAGCAGGAGAGATGGGAGTTCAGGGCCACTCACACATGTCCCC
-10 2 3 TGCCCACTGTCTGTTTTCTGTCCTCTGTAGATCTTTATATAAAATGAGAAACATAAACAA
-9 6 3 CAATCATAATATTAATAGGGATGATACAATCAATCTAGTGGGTTTCCCTGAGGATCTGGG
-9 0 3 TTGGAAACCAGCGGGACAACCCTTGGGACACTTGAGATTTTCCACCATTTGGGGTTGTTA
-8 4 3 TTACTATTTCTCCAGACCTAGCCAATCACTCTGCCAACTGCTAACTCCAGGTACTCTTCT
-7 8 3 CCAGGTGTGGGGAAAGTTCCCCTGAAATATGGCCCTGGTCTTCCACCCCTTTCCCAACCA
-7 2 3 GAGATGGGCAGTGTAGGTTCCATGGCACCATCCTGCCTCACTCTGAGGTTCCAGTGAGAT
-6 6 3 TCTGGGCATCAAGAGATAGCTCTGGGCAAAAGCAAAATCAAGTCAGCCCCTGGACCCAGT
-6 0 3 GCTGGGCTGCTGGGCTTTCTGGGAGCACCTGCTGGCTTGCTACACACTCCTCCTCCCAGA
-5 4 3 AACTCCACACCCACAGCCCTGGGTCTTCCTAGCCCCGAGACTTTCAAGTCCATATGCCTG
-4 8 3 GAGTCCCCCCTCCTGAGACCCTTAACCCTGCATCCTCCGCAACAGAAGACCCCCAGATGC
-4 2 3 ACAGCACACTTCATTACTAATAAACCAGACTTGATCTTCTCCTGATGCCCAAATCCAGCA
-3 6 3 AGCTTTGGGGTGCATTCTCACTCTCAGACCCCAAATCCAAAGTCCCAAGTGCTCCCCTAG
-3 0 3 TATCCAAATATTCCAAACTCTTCAGTTCTACAGTTTATCGGTTGCCCCCTCCTAAATCCA













































































































Figure 3.8 Primer extension analysis. The primer used in the analysis was a 22-mer
oligonucleotide complementary to the sequence 73 to 51 bp downstream from the first
codon. Total RNA (50 p.g) from a human liver was used. Yeast tRNA was used as a
negative control. A sequence ladder was used as a size standard. The arrows show the
multiple extended fragments.
fragment and a 9 kb fragment for LIIA (Figure 3.9B). Only digested CYP2A7A DNA
hybridised with the 5'-end probe (Figure 3.9A). These results showed that the LIIA
contained a genomic DNA fragment which spanned from exon 2 to the 3' end of a
CYP2A gene, and this gene was not identical with CYP2A7A .
The gene in LIIA was partially sequenced from exon 2 to exon 3. This analysis showed
(Table 3.6) that there were several base pair differences between it and both CYP2A6
and CYP2A7A, respectively. One of the sequence differences with CYP2A7A was
only one silent base pair change t(GTA to GTG), which did not result in amino acid
change in the codon 117. The CYP2A7A had two base pair changes in this codon
(GTA to GCG), resulting in a substitution of alanine for valine. At this position the
amino acid encoded by LIIA was the same as CYP2A6. On the other hand, LIIA also
contained a hypervariable region between the deduced amino acid residues 158 and
164, which was identical to the CYP2A7A. Based on these results it is suggested that
the gene in clone LIIA is another allele of CYP2A7, designated CYP2A7B. A
comparison of nucleotide and deduced amino acid differences among the CYP2A7B,
CYP2A7A, CYP2A7 and CYP2A6 is shown in Table 3.6.
In order to distinguish between CYP2A6 and the three alleles of CYP2A7, a PCR
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Figure 3.9 Southern blot analysis of LIIA (L) and CoIIA (C) DNAs. The DNAs
were digested with EcoRl (E); with Hindlll (H), or with EcoRl and Hindlll both


















strategy was carried out using human genomic DNA as template, an oligonucleotide A
( 5'-AGGTGATTATGTAATTAGCC-—3') complementary to the 5' flanking region
of CYP2A7A and an oligonucleotide B (5y—TTCTGCCATAGCCTCCAGTG 3')
complementary to the intron 2 of CYP2A7A and CYP2A7B. The expected PCR
product was a fragment of 817 bp in size (Figure 3.10A). As a consequence of one
base pair difference (G to C at position 141, +1 indicates the start of the open reading
frame) in the exon 1 of both CYP2A7 and the CYP2A7A, a Psfl site is absent from
both genes. The PCR amplified CYP2A6 can be digested with Pstl to two fragments
of 582 bp and 235 bp, whereas the amplified alleles of CYP2A7 was not digested.
After hybridisation to the exon 2 specific oligonuceotide probe, the 582 bp fragment of
CYP2A6 and 817 bp undigested fragment of CYP2A7 alleles could be observed. The
result of this analysis showed that none of the PCR product was digested with Pstl,
indicating that the primers used in the analysis were specific for alleles of CYP2A7
(Figure 3.1 OB). In order to confirm whether the Pstl site existed in amplified CYP2A6
cDNA, the full length CYP2A cDNAs were amplified with an oligonucleotide,
complementary to the 5' end of CYP2A (5'-CATGCTGGCCTCAGGGCTGCTT-3')
and an antisense oligonucleotide, complementary to the 3' end of CYP2A (51-
GCCTTAAGGCTTCCCCCCATTCTTATACC-3'). The amplified products were
cloned into vector pUC18 and screened by Pstl digestion. The sequencing results
indicated that the clone digested with Pstl contained the CYP2A6 cDNA, whereas the
clone not digested with Pstl was CYP2A7 (data not shown).
It was then investigated whether CYP2A7A and CYP2A7B were actually alleles or
represented different genes. In order to do this, a Mbol restriction enzyme (restriction
site, GATC) was used. One Mbol restriction site existed at the intron 1/exon 2
boundary (ag ATC) in CYP2A7B, but the site was absent in CYP2A7A (ag TTC).
The PCR with primers A and B, followed by Mbol digestion generated a 346 bp
fragment for CYP2A7A and a 263 bp fragment for CYP2A7B sequence. Both
























































































and C). The analysis of the PCR product from 18 different individuals showed eight
were homozygous for the CYP2A7B (Figure 3.10, C, track 3), six were homozygous
for the CYP2A7A (Figure 3.10, C, track 2, 4 and 5) and others were heterozygous for
CYP2A7A/CYP2A7B. (Figure 3.10, C, track 1). This gives allele frequencies of
approximately 44.4%, 33.3% and 22.2%, respectively. These data provided more
evidence that the genes encoded by CYP2A7A and CYP2A7B were alleles and it was
likely that both genes were alleles of CYP2A7. However, in the absence of the
CYP2A7 genomic sequence it was not certain that the amplification primers would
actually amplify the CYP2A7 gene.
3.3.4 The promoter elements in the 5'-flanking region of CYP2A7A
gene
A 4.8 kb HindllUEcoRl fragment of CYP2A7A was subcloned into pUC18 (pCoIIA,
H/E4.8) and sequenced except for a narrow gap in the 5'-flanking region. This 4.8 kb
DNA fragment contained 3.0 kb of the 5'-flanking region of the CYP2A7A gene
(Figure 3.6B). A putative TATA box was located at 50 bp upstream from the first
codon of methionine, but there was no CCAAT box. A computer analysis identified
several potential transcription factor binding sites. A modified glucocorticoid-
responsive element (GRE) (Jaiswal et al., 1990), GGTAGGNNNTGTTCT, and a
reverse orientated core sequence of GRE (TGTTCT) on the non-coding strand were
found at -2.75 kb and -2.77 kb (Figure 3.6). In addition, within 0.5 kb 5' flanking
region (Figure 3.11) a consensus sterol responsive element (SRE, 5-CACCCCAC-
3'), which is found in the promoters of several genes involved in steroid metabolism
(Osborne et al., 1988; Smith et al., 1988), and a SRE-like element (7/8 bases of
sequence identity of consensus SRE) were found at the positions of -37 bp and -232
bp. These sequences overlapped with three copies of another promoter motif, CACCC





























Figure 3.10 Analyses of CYP2A7 alleles by PCR. The PCR was carried out as
described in Chapter 2. Genomic DNAs were prepared by Dr Zhong from human blood
samples. A. Schematic diagram of the analysis procedure and the predicted banding
patterns of amplified DNA following the digestion with Mbol. B. The Southern
hybridisation of Pstl digested PCR product with an exon 2 specific probe. 1,
undigested DNA; 2, Pstl digested DNA. C. Southern hybridisation of PCR]Mbol
digested fragments. Homozygous CYP2A7A genotype is shown in tracks 2, 4 and 5;
homozygous CYP2A7B genotype in track 3. Track 1 shows a heterozygote of
CYP2A7A/CYP2A7B.
GCCAAAGTCCA-3', was found at position of -79, which has been reported
(Venepally et al., 1992) recently as a HepG2-specific P4502C factor-1 (HPF-1)
binding site existing in the several CYP2 gene subfamilies, such as CYP2A, CYP2C
and CYP2D. It has been also reported that HPF-1 motif is a functional hepatic nuclear
factor-4 (HNF-4) binding site (Chen et al., 1994). In addition to these conserved
elements, a modified TCDD-AH complex binding site (TTGCTGG) was also found in
this region.
Figure 3.11 The nucleotide sequence of the 0.5 kb 5'-flanking region of CYP2A7A
gene. The putative TATA box and HPF-1 binding site are boxed, the SRE/ CACCC































































3.3.5 Transcriptional regulation of CYP2A7A
(A) Construction of fused plasmids for in vitro transcription assays
PCR was carried out with the clone pCoIIA,H/E4.8 as the template DNA. The 5'-
primer (5'-CCCAAGCTTGGCTGTGCTGAGGAAG-3', 3 kb upstream from the first
codon, including a Hindlll restriction site) and the 3' primer (5'-
GGTAGTGAGATGACAGATGGT-3', starting from 2 bp upstream of first codon)
were used. The 3 kb 5'-flanking region of the CYP2A7A fragment generated by this
PCR was blunted using Klenow polymerase I, then digested with Hindlll, and was
cloned into the ///m/III/blunted Xbal sites of the vector pCAT-basic containing CAT
cDNA (Promega Ltd.) to form the construct pCAT2A7A5'-3.0. The preparation of 5'
deleted constructs were described in Chapter 2.
IB) Promoter activity and xenobiotic induction
The conditions of transient transfection assay are described in Chapter 2. As shown in
Figure 3.12A, the construct containing 3.0 kb 5'-flanking region of CYP2A7A
exhibited only a low CAT activity. With the progressive deletion of the 3.0 kb 5'-
flanking sequence to the position of -1.0 kb (pCAT2A7A5'-1.0), the transcriptional
activity significantly increased and the maximal activity was observed with a fragment
containing approximately 0.5 kb of the 5' end of the gene. To further define the
promoter elements, the 0.5 kb 5' flanking region was analysed in more detail (Figure
3.12B). Deletion down to -95 bp (pCAT2A7A5'-Dl 1) had no effect on the
transcriptional activity. However, further deletion to -72 bp, which removed most of
the HPF-1 element, resulted in a 80% decrease in activity, suggesting that the HPF-1
was a basal promoter element for the expression of the CYP2A7A gene in HepG2 cells.
To examine the potential inducing effects of xenobiotic on promoter activity of the
CYP2A7A, chemicals, which have been found inducing CYP2A gene expressions in
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animal experiments, were used. In my experiments, five chemicals, B-naphthoflavone,
phenobarbital, pyrazole, DEX and TCPOBOP, were used and the concentrations of
these chemicals were chosen as described by Maurice et al. (1991), who treated the
cultured human primary hepatocytes with B-naphthoflavone, phenobarbital and
pyrazole, and as described by Jaiswal et al. (1990), who treated rat hepatoma H4II cells
with DEX. The concentration of TCPOBOP was used as described by Smith et al.
(1993). In my experiments, cells transfected by pCAT2A7A5'-3.0 were grown in the
presence of TCPOBOP (20 |lM), phenobarbital (2 mM), DEX (0.1 |lM), pyrazole (50
(lM) and B-naphthoflavone (10 p.M) for 24-36 hr, and then the CAT activities in treated
cells were assayed. The results showed that the treatment with DEX (52% increase;
N=4; P < 0.001) and pyrazole (61% increase; N=3; P < 0.001) resulted in a slight
increase in activity; phenobarbital treatment was inhibitory (52% decrease; N=4; P <
0.001) and TCPOBOP and B-naphthoflavone produced no effect (Figure 3.13).
However, the induction assay was carried out by using a single dosage of each
chemicals, and different concentrations of each chemical might change the induction
patterns. A full dose-response curve need to be carried out in future work to
characterise the inducible expression of the human CYP2A7A gene in more details.
Figure 3.12 Constitutive expression of CYP2A7A gene in HepG2 cells. CAT
activities were determined by liquid scintillation counting and normalised to 8-
galactosidase activity. Values are expressed as the percentage of activity relative to the
activity of pCAT2A7A5'-0.5. Each value is an average of three experiments. CAT
activities measured by TLC are also shown below the maps of the deleted 5' flanking
region. A shows the reporter plasmids constructed with the deleted 3 kb CYP2A7A
promoter region, B represents the report plasmids constructed with the deleted 0.5 kb
















































Figure 3.13 The xenobiotic induction of promoter activity. Cells transfected with
pCAT2A7A5'-3.0 were grown in the presence of different xenobiotics. The CAT
activity is expressed as the percentage of activity relative to the control cells. 1, control;
2, phenobarbital (2 mM); 3, TCPOBOP (20 (iM); 4, 8-naphthoflavone (10 p,M); 5,
pyrazole (50 jiM) and 6, DEX (0.1 |iM). All of these chemical induction were carried





Two genomic clones, CoIIA and LIIA, containing alleles of CYP2A7, were isolated.
CoIIA contained a full length CYP2A7A which was approximately 8 kb in size.
Although it shared several common differences with CYP2A7 to CYP2A6, CYP2A7A
contained 13 nucleotides resulting in 5 deduced amino acid differences with the
CYP2A7. These data suggested that CYP2A7A appeared to be an allele of CYP2A7.
Like Cyp2a genes in mice, CYP2A7A contained 9 exons which were divided by 8
introns at exactly the same positions as Cyp2a4 and Cyp2a5 .
The nucleotide and deduced sequences from exon 2 to 3 of CYP2A7B showed that
there were eight nucleotide and six deduced amino acid differences in the region of
amino acid residue 61 to 153 (nucleotide 181 to 457) between CYP2A7B and
CYP2A7A, but except for two silent nucleotide changes, it was identical with CYP2A6
in this region. On the other hand, there were four amino acid differences in the region
of amino acid 158 to 164 between CYP2A7B and CYP2A6, although it was identical
with that of CYP2A7A (Table 3.6). Analysis of cDNA sequences in other CYP2
subfamilies, for example CYP2B1 and CYP2B2, (Atchison and Adesnik, 1986) has
revealed that regions of high nucleotide similarity are interspersed with regions of low
similarity, and the mechanism underlying this phenomenon is considered to be gene
conversion (Gonzalez, 1989). In the case of the human CYP2A subfamily, CYP2A7A
and CYP2A7B, compared with CYP2A6, also have clusters of hypervariable regions,
suggesting that gene conversion could be one of the mechanisms of CYP2A gene
divergence during evolution. In addition, based on the PCR analysis of human genomic
DNA, CYP2A7B appears to be another allele of CYP2A7 (Figure 3.10). However, as
only a partial sequence was available it is not clear whether CYP2A7B encodes a
functional protein.
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It has been found that expression of genes in the CYP2 subfamily is constitutive or
inducible by PB, DEX or other chemicals. In addition, tissue specific and sex-
dependent regulation has also been described (Gonzalez, 1989). To date, however,
little information is available about the cA-acting elements involved in the regulation of
human CYP2 genes and no receptor or transcription factors have been described
because of lack of a suitable cell line that can express human CYP2 genes normally. In
my study it was found, by transient expression, that the deletion of the HPF-1 binding
site in a fused gene construct pCAT2A7A-5'-D21 resulted in an 80% decrease of the
promoter activity in HepG2 cells. A similar result was obtained in mouse Hepal cells
(data not shown). Recently, it was reported that HPF-1 was highly homologous to
HNF-4 and present in liver and kidney. Both factors can bind to either the HPF-1 or
HNF-4 site (Chen et al., 1994). In the case of the rabbit CYP2C gene (Venepally et al.,
1992), a large reduction of promoter activity in HepG2 cells is caused by deletion of the
HPF-1 binding site, but this effect is rather moderate in COS-1 cells. These results
show that HPF-1 is an essential element in the basal transcription of the human
CYP2A7A in HepG2 cells and HPF-1 and HNF-4 may play a common role for the
regulation of CYP2 gene expression in humans and in other mammals. Upon treatment
of the transfected HepG2 cells with various known inducers, I did not observe a
significant induction by PB, DEX'and TCPOBOP. This may be explained either by the
absence of the specific transcription factors or receptors in the cultured HepG2 cells, or
by the use of a single dosage of the chemicals, while different concentrations may have
changed the induction pattern.
Computer analysis identified in the 0.5 kb flanking region of CYP2A7A three copies of
the CACCC box, which has been found in the promoters of several genes including
CYP2H1 (Walters and Martin, 1992; Hahn et al., 1991). Published results including in
vitro mutagenesis and gel mobility shift assays have clearly revealed that the CACCC
box plays an important role in these constitutive promoter activities and has been
identified as a binding site of Sp-1, Sp-3 and Sp-4 (Yu et al., 1991; Hagen et al.,
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1992). Co-operation with the progesterone receptor (PRE) or GRE, CACCC box can
enhance the transcription activity dramatically (Schule et al., 1988a).
It has been reported that SRE plays an essential role in the co-ordinate transcriptional
regulation of the genes involved in the maintenance of cholesterol homeostasis and
function like an enhancer (Osborne et al., 1988; Smith et al., 1988). Recently it has
also been found that a SRE was positioned in the promoter of the human CYP7 gene
which is responsible for the metabolism of cholesterol and bile acid biosynthesis
(Molowa et al., 1992). Interestingly, our finding that a SRE element (CACCCCAC)
overlapped with two directly repeated CACCC elements at the 5'-flanking region of
CYP2A7A is reminiscent of cholesterol homeostasis that is related to the LDL receptor
gene, in which the SRE is located between two Spl sites (Goldstein and Brown,
1990). Although the function of the CYP2A7A gene is still unclear, this finding
together with the facts that murine Cyp2a proteins metabolise steroid hormones
(Lindberg et al., 1989a; Burkhart et al., 1990) suggest that function and regulation of
the CYP2A7A gene may be related with steroid metabolism.
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CHAPTER 4: EXPRESSION AND ALTERNATIVE SPLICE OF CYP2A7
4.1 Introduction
The levels of P450s are determined by many factors, including genetic background,
dietary habits, hormonal levels and exposure to foreign chemicals that act as inducers or
repressors (Gonzalez, 1990). As a consequence, the enzymatic activities of hepatic
P450s, particularly those in the CYP2 family, are subject to a marked inter- and intra-
species variability. A significant proportion of chemical metabolising enzymes are
polymorphic in man, and this results in a huge inter-individual variability of some P450
activities (Idle et al., 1992). In order to define the inter-individual differences in P450
activity, it is important to delineate the underlying mechanism.
4.1.1 Polymorphisms of cytochrome P450 activities
Over the past 10 years, a great deal of information regarding the regulation of the
expression and catalytic activities of the human P450s has been available and several
well-defined polymorphisms in xenobiotic metabolism have been discovered. The
importance of genetic polymorphisms is exemplified by studies on the genetic
polymorphism at the CYP2D6 locus. It has been demonstrated that CYP2D6 has
debrisoquine 4-hydroxylase activity (Mahgoub et al., 1977). The vast majority of
individuals receiving debrisoquine excrete large amounts of hydroxlated metabolites in
their urine (EM phenotype). About 5-10 % of the Caucasian population (Eichelbaum et
al., 1992a) excrete the drug virtually unchanged (PM phenotype). However, only 0.5-
1.0% of Chinese and Japanese are PM phenotype (Eichelbaum and Gross, 1992b;
Nakamura et al., 1985), and the PM individuals are as high as 16% in Nigeria
(Gonzalez and Nebert, 1990). These studies suggest that significant ethnic differences
exist in chemical metabolism. In addition to debrisoquine, more than 25 other drugs are
metabolised poorly by PM individuals (Meyer et al., 1990), and the ability of the EM
individuals to metabolise these chemicals is 10-200 times higher than that of individuals
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with PM phenotype (Gough et al., 1990). The PM phenotype is inherited in an
autosomal recessive fashion with the EM phenotype comprising both the homozygous
dominant and heterozygote genotype (Morais et al., 1994). Because frequency
variations of both phenotypes occur in different populations, genetic polymorphism of
drug metabolism is seen as a principal determinant in inter-individual differences in
toxic responses to clinical drugs and in susceptibility to chemicals.
Data reveal that the polymorphic enzymatic activity and expression of P450 can be
caused by either a defect in the regulatory factors governing the transcription of the
genes or direct mutations of the P450 genes. The PM phenotype has been found to be
the result of defective CYP2D6 alleles, including point mutation and deletion. In the last
5 years, more than 90% of the CYP2D6 mutations that cause absence of CYP2D6
protein and result in the poor metaboliser phenotype have been identified by
PCR/restriction fragment length polymorphism (RFLP) studies (Smith et al., 1992;
Daly et al., 1991; Broly et al., 1991; Skoda et al., 1988). The most common mutant
allele (>70% of PM alleles) is characterised by a point mutation at a splice-site
recognition sequence that leads to a frame shift. 5% of PM individuals have a 1 bp
deletion in the coding region and another 10-15% of cases are caused by deletion of the
entire CYP2D6 gene (Meyer, 1994).
The genetic defect provides an explanation at a molecular level for the poor metaboliser
phenotype. However, the mechanisms underlying the extensive metaboliser still remain
unclear. Recent studies (Johansson et al., 1993) have shed some light on this problem.
In two families of extremely rapid metabolisers of debrisoquine, the CYP2D6 gene was
amplified and this amplification caused ultrarapid metabolism. In the three members in
one family, one allele of CYP2D6 was amplified 12-fold. Two gene copies of the same
allele of CYP2D6 existed in another family of extremely rapid metabolisers. The
duplicated and amplified allele was named CYP2D6L. This new finding provided a
molecular explanation for the rapid metabolism phenotype.
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4.1.2 Alternative splice
Almost all protein-coding genes in eukaryotes are split into coding (exon) and non-
coding (including intron) sequences. The intron sequences are precisely spliced out of
the initial gene transcript before the mRNA is transported to the cytoplasm for
translation. Each intron is removed in a two-step process. First, cleavage at the
boundary between the intron and the exon upstream (the 5' splice site or splice donor)
occurs, with concomitant joining of the 5' phosphate at the 5' splice site to a 2'
hydroxyl of a residue within the intron. This lariat intermediate undergoes cleavage at
the junction between the intron and the downstream exon (the 3' splice site or splice
acceptor), with the co-ordinated ligation of the two free exons to form mature mRNA
(Figure 4.1). These processes are called the general or constitutive splice pathway
(Shapiro and Senapathy, 1987; Norton, 1994).
Since splicing signals are usually 5-10 nucleotides long, it is possible that a splice site
is created or destroyed with an appreciable frequency by mutation or other genetic
changes. This can result in the production of different polypeptides from the same gene
by alternative splicing. In this case, the distinction between exons and introns is no
longer absolute but depends on the mRNA reference. When the newly formed splice
site is much stronger than the did one, it will have deleterious effects and is not
expected ever to become fixed in the population as this process would lead to the
inactivation of a previously functional protein. On the other hand, if the alternative
splice site is much weaker, most mRNA will be of the original type, and only small
quantities of aberrantly spliced mRNA will be made. This creates an opportunity to
produce a new protein, possibly with a new useful function (Li and Graur, 1991). For
example, the human insulin receptor is encoded by a single gene and composed of 22
exons. The mature insulin receptor, however, exists as two isoforms, designated A and
B, which result from alternative splicing of the primary transcript. The A isoform is
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Figure 4.1 Pre-mRNA splicing pathway. At the top is a sample model of pre-mRNA,
with consensus elements within the intron shown: boxes, exons; line, intron; n is any
residue; R is either A or G; Y is either U or C; The site of branch site formation is
indicated by an asterisk. In the presence of nuclear extract, the indicated snRNPs
associate with specific regions of the pre-mRNA. Formation of the higher order
structure has been proposed to bring the two ends of the intron into close proximity.
Splicing occurs in two steps: the characteristic intermediates and products of the
reaction are shown. (Norton, P.A., 1994)
| exon 1 |GUAAGU YURAY (YlnAGj" exon 2 |
U1. U2. U4/U6. U5
Spliceosome assembly
Step 1
| exon 1 ~]
Step 2
j exon 1 | exon 2 |
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expressed only in lymphocytes, brain and spleen; the isoform B is expressed
predominantly in liver, muscle, adipocytes, and kidney. It has been suggested that
isoform B plays an important role in signalling in insulin-sensitive tissues (Kosaki et
al., 1993). Alternative splicing may be used as a means of developmental and tissue
specific regulation or as a rate-limiting regulation of special genes as well (Ali et al.,
1992; Guo and Helfman, 1993; Zanussi et al., 1992).
It is intriguing to note that alternatively spliced mRNAs have also been reported in
several genes of the CYP2 family, such as human CYP2B, and rat CYP2C (Miles et
al., 1988; Okino et al., 1987; Kimura-H. et al., 1989; Zaphiropoulos, 1993). The
alternative splicing has led to inactive protein products. For example, two types of
mRNA are transcribed from one rat CYP2C6 gene by alternative splicing in exon 8 and
both of the two mRNAs are expressed in rat liver in an age-dependent manner. The 142
bp exon 8 in the wild type transcript of CYP2C6 is replaced by a 159 bp fragment,
resulting in a disruption of the open reading frame. Although the aberrantly spliced
mRNA can be translated into a protein, its haem-binding capacity is lost and the protein
does not function as a P450 monooxygenase (Kimura-H. et al., 1989). Recently, it has
been reported (Morais et al., 1994) that a principle defect in the poor metaboliser
phenotype of S-mephenytoin hydfoxylation was a single base pair mutation in exon 5
of CYP2C19, which creates an alternative splice site. The mutation alters the reading
frame of the mRNA and produces a premature stop codon, which results in a non¬
functional protein in man.
Another example is the expression of the human CYP2B6 gene. The investigation on
this gene, whose expression has been found to be co-regulated with the CYP2A gene,
indicates that three types of transcripts from the gene are formed by aberrant splicing in
exon 8 in all the 15 tested human liver samples, but their ratios vary among the samples
(Miles et al., 1988). The alternatively spliced mRNAs from the CYP2B6 gene generate
a protein product without activity. Taken together, these results suggest that alternative
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splicing of mRNA should be one of the principal regulating mechanisms in the CYP2
gene family, and appears to be one of the molecular explanations for inter-individual
variation in the activity and expression of P450.
4.1.3 Research purpose
In order to determine the role of P450s in individual adverse drug reactions and
chemical toxicity, the basis for polymorphisms in gene expression needs to be
established. In this regard the genes of the human CYP2A subfamily have not been
extensively investigated. Both genes CYP2A6 and CYP2A7 are expressed in human
liver, but only CYP2A6 has been found to be responsible for the metabolism of
coumarin (Yamano et al., 1990; Miles et al., 1990) as well as the carcinogen aflatoxin
Bi (Crespi et al., 1991). The functions of CYP2A7 are currently unknown.
The expression level of CYP2A6 is highly variable within the population. Coumarin
hydroxylase (COH) activity varies greatly as well (up to 100-fold, Yun et al., 1991).
This appears to be consistent with the difference in hepatic CYP2A expression in
previously published results (Pelkonen et al., 1993; Yamano et al., 1990). Northern
blot analysis with CYP2A6 cDNA as a probe identifies two mRNAs of 2.3 and 2.8 kb
in human liver, and immunoblotting of liver microsomes also reveals two or three
bands, 49 kDa, 51 kDa and 55 kDa (Yamano et al., 1990; Miles et al., 1990; Forrester
et al., 1992). These results suggest that more than two CYP2A genes may be expressed
in human.
In order to study the factors involved in the inter-individual variability at the expression
levels of human CYP2A genes, the expression levels of CYP2A genes in human liver
was studied using RT-PCR. Three mRNA species encoding CYP2A6, CYP2A7 and an
alternatively spliced form of CYP2A7 have been subcloned and isolated in this work.
The identification of the latter mRNA exemplifies previous reports indicating that
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alternative splicing is an important factor in determining cytochrome P450 levels in
man.
4.2 Results
4.2.1 Determination of CYP2A mRNA levels in human liver
Analysis of the human CYP2A6 and CYP2A7 cDNA sequences (Miles et al., 1990)
showed the presence of a Pstl restriction site at bp 143 (+1 indicates the start of the
open reading frame) of CYP2A6, which is absent in CYP2A7. This restriction enzyme
Pstl digestion combined with a protocol of RT-PCR was employed to establish the
relative mRNA levels encoded by these two genes. To amplify a fragment spanning
exons 1 to 5 of the CYP2A6 and CYP2A7 genes, an upstream oligonucleotide A, 5'-
CATGCTGGCCTCAGGGCTGCTT-3' and a downstream oligonucleotide C, 5'-
GAAGTCCTCCAGCCCTTGCAGC-3', were used. The human livers employed in
this determination were obtained from kidney transplant donors. Livers were stored at
-70°C within 1 h of removal. Information about the patient case histories have been
described previously (Miles et al., 1990; Forrester et al., 1992). Total cellular RNA
was prepared by the guanidinium isothiocyanate method or a single-step method
described in chapter 2. RNA concentration and purity were estimated
spectrophotometrically. Before reverse transcription, RNA was tested for integrity by
ethidium bromide staining following separation on a denaturing formaldehyde gel.
First, hepatic mRNA was reverse transcribed using a oligo (dT)6-8 and reverse
transcriptase (MuLV from BRL Ltd.), and then CYP2A6 and CYP2A7 were amplified
by PCR using Taq polymerase (Promega Ltd.). The expected 750 bp fragments of
CYP2A6 and CYP2A7 were observed (Figure 4.2, the tracks marked by U).
Following digestion with Pstl (20 units and four hours incubation at 37°C), CYP2A6
cDNA was as expected cut into two fragments of 607 bp and 143 bp, whereas
CYP2A7 cDNA was unaffected by this procedure. During subsequent electrophoresis
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the 143 bp fragment migrated out of the gel and was not seen. In a separate experiment,
0.4 p.g pBluescript plasmid DNA was added into the reaction mixture as an internal
control (Figure 4.2A) to verify complete digestion. In order to ensure that the analysis
was reproducible, the RT-PCR followed by Pstl digestion for samples L8, L6 and L4
were carried out twice. The results showed that the ratio of CYP2A7 to CYP2A6 in
these three RNA samples were reproducible (results not shown). Both CYP2A6 and
CYP2A7 were expressed in all these liver samples. The ratio of the expression level of
CYP2A7 to that of CYP2A6 was subject to some variation ranging from slightly less
than one in sample 3 to about three to four in (Figure 4.2B). The relative expression of
Figure 4.2. The relative amounts of CYP2A6 and CYP2A7 mRNA in six human
liver samples. (A) Agarose gel electrophoresis of Pstl digested RT-PCR products. 0.4
p,g plasmid pBluescript DNA (2.94 kb) was added into the reaction mixture to verify
complete digestion. M, 1 kb ladder marker; lanes 1 to 3, digested pBluescript DNA
(2.94 kb) with RT-PCR products from RNA samples L8, L9 and LI 1, respectively; 4,
uncut pBluescript DNA. (B) Southern blot analysis of Pstl digested RT-PCR products.
Number 1 to 6 represent the RNA samples L12, L8, L6, L16, L14 and L4,
respectively. The fragment of 607 bp represents the digested CYP2A6 and that of
fragment of 750 bp is CYP2A7. (C)The ratio of relative expression of the CYP2A7 to
CYP2A6 over a range of PCR cycles with RNA sample L6; lane U, uncut PCR
product; lanes P, Pstl digested product. The designation of the samples is the same as
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the CYP2A7 to CYP2A6 in one RNA sample (L6) was determined over a range of
PCR cycles. The amplified DNA was cut with Pstl and the results showed that the
expression level of CYP2A 7 to that of CYP2A6 was constant with the number of PCR
cycles (Fig. 4.2C).
4.2.2 The identification of an alternatively spliced CYP2A7 mRNA
As part of the analysis of CYP2A6 and CYP2A7 mRNA's, RT-PCR was carried out to
amplify the full length cDNA of CYP2A genes using a human total liver RNA sample
L8 and oligonucleotide primers. The primer A was complementary to the 5' end, bp 1-
22, (See section 4.2.1). The primer B was complementary to the 3' end, bp 1583-1564
(5'-GCCTTAAGGCTTCCCCCCATTCTTATACC-3', containing an additional EcoRl
site). In addition to the expected fragment of 1.6 kb, a low abundance fragment of
about 1.45 kb was observed. The PCR products were subcloned into the Smal/EcoRl
sites of vector pUC19. Pstl digestion was used to screen the colonies as this site is
present at bp 143 (+1 indicates the start of the open reading frame) of CYP2A6 , but
absent in CYP2A7. Three colonies with different Pstl digestion patterns were isolated
and sequenced. The results indicated that the colonies with a 1.6 kb insert contained a
CYP2A6 or a CYP2A7 cDNA. The colony with a 1.45 kb insert appeared to contain
an alternatively spliced version of CYP2A7 (CYP2A7AS).
Comparing the genomic sequence of CYP2A7 gene with that of CYP2A7AS, it was
confirmed that the CYP2A7AS was an alternatively spliced version of CYP2A7 in
which the 163 bp of exon 2 was replaced by a 10 bp segment of intron 1 (Figure
4.3A). The alternatively spliced exon 1 was designated exon 1A. Translation of
CYP2A7AS mRNA would result in an in-frame deletion of 51 amino acids to generate
a protein product ofMr 44 kDa. The 10 bp segment of intron 1 added three amino acid



















































































































































































































































(Figure 4.3B). All the intron/exon junctions conformed to the GT/AG consensus splice
recognition site. However, intron 1 contained an additional 5'-splice site, G/gcagg,
which resulted in CYP2A7AS (Figure 4.4). This alternative 5'-splice site did not
conform to the GT/AG consensus sequence, however, it was similar to a "non¬
conforming" 5' splice site sequence found in a few genes (Shapiro and Senapathy,
1987; Miles et al., 1989b).
4.2.3 The expression of the alternatively spliced CYP2A7 in human
liver and a skin fibroblast cell line
To investigate the extent of alternative splicing of CYP2A7, five human liver RNA
samples and total RNA from cultured human skin fibroblast cells were assayed by RT-
PCR. The expected wild type PCR product using oligonucleotide A and C as primers is
a fragment of 750 bp. The product from the alternatively spliced mRNA is 600 bp
(Figure 4.5A). An ethidium bromide stained band of 750 bp appeared in four of five
liver RNA samples, whereas a weak band of 750 bp and a much stronger 600 bp band
existed in the PCR product of the skin fibroblast cell RNA (Figure 4.5B). After
transferring to a Hybond-N nylon membrane and hybridising with a 0.78 kb probe
(spanning exon 1 to exon 5 of CYP2A7), four of five samples, including sample L5
i
Figure 4.5 Analysis of CYP2A7 species. (A) Analysis procedure: RT-PCR was
carried out with primers A and C. (B) The products were analysed by ethidium
bromide staining. Lane 1, human fibroblast total RNA. Lanes 2-6, Human liver RNA
samples L14, LI5, L8, L6 and L4, respectively. (C), Southern hybridisation of the
RT-PCR products with a 0.78 kb cDNA probe containing exon 1 to 5 of CYP2A7.

























































(after longer exposure), contained alternatively spliced CYP2A7 mRNA. Variability in
the relative level of this mRNA vs. normal CYP2A7 mRNA was found between
samples (Figure 4.5C). Indeed, in sample L5 the level of the alternatively spliced
mRNA was 3 to 4-fold higher than the correctly spliced transcript. However in the
other samples, the normal transcript was the predominant mRNA species. Interestingly,
the major CYP2A7 mRNA species in the skin fibroblast cell line appears to be the
alternatively spliced mRNA, with only a very low amount of the normal transcript
(Figure 4.5B and 4.5C, track 1).
4.2.4 Functional analysis of CYP2A transcripts
To investigate whether these mRNAs could be translated, the CYP2A6, CYP2A7 and
alternatively spliced CYP2A7 cDNAs were subcloned separately into a vector pCMVzp
The pCMV4 is a mammalian expression vector which contains the promoter-enhancer
sequence of the major immediate early gene of human cytomegalovirus, and the
polyadenylation region of the human growth hormone gene. The SV40 origin of
replication in pCMV4 can increase transfectional efficiency in COS cells which had been
previously transformed with large T antigen of SV40 (Andersson et al., 1989)
The subcloning strategy is as follows: the full length CYP2A6 cDNA was described
previously by Miles et al. (1990). The subcloned CYP2A6, CYP2A7 and CYP2A7AS
cDNAs in vector pUC19 were digested with EcoRl, blunted using Klenow enzyme and
then cut with Hindlll. The resulting fragments were then ligated into the Smal-Hindlll
sites of pCMV4, separately, to form the expression plasmids pCMV4-CYP2A6,
pCMV4-CYP2A7 and pCMV4-CYP2A7AS (Figure 4.6). These constructs were used
to transiently transfect COS cells. The transfected COS cells were lysed by sonication
using an MSE Soniprep (two 5 second bursts at an amplitude of 12 mm with sample
kept on ice). The lysed samples were centrifuged at 13000 rpm for 10 min to prepare
crude supernatant and pellet fractions for Western blot analysis. Proteins were
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Figure 4.6 Structure of human CYP2A expression vector. Plasmid PCMV4
represents the starting expression vector and contains the immediate early promoter
region of human cytomegalovirus (CMV, stippled block), a DNA copy of a segment of
the alfa mosaic virus 4 RNA that contains a translational enhancer (A), a polylinker
containing unique sites for the indicated restriction enzymes, transcription termination
and polyadenylation signals from the human growth hormone gene (hGH, hatched
block), and the SV40 origin ofDNA replication and early region enhancer sequences
(SV40 on, white block). The plasmid also contains an E. coli gene encoding ampicillin
resistance (Ampr) and a bacteriophage fl origin of DNA replication (fl). Plasmid
pUC19-CYP2A represents the plasmids containing inserts of the CYP2A6 or CYP2A7
or CYP2A7AS . Plasmid pCMV4-CYP2A contains an inserted fragment of the human
CYP2A6 or CYP2A7 or CYP2A7AS cloned into the Smal and Hindlll sites of the
polylinker region of pCMV4. The approximate position of the initiator methionine


















separated by SDS/PAGE (Laemmli, 1970), transferred to nitro-cellulose membrane and
probed with anti-rat CYP2A antiserum using the method of Lewis et al. (1988).
Western blot analysis of the membrane fractions showed that all three cDNAs gave
protein products (Figure 4.7A, tracks 2 to 4). The molecular weight of the CYP2A6
and CYP2A7 proteins was identical, Mr 49 kDa, with an identical mobility to the major
immunostained band identified in human liver microsomes with anti-rat CYP2A1
antibody. The alternatively spliced CYP2A7 gave two protein bands, Mr .44 kDa and 42
kDa (Figure 4.7A, track 4). Since abnormal mRNA often leads to an unstable protein
product, the 42 kDa protein could be a degradation product. A protein band which co-
migrated with the 44 kDa protein was also found in the crude membrane fraction of the
human skin fibroblast cells, but not in the human liver microsomal sample. No
detectable 49 kDa protein was observed in the fibroblast cell line (Figure 4.7A, track
5).
In order to determine whether the expressed proteins are catalytically active, coumarin
hydroxylase activity was measured by HPLC in the transfected cells as follows. The
transfected COS cells were washed with PBS and then re-fed with 5 ml fresh, serum
free medium. 25 jllI of 10 mM coumarin in DMSO and 10 pi of (3-14C) labelled
coumarin (13.25 pCi in 0.5 ml DMSO) were added into the flask and then the cells
were cultured for 6 h at 37°C. After incubation the medium was collected and an equal
volume of ice cold methanol was added. The various polar products including 3-,4- and
7-hydroxycoumarins were determined in the medium by HPLC analysis (Iersel et al.,
in press). The 7-hydroxylcoumarin was considerable higher in the cells expressing
CYP2A6 than the controls. However, the 7-hydroxylcoumarin and the total polar
products in the cells transfected with the different forms of CYP2A7 did not change
(Figure 4.7B).
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Figure 4.7. A. Expression of CYP2A cDNAs in COS-7 cells. cDNAs encoding
CYP2A6, CYP2A7 or CYP2A7AS were subcloned into pCMV4 and transfected into
COS-7 cells as described in the Materials and Methods. Western blotting analysis of
proteins from the crude pellet fractions of transfected COS cells (100 (ig) and of
cultured human skin fibroblast cells (100 jug) was done using an antibody to rat
CYP2A1. Human liver microsomal protein (10 |lg, lane C) was used as a positive
control. Track 1, untransfected COS-7 cells; track 2, pCMV4-CYP2A6; track 3,
pCMV4-CYP2A7; track 4, pCMV4-CYP2A7AS and track 5, human skin fibroblast
cells (in the same Western blotting analysis).
B. Coumarin-7-hydroxylase activity. A proportion of the cells from the same samples
analysed by Western blot analysis were assayed for coumarin hydroxylase activity as
described in the Materials and Methods by HPLC. Coh activitie is expressed as
pmol/incubated (5 x 106 cells)/6 h. Tracks are: 1, untransfected cells; 2, pCMV4-2A6;
3, pCMV4-2A7; 4, pCMV4-2A7AS. The HPLC was done by Dr Lake from BIBRA













CYP2A7 mRNA can be alternatively spliced to give a transcript missing exon 2 but
containing an additional three amino acids derived from intron 1. This alternatively
spliced mRNA can be translated to give a protein product of the predicted molecular
weight in cDNA directed expression and in a human fibroblast cell line. The relative
hepatic level of the CYP2A7AS versus CYP2A7 mRNA varied considerably between
individuals and in one case CYP2A7AS was the more abundant of the two mRNA
species. In the human fibroblast cell line both CYP2A7 transcripts were detected, but
the major product was CYP2A7AS.
It is intriguing that aberrantly spliced mRNAs have also been reported for several other
genes in the CYP2 family. For example, two mRNAs are derived from the rat CYP2C6
gene by alternative splicing in exon 8. This like many other examples leads to a
disruption of the open reading frame. Although the alternatively spliced mRNA can be
translated into a truncated protein, its haem-binding capacity is lost and therefore the
protein cannot function as a P450 monooxygenase (Kimura-H. et al., 1989). The
transcript of human CYP2B6, whose expression may be co-regulated with CYP2A
(Miles et al., 1989a), is also alternatively spliced, and at least four mRNA species are
derived from this gene (Miles et al., 1989b). The related levels of different mRNAs are
subject to considerable inter-individual variability. Similar to the findings here, a variant
of CYP2B6 is generated using a cryptic "non-conforming" 5'-splice site, G/gcaag.
Alternative splicing has also been described for human CYP2D genes (Gonzalez et al.,
1988; Gough et al., 1990). Taken together, these results suggest that alternative
splicing is an important determinant in the expression of many P450 genes and this
effect will contribute to the inter-individual variation in the enzyme levels. In addition,
alternative splicing using cryptic non-GT conforming 5'-splice site is considered as a
rate-limiting regulation for some genes (Shapiro and Senapathy, 1987).
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Cytochrome P450 is synthesised on membrane-bound polysomes (Bar-Nun et al.,
1980) and inserted into the endoplasmic reticulum membrane using the first 29 N-
terminal amino acids as an anchor (Sakaguchi et al., 1987). The C-terminus of
cytochrome P450 is important for haem -binding. The protein product of alternatively
spliced CYP2A7 still contains the conserved P450 haem binding region and could
conceivably still function as a monooxygenase enzyme. However, CYP2A7AS does
not contain exon 2 which might form a potential transmembrane domain (Nelson and
Strobel, 1988) and contains specific amino acids responsible for substrate recognition
(Gotoh, 1992). The results of cDNA directed expression in COS cells showed that the
alternatively spliced CYP2A7 produces a truncated protein of Mr 44 kDa and this
protein was associated with the crude membrane fraction (Figure 4.7A). No detectable
CYP2A7AS protein was found in the crude supernatant fraction (results not shown).
This result agrees with recent membrane topology models of P450 suggesting that only
exon 1 of P450s codes for the membrane anchor (Black, 1992). Since the expression
level of CYP2A7AS in COS-7 cells was too low to establish whether the truncated
protein still binds haem or not, studies to establish whether this is the case using other
expression systems are in progress.
Studies on the CYP2A subfamily in mouse and rat have revealed the evolution and
regulation of its enzyme activity. Though there are species differences in gene
expression and in the number of genes, the enzymes in the CYP2A subfamily exhibit a
conserved coumarin 7-hydroxylation activity. The CYP2A6 enzyme is reported to be
the major enzyme catalysing coumarin 7-hydroxylation in human liver (Yamano et al.,
1990; Miles et al., 1990), and the level of enzyme activity varies with different livers
(Maurice et al., 1991). This conclusion was based on the observed correlation between
the level of CYP2A6 protein and the enzyme activity in human livers. Although in some
tested human liver samples the intensity of the stained band in the immunoblotting
assay appears to correlate with the level of coumarin 7-hydroxylase activity (Pearce et
al., 1993; Yamano et al., 1990), some other tested samples in their reports do not show
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such correlation. In my experiments cDNA directed expression of CYP2A6 and
CYP2A7 in COS-7 cells indicated that CYP2A7 had exactly the same mobility as
CYP2A6 on SDS-PAGE and both protein products were 49 kDa (Figure 4.7A) Since
only CYP2A6 had coumarin 7-hydroxylase activity and the function of CYP2A7 has
not yet been demonstrated, my finding revealed that the amount of 49 kDa protein did
not seem to correlate, at least in some livers, with the level of coumarin 7-hydroxylase
activity because the protein band of 49 kDa in immunoblotting assay should be a
mixture of CYP2A6 and CYP2A7 products.
Immunohistochemical techniques have been used to identify the presence of P450 in
skin. Enzymes of the CYP2 and CYP3 families were found in cultured rat skin cells
and in normal and transformed human epidermal keratinocyte cell lines as well
(Hotchkiss, 1992). The activities of P450s in skin cells are much lower than those in
liver, ranging from 0.1 to 27 % (Hotchkiss, 1992). In my experiment, a high level of
the alternatively spliced CYP2A7 mRNA, compared with the normal mRNA, existed in
cultured human skin fibroblast cells. Western blot analysis using anti-rat CYP2A
antiserum showed that there was a weakly-staining 44 kDa protein band representing
the product of alternatively spliced CYP2A7 mRNA in the membrane fraction of the
skin cells, but there was no detectable 49 kDa protein which was the product of
CYP2A7 mRNA. This evidence clearly demonstrated that CYP2A7 gene was not only
expressed in liver, but also in cultured skin cells.
The mechanism of alternative splicing of CYP2A7 mRNA is not known. The basis for
the variability in alternative splicing of CYP2A7 mRNA could be determined by either
genetic and/or environmental factors. The results presented in this chapter suggest that
the alternate splicing process may be an important determinant in the expression of
CYP2A7 genes and play a rate-limiting regulation for this gene. The latter may be
related to the inter-individual variation of CYP2A enzyme levels. Since a high level of
alternatively spliced CYP2A7 was observed in cultured skin cells and in one of the
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tested livers in my experiment, environmental factors or in vitro culture conditions
play a function in the alternative splicing of CYP2A7 mRNA as well.
♦
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CHAPTER 5: SUMMARY AND FUTURE WORK
In this thesis, the structure and regulation of the human CYP2A7A gene have been
described. The results of genomic DNA cloning and PCR/RFLP analysis indicated that
there were two alleles of CYP2A7 (CYP2A7A and CYP2A7B) in humans. In addition,
based on the results of expression levels of CYP2A genes in human livers and
alternative splicing ofCYP2A7 mRNA, the possible mechanisms of the inter-individual
variability of coumarin 7-hydroxylase (Coh) activity have been discussed in detail.
5.1 The Structures of CYP2A7 Alleles
Two genomic clones, CoIIA and LIIA, containing alleles of human CYP2A7 were
isolated. The clone CoIIA, isolated from a human cosmid library, contained a full
length version of the CYP2A7 gene which was approximately 8 kb in size. The
sequence comparison indicated that there were 13 nucleotide and 5 deduced amino acid
differences between the coding region of the CoIIA and CYP2A7 cDNA. These data
suggest that the gene in CoIIA appears to be an allele of CYP2A7, and it is named
CYP2A7A.
The second clone, LIIA, was isolated from a human genomic DNA library EMBL3. It
did not hybridise with the CYP2A7 exon 1 specific probe, but hybridised with the 3'-
end specific probe (a fragment containing exon 5 to 9). A comparison of restriction
maps and nucleotide sequences between the gene in clone LIIA and CYP2A7A
indicates that the gene is not identical with CYP2A7A. The PCR/RFLP analysis of 18
human genomic DNA samples revealed that it appears to be another allele of CYP2A7,
designated CYP2A7B. Of the 18 individuals tested, the frequency of CYP2A7B
homozygotes is approximately 44.4%; that of CYP2A7A homozygotes is 33.3% and
the frequency of heterozygotes of CYP2A7A ICYP2A7B is 22.2%. The primers used
in PCR/RFLP are CYP2A7 allele specific, and the PCR products contain no CYP2A6
DNA. However, in the absence of the CYP2A7 genomic sequence it is uncertain
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whether the intronic amplification primers could actually amplify the CYP2A7 gene. In
addition, the restriction enzyme used in this analysis cannot distinguish the genotype of
CYP2A7A from that of CYP2A7. Therefore, to isolate a full length CYP2A7 gene in
further studies will help us to determine the frequency of the CYP2A7 genotype in
humans.
5.2 The Relationship between the Alleles of CYP2A7 and the Inter-
individual Variability of Coh Activity in Man
It has been found that the level of Coh activity varies >100-fold in man (Yun et al.,
1991; Cholerton et al., 1992). This is consistent with the difference in hepatic CYP2A
gene expression determined by Northern blotting (Miles et al., 1989a). The Western
blot of human liver microsomal protein shows that the intensity of the stained 49 kDa
protein band in the immunoblotting assay correlates with the level of the Coh activity in
some tested microsomal samples. However, it is not difficult to notice that in some
other samples, there is not such a correlation (Yamano et al., 1990). In Figure 5.1, for
example, both samples M2 and K18 have a low Coh activity, but the intensity of the
immunoreactive 49 kDa protein band of the sample K18 is much higher than that of
M2. My research results provided possible explanations of this lack of correlation at
protein and mRNA levels. Firstly, the cDNA directed expression of CYP2A6 and
CYP2A7 in COS-7 cells (Chapter 4) indicated that both cDNAs produced an identical
49 kDa protein, but only CYP2A6 had Coh activity. Secondly, it could be argued that
although CYP2A7 did not have Coh activity, it might not be expressed in most human
livers, and therefore would not affect the correlation. However, the results of the
expression levels of CYP2A genes in human liver demonstrated clearly that it was
expressed in six tested liver samples, and that the ratio of CYP2A6 mRNA to CYP2A7
mRNA ranged between 1:0.5 to 1:3, respectively. These data suggest that the lack of
correlation of the level of CYP2A6 protein with the Coh activity in some individuals,
may be explained by the possibility that in these samples CYP2A7 is the major protein
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Figure 5.1 Coh activities and Western immunoblotting analysis of CYP2A protein
contents in 12 human liver specimens. Each liver microsome sample was subjected to
immunoblotting analysis (20 |ig/well) and coumarin 7-hydroxylase activity. The arrows




Two cDNAs, CYP2A6 and CYP2A7, have been isolated from a human liver cDNA
library, and an enzymatically inactive allele CYP2A6v has also been found in human
liver (Yamano et al., 1990). However, the phenotype study for coumarin 7-
hydroxylation in man using thin-layer chromatography combined with fluorescence
densitometry cannot explain the inter-individual variability on the basis of the alleles
CYP2A6 and CYP2A6v (Idle et al., 1992).
In the studies on mouse Cyp2a, it has been found that three amino acid residues,
Vail 17, Phe209 and Met365, play a very important role in coumarin 7-hydroxylation
activity of Cyp2a5, and a single amino acid change (Vail 17 to Alal 17) results in a 10-
fold lower enzyme activity in some strains of mice (Lindberg et al., 1989b; 1992;
Gonzalez, 1992).
In humans, CYP2A6 is a Coh. The studies on the structure and regulation of
CYP2A7A demonstrated that two genomic clones isolated from human genomic
libraries were alleles of the CYP2A7 gene, and this result was confirmed by
PCR/RFLP analysis of human genomic DNAs (Chapter 3). Sequence comparison with
CYP2A6 which encoded a valine* at position 117 showed that two base pair changes
(GTA to GCG) in codon 117 of both CYP2A7 and CYP2A7A resulted in a substitution
of alanine for valine. However, CYP2A7B had only one silent base pair change (GTA
to GTG) in codon 117, which did not lead to a change of the valine at this position
(Table 5.1). This analysis suggests that the residue difference at position 117 among
human CYP2A genes may be similar to Cyp2a genes, and hence responsible for the
inter-individual variability in coumarin 7-hydroxylation in man. It is, therefore,
important in future work to determine if there are any relationships between CYP2A7A
or CYP2A7B homozygotes and the levels of the Coh activity. For example, CYP2A7
allelic genotypes of individuals with high or low Coh activity could
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Table 5.1 Scheme showing the relationships of important substitutions among the
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be determined using allele-specific PCR in combination with the restriction enzyme
Mbol digestion described in Chapter 3. In view of the involvement of CYP2A enzymes
in the metabolism of the tobacco-derived nitrosamine NNK and carcinogen aflatoxin
Bl, further studies on whether the genotypes of CYP2A7 alleles are related with the
metabolism of these procarcinognes will be helpful to understand the susceptibility of
individuals to the toxic and carcinogenic effects of environmental chemicals.
5.3 Regulation of the CYP2A7A Gene
Some chemicals such as PB, DEX and TCPOBOP can induce an elevation in the
transcription level of CYP2A genes in rodents (Pelkonen et ai, 1993) and in monkeys
as well (Pearce et al., 1992). However, the human CYP2A genes had not been
extensively studied, because a suitable cell culture system is lacking for defining the
inducible regulatory elements, and because no human CYP2A gene had ever been
isolated and characterised. In this study, a human CYP2A7A gene was first isolated
and then an attempt was made to determine the chemical inducible promoter activities of
the gene in human HepG2 cells. The results revealed that the promoter activity of
CYP2A7A was only slightly induced by DEX (50% increase) and pyrazole (61%
increase). Phenobarbital treatment was inhibitory (58% decrease), TCPOBOP and 13-
naphthoflavone were without effect on promoter activity. One explanation for these
results is that although CYP2A7A is similar to the mouse Cyp2a genes in structure,
regulatory elements involved in the expression are different in rodents and in humans.
Another possible explanation is the absence of the specific transcription factors or
receptors, which are responsible for the xenobiotic induction, in cultured HepG2 cells.
Results of the promoter activity assay described in Chapter 3 clearly showed that the
0.5 kb fragment of the 5'-flanking region of CYP2A7A gene revealed a maximal
promoter activity. Progressive deletion of the HPF-1 binding site (5'-
GCCAAAGTCCA-3') resulted in a 80% decrease in promoter activity. This result
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shows that the HPF-1 binding site is an essential promoter element in basal
transcription of human CYP2A7A in cultured HepG2 cells. Recently, Chen et al.
(1994) reported that the HPF-1 binding site was highly homologous to the hepatocyte
nuclear factor 4 (HNF-4) binding motif, and both factors (HPF-1 and HNF-4) can bind
to either HPF-1 or HNF-4 binding site. These findings suggest that HPF-1 might be an
important factor in the hepatic expression of CYP2A7A. In future studies, other
approaches can be adopted to demonstrate the mechanism of the constitutive and tissue
specific expression of P450s. For example, mobility shift of DNA-binding assay can
be carried out to determine the binding reaction between regulatory proteins, such as
HNF-4 factor, and promoter elements of CYP2A7A using protein extracts from liver
or from other tissues. This technique can also be used to characterise the mechanism of
liver specific expression of P450. Co-transfection of the construct containing the
promoter element of the CYP2A7A gene with another construct, which is capable of
generating HNF-4 protein, into COS cells could be an alternative way to determine the
function of the HPF-1 motif in liver-specific expression.
It has been found that the steroid regulatory element (SRE, 5'-CACCCCAC-3') plays
an essential role in co-ordinating the transcriptional regulation of the genes involved in
the maintenance of cholesterol homeostasis, and functions as an enhancer (Osborne et
al., 1988; Smith et al., 1988). A SRE has also been reported existing in the promoter
region of the human CYP7 gene which is responsible for the metabolism of cholesterol
and bile acid biosynthesis (Molowa et al., 1992). In this study a consensus SRE was
identified by sequencing the 0.5 kb 5' flanking region of CYP2A7A, and the SRE was
found overlapping with two directly repeated CACCC elements (CCACCCCACCC),
which function like Spl binding site. This is similar to the promoter region in the
cholesterol homeostasis related LDL receptor gene, in which the SRE is located
between two Spl binding sites (Goldstein and Brown, 1990). Although the function of
the CYP2A7A gene is still unclear, this finding together with the fact that mouse Cyp2a
proteins metabolise steroid hormones (Lindberg et al., 1989a; Burkhart et al., 1990)
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suggest that the function and regulation of the CYP2A7A gene may be related to steroid
metabolism.
It is interesting to notice that by the transient transfection assay, the construct containing
a 3.0 kb 5'-flanking region of CYP2A7A exhibited only a low promoter activity in
HepG2 cells. With the progressive deletion of the 3.0 kb 5'-flanking sequence to the
position of -1.0 kb, the transcription activity significantly increased and the maximal
activity was observed with a fragment containing approximately 0.5 kb of the 5'
flanking region of the gene (Chapter 3). This result suggests that in human liver, the
expression of CYP2A7A is under multiple control mechanisms, possibly including
positive and negative control elements.
In order to characterise these control elements, a series of fused constructs could be
made in future studies, which contain a reporter and a truncated fragment from different
parts of the 3.0 kb 5'-flanking region of CYP2A7A. These constructs can be
transfected into cultured cells to determine their transcriptional activities. This study will
shed light on why the 3.0 kb 5'-flanking region of the CYP2A7A only has a low
promoter activity in HepG2 cells.
5.4 Alternative Splicing of (^!YP2A7
As part of the analysis of CYP2A6 and CYP2A7 mRNAs, RT-PCR was carried out to
amplify full length CYP2A cDNAs using a human liver RNA sample L8 (Chapter 4).
The results showed that in addition to the expected fragment of 1.6 kb, a small amount
of a 1.45 kb DNA fragment was observed after electrophoresis separation on an
agarose gel. The PCR products were subcloned into pUC19, and a restriction enzyme
Pstl digestion was used to screen the colonies as a Pstl site was only present at 143 bp
(+1 indicates the start of the open reading frame) of CYP2A6 cDNA. Three clones with
different digestion patterns were isolated and sequenced. The first two, both with a 1.6
kb insert, contained a CYP2A6 and a CYP2A7 cDNA, respectively. The third one,
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with a 1.45 kb insert, contained an alternatively spliced version of CYP2A7
(iCYP2A7AS).
Comparing the sequence of CYP2A7AS cDNA with the genomic DNA of CYP2A7, it
was found that both coding regions were identical except that the 163 bp exon 2 of
CYP2A7AS was replaced by a 10 bp segment of intron 1. Translation of CYP2A7AS
mRNA resulted in an in-frame deletion of 51 amino acids, and in the generation of a
protein product of Mr 44 kDa. The 10 bp segment of intron 1 added three amino acids
at residue 60 and was then linked to the amino acid 114 in exon 3. All the intron/exon
junctions conformed to the GT/AG consensus splice recognition site. However, intron
1 contained an additional splice site, G/gcagg (exon sequence is designated by upper¬
case letter and intron sequences are designated by lower-case letters), which resulted in
CYP2A7AS. Interestingly, CYP2A7AS was the major CYP2A7 mRNA detected in a
human skin fibroblast cell line. This finding shows that the alternative splicing of
CYP2A7 may be tissue-specific.
The cDNA directed expression of the CYP2A6, CYP2A7 and CYP2A7AS in COS-7
cells described in this study indicate that both CYP2A6 and CYP2A7 products are 49
kDa, and CYP2A7AS is a truncated protein of Mr 44 kDa. But only CYP2A6 has a
i
coumarin 7-hydroxylation activity. To date, no substrate for CYP2A7 has been
identified. The analyses of CYP2A mRNA levels in human livers clearly demonstrated
that in certain liver samples CYP2A7 was expressed at higher levels than CYP2A6 , or
even was a dominant mRNA species of CYP2A. It will, therefore, be important to
determine the substrate(s) for this enzyme in future studies. In addition, as the
expression system used for P450 expression in mammalian cells is usually not efficient
enough to characterise protein biosynthesis, structure and function of P450, further
studies on other high expression systems, such as amplifiable systems leading to an
overproduction of foreign proteins in mammalian cells, will provide evidence for the
characterisation of the functions of CYP2A7A. Alternatively, a cell line stably
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expressing CYP2A7 cDNA can be established to determine the function of CYP2A7 in
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Expression and alternative splicing of the cytochrome P-450 CYP2A7
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In order to investigate the relative levels of expression of human
cytochrome P-450 (P-450) CYP2A genes and determine how this
relates to polymorphism in coumarin hydroxylase activity, cDNA
clones for members of the CYP2A gene family were isolated.
These clones were CYP2A6, CYP2A7 and an alternatively spliced
version of CYP2A7 (CYP2A7AS). The latter clone was missing
exon 2, but contained a 10 bp segment of intron 1. Translation
of CYP2A7AS resulted in an in-frame deletion of 51 amino
acids. The expression of these cDNAs in COS-7 cells showed that
both CYP2A6 and CYP2A7 generated a protein of molecular
mass 49 kDa, whereas the protein product of CYP2A7AS was
about 44 kDa. Only the CYP2A6 had coumarin hydroxylase
activity. The relative level of CYP2A7 and CYP2A7AS mRNA
was investigated by reverse transcription followed by PCR
(RT-PCR) using human liver RNAs and an RNA sample from a
human skin fibroblast cell line. In one of five liver RNAs studied,
the aberrantly spliced CYP2A7 mRNA was 3^1-fold more
abundant than the normal mRNA. The other samples contained
very low levels of this mRNA species. Interestingly, CYP2A7AS
mRNA was themajor CYP2A7 mRNA detected in the fibroblast
cell line. In this case only a protein band of 44 kDa was observed
by Western-blot analysis. The relative level ofmRNA encoding
CYP2A6 and CYP2A7 was established in seven human liver
samples by RT-PCR and found to range between 1:0.5 and 1:3.
These data strengthen the previous findings that alternative
splicing is an important factor in determining the levels ofmany
human P-450s and that this may be subject to tissue-specific
effects. Whether in this case the protein product has some
function remains to be determined.
INTRODUCTION
In mammals, cytochrome P-450 (P-450) enzymes play a pivotal
role in the biotransformation ofendogenous compounds involved
in intermediary metabolism and of xenobiotic substances such as
drugs, environmental toxins and carcinogens [1,2]. It is recognized
that P-450s are not only inducible by foreign chemicals, but also
subject to hormonal regulation and genetic polymorphism. As a
consequence, hepatic P-450 levels in man are subject to marked
individual differences. The importance of these differences is
exemplified by studies on the genetic polymorphism at the
CYP2D6 locus. Two distinct phenotypes, namely 'extensive
metabolizer' (EM) and 'poor metabolizer' (PM), have been
described [3]. The ability of individuals with the EM phenotype
to metabolize some chemicals is 10-200 times higher than that of
individuals with the PM phenotype [4], In some cases the
distribution of phenotypes is changed in disease populations [5]
and can also be a critical determinant in inter-individual differ¬
ences in toxic responses to clinical drugs.
In order to be able to determine the role of P-450s in adverse
drug reactions and chemical toxicity, the basis for individuality
in gene expression needs to be established. In this regard the
genes of the human CYP2A subfamily have not been extensively
investigated. Two cDNAs, designated CYP2A6 and CYP2A7,
have been isolated. Both genes are expressed in human liver and
share 96 % nucleotide sequence identity and 94 % identity at the
amino acid level [6,7], CYP2A6 has been found to be responsible
for the metabolism of coumarin [7,8] as well as the carcinogen
aflatoxin Bj [9,10], The functions of CYP2A7 are currently
unknown.
The level of expression of CYP2A6 is highly variable within
the population. Coumarin hydroxylase activity varies greatly as
well (up to 144-fold). This is consistent with the difference in
hepatic CYP2A6 expression [11,12]. Northern-blot analysis with
CYP2A6 as a probe identifies two mRNAs of 2.3 and 2.8 kb in
human liver [8], and immunoblotting of liver microsomes also
reveals two or three bands with molecular masses of 49, 51 and
55 kDa [7,8,12], These results suggest that more than two CYP2A
genes are expressed in this tissue.
In order to study the factors involved in the inter-individual
variability in the expression levels of human CYP2A genes, we
have studied the expression of CYP2A genes in human liver. We
report the identification of three mRNA species encoding
CYP2A6, CYP2A7 and an alternatively spliced form ofCYP2A7,
designated CYP2A7AS. The identification of this latter mRNA
exemplifies previous reports indicating that alternative splicing is




A Simian-virus-40-transformed monkey kidney fibroblast cell
line (COS-7) was maintained under standard cell-culture condi¬
tions in Dulbecco's modified Eagle's medium (DMEM), supple¬
mented with 10% foetal-calf serum, glutamine (2 mM), and
antibiotics (penicillin and streptomycin); the human skin fibro¬
blast cell line was kindly donated by Dr. S. Keyse
Abbreviations used: P-450, cytochrome P-450: CYP2A7AS, an alternatively spliced form of the cytochrome P-450 CYP2A7; RT-PCR, reverse
transcription followed by PCR; DMEM, Dulbecco's modified Eagle's medium; DMSO, dimethyl sulphoxide.
t To whom correspondence should be addressed.
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(Biomedical Research Centre, Dundee, Scotland) [13], and the
cells were cultured in DMEM supplemented with 15% foetal-
calf serum.
Preparation of radioactive DNA probes
A 0.78 kb cDNA fragment (from exon 1 to exon 5) of the
CYP2A7 gene was radioactively labelled with [a-32P]dCTP
(3000 Ci/mmol) by random primer extension [14].
Isolation of CYP2A genomic clone
A human acute-lymphocytic-leukaemia DNA library in an
Epstein-Barr-virus-based cosmid vector cos202 (a gift from Dr.
D. Kioussis, The Middlesex Hospital Medical School, London,
U.K.) was screened using a 0.7 kb cDNA fragment of CYP2A6
cDNA as a probe. Hybridization and washing of replica filters
were performed as described by Kioussis et al. [15]. Analyses by
restriction-enzyme digestion were carried out using standard
techniques [16].
Southern-blot hybridization analysis
DNA was separated on 1 %-agarose gels and then transferred to
a Hybond-N nylon membrane using the conditions recommended
by the manufacturer (Amersham International). The membrane
was hybridized with the cDNA probe spanning exons 1 to 5 of
CYP2A7 at 65 °C overnight, followed by washing the membrane
in a final salt concentration of 0.1 x SSC/0.1 % SDS at 65 °C
(1 x SSC is 0.15 M NaCl/0.015 M sodium citrate).
DNA sequencing
The dideoxy chain-termination method with [a-35S]dATP (400
Ci/mmol) was used to sequence plasmid DNA. The DNA was
prepared by alkaline lysis. RNAase A was added to final
concentration of 50-100 /ig/ml and incubated at 37 °C overnight.
The degraded RNA was removed by precipitating plasmid DNA
with 20% poly(ethylene glycol) 6000/2.5 M NaCl (3:5, v/v).
Sequences were compiled and analysed by using Gene Jockey
software (published and distributed by BIOSOFT).
RNA preparation from human liver and tissue-culture cells
Human livers were obtained from kidney-transplant donors.
Livers were stored at —70 °C within 1 h of removal. Information
about the patient case histories has been described previously
[8,9]. Total cellular RNA was prepared by the guanidinium
isothiocyanate method [16] or a single-step method [17] from
human liver and from cultured human skin fibroblast cells. The
designation of the RNA samples is the same as that described in
the literature. RNA concentration and purity were estimated
spectrophotometrically.
Reverse transcription and PCR (RT-PCR)
Before reverse transcription, RNA was tested for integrity by
ethidium bromide staining following separation on a denaturing
formaldehyde gel. The reagents were mixed in 1 x PCR buffer
(Promega), as described by Innis et al. [18], in a final volume of
20 /A. These were dNTPs (1 mM), MgCl2(4 mM), 1 unit//tl of
RNasin, 0.1 fig of oligo(dT)6_8, 1-5 //I of total RNA sample
(10 fig) and 200 units ofMoloney-murine-leukaemia-virus reverse
transcriptase. A negative control without RNA was carried out
in all the RT-PCR reactions, and no product was found in these
negative controls. The mixture was incubated for 15min at
23 °C, 60 min at 43 °C and then transferred to a water bath at
95 °C for 6 min. After heat treatment the reaction mixture was
quickly chilled on ice. An 80 /A volume of 1 x PCR buffer,
containing 10-50 pmol of each primer, MgCL (1 mM) and 2.5
units of Taq polymerase (Promega) was then added. Mineral oil
(100 /d) was then layered on top of the solution. To amplify the
full-length CYP2A cDNAs, oligonucleotide A (upstream
primer):
5-CATGCTGGCCTCAGGGCTGCTT-3'
and oligonucleotide B (downstream primer):
5-GCCTTAAGGCTTCCCCCCATTCTTATACC-3'
containing an additional EcoKl site were used. To amplify a
cDNA fragment spanning exons 1-5, oligonucleotide A and
oligonucleotide C:
5'-GAAGTCCTCCAGCCCTTGCAGC-3'
were used. The thermal cycle was: (1) denaturing; 1 min at
94 °C; (2) annealing; 1 min at 58 °C; and (3) primer extension;
1 or 2 min at 72 °C. After 30-35 cycles, the reaction mixture was
incubated for 8 min at 72 °C. The PCR product was purified by
phenol/chloroform (1:1, v/v) and chloroform extractions. After
ethanol precipitation the amplified product using oligo¬
nucleotides A and C was resuspended in 50 /A of TE buffer
(10 mM Tris/1 mM EDTA, pH 8.0). Samples (10 /zl) were
digested for 4 h at 37 °C with 20 units of Pstl.
Isolation of CYP2A7 cDNAs
Full-length CYP2A7 and CYP2A7AS cDNAs were obtained by
RT-PCR using oligonucleotides A and B. The amplified products
were first blunted using Klenow DNA polymerase, digested with
EcoRI and then ligated into the EcoRl-Smal sites of pUC19 and
transformed into Escherichia coli DH5a.
Construction ol expression piasmids
The full-length CYP2A6 cDNA was described previously by
Miles et al. [8]. In order to clone the CYP2A6, CYP2A7 and
CYP2A7AS into the mammalian expression vector pCMV4 [19],
the subcloned cDNAs were digested with EcoRI, blunted, and
then cut with HinAWl. The fragments were then ligated into the
Smal-Hindlll sites of pCMV4 to form the expression piasmids of
pCMV4-CYP2A6, pCMV4-CYP2A7 and pCMV4-CYP2A7AS.
Transient transfection
COS-7 cells were seeded at a density of 3 x 106cells/75 cm2 flask
and incubated overnight at 37 °C. Cells were then transfected
using the DEAE-dextran method [20], Briefly, 5 fig of plasmid
DNA in 100 mM NaCl/10 mM Tris/HCl, pH 7.5, was diluted to
2.0 ml with PBS (Ca2+- and Mg2+-free; Gibco) containing
0.5 mg/ml of DEAE-dextran (Pharmacia; molecular mass
500 kDa). Then the mixture was added to the PBS-washed cells
and incubated at 37 °C for 30 min with occasional shaking.
Culture medium (10 ml), supplemented with 80 //M chloroquine,
was then added to the flask and the cells incubated for 2.5 h at
37 °C. The transfection mixture was aspirated off and replaced
for 2.5 min with medium (10 ml) containing 10% dimethyl
sulphoxide (DMSO), followed by washing once with fresh
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medium; then fresh medium (15 ml) was added and the cells were
cultured for 48 h before use.
Assay of coumarin 7-hydroxylase activity in transfected COS-7
cells
The transfected cells were washed with PBS and then re-fed with
5 ml of fresh serum-free medium, 25 fil of 10 mM coumarin in
DMSO and 10 yd of [3-14C]coumarin (13.25 /<Ci in 0.5 ml of
DM SO) were added to the flask and the cells were then cultured
for 6 h at 37 °C. After incubation the medium was collected and
an equal volume of ice-cold methanol was added. 7-Hydroxy-
coumarin was then assayed in the medium by h.p.l.c. analysis
[21].
Western-biot analysis
The transfected COS cells and cultured skin fibroblast cells were
harvested by trypsin treatment and resuspended in 0.5 ml of
10 mM sodium phosphate buffer, pH 8.0, containing 2 mM
MgCl2, 2 mM dithiothreitol and 1 mM EDTA. Samples were
lysed by sonication using an MSE Soniprep (two 5 s bursts at an
amplitude of 12/tm with the sample kept on ice). The lysed
samples were centrifuged at 11 600 g for 10 min to prepare crude
supernatant and pellet fractions for Western-blot analysis.
Proteins were separated by SDS/PAGE [22], transferred to
nitrocellulose membrane and probed with anti-(rat CYP2A)
antiserum using the method of Lewis et al. [23]. For human liver
microsomal preparation [8], 10 fig of protein was loaded per
track, whereas for transfected COS cells and skin fibroblast cells,
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Determination of CYP2A mRNA levels
Analysis of the human CYP2A6 and CYP2A7 cDNA sequences
[7] shows the presence of a Pstl restriction site at bp 143 (+1
indicates the start of the open reading frame) of CYP2A6, which
is absent in CYP2A7. This restriction site was used to establish
the relative mRNA levels encoded by these two genes. Hepatic
mRNA was reverse-transcribed, and CYP2A6 and CYP2A7
were amplified by PCR using oligonucleotides A and C as
primers. The expected 750 bp fragments of CYP2A6 and
CYP2A7 were observed (Figure lb; the tracks indicated by a
'U'). After digestion with Pstl (20 units and 4 h incubation at
37 °C), CYP2A6 cDNA was, as expected, cut into two fragments
of 607 bp and 143 bp, whereas CYP2A7 cDNA was unaffected
by this procedure. During subsequent electrophoresis the 143 bp
fragment migrated out of the gel and was not revealed (Figure
lb). In a separate experiment, 0.4 mg of pBluescript DNA was
added into the reaction mixture as an internal control (Figure la)
to verify a complete digestion. In order to ensure that the
analysis was reproducible, the RT-PCR and Fx/I digestion for
samples L8, L6 and L4 were carried out twice. The results
revealed that the ratio of CYP2A7 to CYP2A6 in these three
RNA samples were reproducible (results not shown). Both the
CYP2A6 and CYP2A7cDNA were expressed in all liver samples.
The ratio of the expression level of CYP2A7 to that of CYP2A6
was subject to some variation, ranging from slightly lower than
1:1 in sample L6, to about 3-4:1 in sample L4. The relative
expression of CYP2A7 to CYP2A6 in one RNA sample (L6) was
determined over a range of PCR cycles. The results showed that
the expression level of CYP2A7 to that of CYP2A6 was constant
with the number of PCR cycles (Figure lc).
Figure 1 Relative amounts of CYP2A6 and CYP2A7 mRNA in six human
livers
The amplified DNA was cut with 20 units of ft/I and longer incubation (4 h). (a) Agarose-gel
electrophoresis of ft/1 digested RT-PCR products. A 0.4 portion o! plasmid pBluescript DNA
(2.94 kb) was added to the reaction mixture to verify complete digestion. Lanes M, 1 kb ladder
marker; lanes 1-3, digested pBluesript DNA (2.94 kb) with RT-PCR products from RNA
samples L8, L9 and L11 respectively; 4, uncut pBluesript DNA. (b) Southern-blot analysis of
ft/I digested RT-PCR products. The fragment of 607 bp represents the digested CYP2A6, and
that of 750 bp is CYP2A7. (c) The ratio of the expression of the CYP2A7 relative to CYP2A6
over a range of PCR cycles with RNA sample L6; lanes U, uncut PCR product; lanes P, ft/l-
digested product. The designation of the samples is the same as that described in the literature
[8,9].
The identification of an alternatively spliced CYP2A7 mRNA
As part of the analysis of CYP2A6 and CYP2A7 mRNAs, RT-
PCR was carried out on the entire coding region of the CYP2A
genes using a human total liver RNA sample (L8) and oligo¬
nucleotide primers; A (complementary to the 5' end, bp 1-22)
and B (complementary to the 3' end, bp 1583-1564). In addition
to the expected fragment of 1.6 kb, a weak fragment of about
1.45 kb was observed. The PCR products were subcloned into
the vector pUC19. Pstl digestion was used to screen the colonies,
as this site is present at bp 143 (+ 1 indicates the start of the open
reading frame) of CYP2A6, but absent in CYP2A7. Three
colonies with different Pstl digestion patterns were isolated and
sequenced. The results indicated that the colonies with a 1.6 kb
insert contained a CYP2A6 or a CYP2A7 cDNA. The colony
with a 1.45 kb insert appeared to contain an aberrantly spliced
version of CYP2A7 (CYP2A7AS).
To determine the basis for the alternative splicing, we isolated
164 S. Ding and others
(a)





Amino acid (CYP2A7) Thr Glu His lie Cys Asp Ser lie Met Lys lie Ser Glu Arg -//-
(CYP2A7AS) Thr Glu His He Cys Asp Ser lie Met Lys Val Ser Gin -//-
Exon 1 1
cDNA (CYP2A7) aca gag cac ata tgt gac tcc atc atg aag i atc agt gag c gc -II-
(CYP2A7AS) aca gag cac ata tgt gac tcc atc atg aag gtg tcc caa g | -//-
Exon 1A '
115
Amino acid (CYP2A7) Phe LysGlyTyr Gly Val Ala PheSer AsnGly Glu Arg Ala
(CYP2A7AS) —//— Gly Val Ala PheSer AsnGly Glu Arg Ala
cDNA (CYP2A7) tca aag gct atg G iCG tgg cgt tca gca acg ggg agc gcg cca
(CYP2A7AS) —// cg tgg cgt tca gca acg ggg agc gcg cca
► Exon 3
Figure 2 (a) Structures of the normal and alternatively spliced CYP2A7
mRNAs, and (b) deduced amino acid sequences of CYP2A7 and CYP2A7AS
(a) Exon 1A contains exon 1 plus the first 10 bp of intron 1. (b) In CYP2A7AS the 54 amino
acids of exon 2 are replaced by the three amino aeid residues Val-Ser-Gln.
Exon 1A 1
Alternative
Exon 1 ——i splicing site






309 AGTGAGCGCTA- EX°n 2
Figure 3 Sequence covering the alternatively spliced region of CYP2A7
The alternative splice site is indicated by a vertical broken line. The exon sequences are
designated by upper-case letters; intron sequences are indicated by lower-case letters.
one clone from a human genomic cosmid library, designated
CoIIA, using a 0.7 kb CYP2A6 cDNA fragment (exons 1-5) as
probe. The restriction-enzyme digestion followed by Southern-
hybridization analysis using three CYP2A6 cDNA probes (a
150 bp Sall-Pstl fragment containing exon 1 [6], a 400 bp and a
300 bp PCR fragment containing exons 5 and 6, and exons 8 and
9 respectively) revealed that the CoIIA contained an entire
coding region within the 35 kb insert. In order to sequence the
coding region in CoIIA, several restriction fragments of CoIIA
were subcloned into pUC18 vector and sequenced. In addition,
oligonucleotides based on the intron/exon organization of
CYP2A subfamily genes were used to sequence all exons and
parts of the introns.
Comparing the genomic sequence of CYP2A7 gene with those
of cloned CYP2A cDNAs, we found that the CYP2A7AS was an
aberrantly spliced version of CYP2A7 in which the 163 bp of
exon 2 was replaced by a 10 bp segment (Figure 2a). The
alternatively spliced exon 1 was designated exon 1A. Translation
of CYP2A7AS mRNA would result in an in-frame deletion of 51
amino acids to generate a protein product of molecular mass
44kDa. The sequence of the 10 bp segment adds three amino
acid residues at position 60 and links to the amino acid at
position 114 in exon 3 (Figure 2b). All the intron/exon junctions
conformed to the normal GT/AG consensus splice recognition
site. However, the intron 1 contained an additional 5'-splice site,
G/gcagg (exon sequences are designated by upper-case letters
and intron sequences by lower-case letters), which resulted in
CYP2A7AS (Figure 3). This alternative 5'-splice site does not
conform to the GT/AG consensus sequence; however, it is
similar to a 'non-conforming' 5' splice site sequence found in a
few genes [24,25].
Expression of the alternatively spliced CYP2A7 in human liver
and a skin fibroblast cell line
To investigate the extent of alternative splicing of CYP2A7, five
human liver RNA samples and total RNA from cultured human
skin fibroblast cells were assayed by RT-PCR. The expected
wild-type PCR product is a fragment of 750 bp, and the product
from the alternatively spliced mRNA is 600 bp (Figure 4a). An
ethidium bromide-stained band of 750 bp appeared in four out
of five liver RNA samples, whereas a weak band of 750 bp and
a much stronger 600 bp band existed in the PCR product of the
skin-fibroblast-cell RNA (Figure 4b). After transfer to a Hybond-
N nylon membrane and hybridizing with a 0.78 kb probe
(spanning exons 1-5 of CYP2A7), four of five samples, including
sample LI5 (after longer exposure), contained alternatively
spliced CYP2A7 mRNA. Variability in the relative level of this
mRNA as compared with normal CYP2A7 mRNA was found
between samples (Figure 4c). Indeed, in RNA sample L15 the
level of the alternatively spliced mRNA was 3^1-fold higher than
the correctly spliced transcript. However, in the other samples
the normal transcript was the predominant mRNA species.
Interestingly, the major CYP2A7 mRNA species in the skin
fibroblast cell line appeared to be the alternatively spliced mRNA,
with only a very low amount of the normal transcript (Figures 4b
and 4c, track F).
Funciionai analysis of CYP2A transcripts
To investigate whether these mRNAs could be translated, the
CYP2A6, CYP2A7 and alternatively spliced CYP2A7 cDNAs
were subcloned into the vector pCMV4 and transfected into COS
cells. Western-blot analysis of the membrane fractions showed
that all three cDNAs gave protein products (Figure 5, tracks
2^t). The molecular masses of CYP2A6 and CYP2A7 proteins
were identical (49 kDa), and they showed a mobility identical
with that of the major immunostained band identified in human
liver microsomes with anti-(rat CYP2A1) antibody. The alterna¬
tively spliced CYP2A7 gave two protein bands (molecular masses
44 kDa and 42 kDa; Figure 5, track 4). Since the abnormal
mRNA often leads to an unstable protein product, the 42 kDa
protein could be a degradation product. A protein band which
co-migrated with 44 kDa protein was also found in the crude
membrane fraction of the human skin fibroblast cells, but not in
the human liver microsomal sample. No detectable 49 kDa
protein was observed in the fibroblast cell line (Figure 5a, track
5).
In order to determine whether the expressed proteins are
catalytically active, coumarin hydroxylase activity in the trans¬
fected cells was measured by h.p.l.c. (Figure 5b). Relative to
controls, cells expressing CYP2A6 had considerable activity.
However, no activity could be measured in cells transfected with
the different forms of CYP2A7.
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750 bp
PCR product of wild-type mRNA
F L14 L15 L8 L6 L4
_JA_ 3 I 4 I 5
• 600 bp ■
PCR product of alternatively spliced
mRNA
(c)
F L14 L15 L8 L6 L4
■ 750 bp
• 607 bp
*|ure 4 Analysis of CYP2A7 species
Analysis procedure: RT-PCR was carried out with primers A and C as described in the Experimental section, (b) The products were analysed by ethidium bromide staining. Lane F, human
roblast total RNA. (c) Southern hybridization with a 0.78 kb cDNA probe containing exons 1-5 of CYP2A7. The track of L15 underwent a longer exposure.
(b)
■gure 5 (a) Expression of CYP2A cDNAs in COS-7 cells, and (b) coumarin-
■hydroxylase activity
cDNAs encoding CYP2A6, CYP2A7 or CYP2A7AS were subcloned into pCMV4 and
isfected into COS-7 cells as described in the Experimental section. Shown is a Western-
'ting analysis of proteins from the crude pellet fractions of transfected COS cells (100 /zg)
of cultured human skin fibroblast cells (100 /zg) using an antibody to rat CYP2A1. Human
r microsomal protein (10 /zg, lane C) was used as a positive control. Track 1, untransfected
5-7 cells; track 2, pCMV„-CYP2A6; track 3, pCMV4-CYP2A7; track 4, pCMV4-CYP2A7AS
track 5, human skin fibroblast cells (in the same Western-blotting analysis), (b) A proportion
the cells from the same samples analysed by Western-blot analysis were assayed for
imarin hydroxylase activity as described in the Experimental section. Activities are expressed
pmol/6 h per incubation mixture (= 5 x 106 cells). Tracks are: 1, untransfected cells; 2,
MV4-2A6; 3, pCMV4-2A7; 4, pCMV4-2A7AS.
—5CUSSION
the present paper we have shown that CYP2A7 mRNA can be
crnatively spliced to give a transcript missing exon 2, but
itaining three amino acids derived from intron 1. This mRNA
l be translated to give a protein product of the predicted
ilecular mass in cDNA-directed expression and in a human
roblast cell line. The relative hepatic level of the CYP2A7AS
sus CYP2A7 ntRNA varied considerably between individuals,
and in one case CYP2A7AS was the more abundant of these two
mRNA species. In the human fibroblast cell line, CYP2A
transcripts were detected, but the major product was CYP2A7AS.
The basis for the variability in alternative splicing of CYP2A7
mRNA is not known and could be determined by either genetic
and/or environmental factors.
It is intriguing that aberrantly spliced mRNAs have also been
reported for several other genes in the CYP2 family. For example,
twomRNAs are derived from the rat CYP2C6 gene by alternative
splicing in exon 8. This, like many other examples, leads to a
disruption of the open reading frame. Although the aberrantly
spliced mRNA can be translated into a truncated protein, its
haem-binding capacity is lost and therefore the protein cannot
function as a P-450 mono-oxygenase [26], The transcript of
human CYP2B6, whose expression may be co-regulated with
CYP2A [12], is also alternatively spliced, and at least four
mRNA species are derived from this gene [25], The relative levels
of different mRNAs are subject to considerable individual
variability. Similar to the findings here, a variant of CYP2B6 is
generated using a cryptic 'non-conforming' 5'-splice site,
G/gcaag. Alternative splicing has also been described for human
CYP2D genes [4,27]. Taken together, these results suggest that
alternative splicing is an important determinant in the expression
of many P-450 genes, and this effect will contribute to the inter-
individual variation in the enzyme levels. In addition, alternative
splicing using cryptic non-GT-conforming 5'-splice site is con¬
sidered as a rate-limiting regulation for some genes [24],
CYP2A7AS produces a truncated protein of molecular mass
44 kDa. This protein still contains the conserved P-450 haem-
binding region and could conceivably still function as a mono-
oxygenase enzyme. However, CYP2A7AS does not contain exon
2, which might form a potential transmembrane domain [28] and
contains specific amino acids responsible for substrate recog¬
nition [29], The results showed that the CYP2A7AS protein was
associated with the crude membrane fraction (Figure 5a). No
detectable CYP2A7AS protein was found in the crude super¬
natant fraction (results not shown). These results agree with
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recent membrane-topology models of /M50, suggesting that
only exon 1 of the P-450s codes for the membrane anchor [30].
Since the expressional level of CYP2A7AS in COS-7 cells was
too low to establish whether the truncated protein still binds
haem or not, studies to establish whether this is the case using
other expression systems are in progress.
CYP2A6 is reported to be the major enzyme catalysing
coumarin 7-hydroxylation in human liver [7,8]. This conclusion
was based on the observed correlation between the level of
CYP2A6 protein and the enzyme activity in human livers. Our
finding that CYP2A7 had exactly the same mobility as CYP2A6
on SDS/PAGE indicated that CYP2A7 may also contribute to
this activity. However, cDNA-directed expression of CYP2A6
and CYP2A7 in COS-7 cells indicated that only CYP2A6 had
coumarin 7-hydroxylase activity, although the cellular expression
of this protein was much lower than that of the CYP2A7 protein.
The lack of correlation of the level of CYP2A6 protein with
coumarin hydroxylase activity in some individual samples could
be explained if CYP2A7 were the major protein present.
Enzymes in the CYP2A subfamily play a role in the metabolic
activation of promutagens, such as nitrosamines [31,32],
benzo[a]pyrene and aflatoxin Bj [9,33-35]. To date no substrates
for CYP2A7 have been identified. Analysis of mRNA levels
indicates that, in certain samples, CYP2A7 is expressed at higher
concentration than CYP2A6. It will therefore be important to
determine the substrates for this enzyme.
We are grateful to Dr. C. J. Henderson and Ms. A. W. McLaren for some human liver
RNA samples.
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